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ABSTRACTS
TR-1 Guidelines for Carcinogenic Bioassay
in Small Rodents
Note to the Reader: These guidelines werepublished to
establish standard procedures for toxicology testing in
rodents.
Report Date: February 1976
TR-2 Carcinogenesis Bioassay of
Thichloroethylene (CASNo. 79-01-6)
Trichloroethylene (TCE), a halogenated chemical, has
been tested for carcinogenicity in the National Cancer
Institute's Carcinogenesis Bioassay Program. Tri-
chloroethylene has been used primarily as a solvent in
industrial degreasing operations. Otheruses havebeen as
a solvent in dry cleaning and food processing, as an
ingredient in printing inks, paints. etc., and as a general
anesthetic or analgesic.
Industrial grade (>99% pure) trichloroethylene was
testedusing50animalspergroup at2dosesandwithboth
sexes ofOsborne-Mendel rats and B6C3F1 mice. Twenty
of each sex and species were maintained as matched
controls, in addition to colony and positive carcinogen
controls. Animals were exposed to the compound by oral
gavage 5 times per week for 78 weeks. At the end of
treatment, animals were observed until terminal sacrifice
at 110 weeks for rats and 90 weeks for mice. A complete
necropsyandmicroscopic evaluation ofall animals (except
7 ofthe original 480) was conducted.
Two doses were used with animals started on test at
approximately6weeksofage.Theinitialdosesusedinthis
test were the estimated maximum tolerated dose (MTD)
and 1/2 MTD, aspredicted from data obtained in a6-week
toxicitystudy. Forrats,theinitialdoseswere1,300and650
mg/kg body weight. These were changed, based upon
survival andbodyweightdata, sothatthe"time-weighted
average" doses were 549 and 1,097 mg/kg for both male
and female rats. Formice, the initial doseswere 1,000 and
2,000 mg/kg for males and 700 and 1,400 mg/kg for
females. The doses were increased so that the "time-
weighted average" doses were 1,169 and 2,339 mg/kg for
male mice and 869 and 1,739 mg/kg for female mice.
Clinical signs oftoxicity, including reduction in weight,
were evident in treated rats. These, along with an
increased mortality rate necessitated areduction in doses
duringthe test. In contrast, verylittle evidence oftoxicity
was seen in mice, so doses were increased slightly during
the study. The increased mortality in treated male mice
appears related to the presence ofliver tumors.
A variety of neoplastic lesions were observed in rats
with no significant difference between trichloroethylene-
treated and control animals. The onlylesion thatmightbe
attributed to the treatment was a chronic nephropathy
found in both sexes and at both dose levels.
With both male and female mice, primary malignant
tumors of the liver, i.e., hepatocellular carcinoma, were
observed in high numbers. For males, 26/50 low dose and
31/48high dose animals had hepatocellular carcinomas as
compared with 1/20 matched controls and 5/77 colony
controls. The differences between treated and matched
control males at both doses were highly significant
(P<0.01). For females, hepatocellular carcinomas were
observed in 4/50 low dose and 11/47 high dose animals as
compared with 0/20 matched controls and 1/80 colony
controls. While the difference between the high dose
female mice and matched controls was also highly signifi-
cant (P<0.01), the difference at the low dose was less
(P=0.09). For both male and female mice, age-adjusted
tests for linear trend (dose response) were highly signifi-
cantforhepatocellular carcinoma (P<0.001 formales and
P=0.002 for females).
In male mice at the high doses, hepatocellular car-
cinomas were observed early in the study. The first was
seen at 27weeks; 9 others were found in male mice dying
bythe 78thweek. The tumorwas not observed so earlyin
low dose male or female mice. The diagnosis of
hepatocellular carcinoma was based on size, histologic
appearance, and presence ofmetastasis, especially to the
lung.Nootherlesionwassignificantlyelevated(P<0.05)in
treated mice. The incidence ofhepatocellular carcinomas
in the trichloroethylene-matched controls was typical of
that observed in colony controls.
Carbon tetrachloride (CCl4) was used as a positive
control for the series of chlorinated chemicals which
included trichloroethylene. While virtually all male and
female mice developed hepatocellular carcinomas follow-
ing carbon tetrachloride treatment, the response in the
Osborne-Mendel rats was considerably less. Only about
5% developed hepatocellular carcinomas. Thus, there
appears to be a marked difference in sensitivity to induc-
tion ofcarcinomas bychlorinated compounds between the
B6C3F1 mouse and the Osborne-Mendel rat.
The results of this carcinogenesis test of tri-
chloroethylene clearly indicate that trichloroethylene
induced a hepatocellular carcinoma response in mice.NTP/NIEHS
While the absence ofa similar effect in rats appears most
likely attributable to a difference in sensitivity between
the Osborne-Mendel ratand the B6C3F1 mouse, the early
mortality ofrats due to toxicity must also be considered.
Synonyms: trichloroethene; acetylene trichloride; ethinyl
trichloride; 1,1,2-trichloroethylene, TCE
Report Date: February 1976
Levels ofEvidence ofCarcinogenicity:
Male Rats: Negative
Female Rats: Negative
Male Mice: Positive
Female Mice: Positive
Note: Trichloroethylene was subsequently studied by
gavage in F344 rats and B6C3F1 mice (See TR-243,
reported in 1990) and also in four strains of rats (ACI,
August, Marshall, and Osborne-Mendel) by gavage (See
TR-273, reported in 1988).
TR-3 Bioassay of1,1,1-¶Tichloroethane for
Possible Carcinogenicity (CAS No. 71-55-6)
1,1,1-Trichloroethane is one of a group of halogenated
hydrocarbons selected for testing in the Carcinogenesis
BioassayProgram. Therationale forits selection included
its structural relationship tocarbontetrachloride, itswide
use in industry, its extensive exposure ofhumans, and the
incomplete knowledge of its carcinogenic potential. In
1959, Browning reported that 1,1,2-trichloroethane was
replacing the more toxic industrial solvents: tri-
chloroethylene, tetrachloroethylene, and carbon
tetrachloride. The Environmental Protection Agencyper-
mits 1,1,1-trichloroethane to be used as a solvent or cosol-
vent in pesticide formulations for the postharvest
fumigation ofcitrus fruits.
The carcinogenesis bioassay of technical grade 1,1,1-
trichloroethane was conducted using Osborne-Mendel
rats and B6C3F1 mice. 1,1,1-Trichloroethane was admin-
istered orally by gavage in corn oil to 50 animals ofeach
sex and species at two dose levels 5 days per week for 78
weeks.
Rats: The experimentwas originally started using doses
of3,000 and 1,500mg/kg ofbodyweight. After afewweeks
the study was terminated, and the animals discarded
becauseofmarkedsignsofintoxication.Theexperimentwas
restartedwith rats 7weeks ofagethatwereput ondoses of
1,500 and 750 mg/kg. There was a moderate depression of
bodyweightinthefirstyearofthestudy. Duringthesecond
year a yellow discoloration ofthe fur ofthe lower abdomen
and increased eye and nasal discharge and dyspnea were
noted. Both males and females given the test chemical
exhibitedearlymortalitywhencomparedwiththeuntreated
controls, and the statistical test for dose-related trend was
significant(P<0.04).Allsurvivinganimalswerekilled at117
weeks ofage.
Mice: Maleandfemaleweanlingswerestartedontestat
5 weeks ofage and killed at 96weeks ofage. Initially, the
doses for male and female mice were 4,000 and 2,000 mg/
kgbodyweight. Duringthe 10th week ofthe study, doses
wereincreasedto5,000and2,500mg/kg,sincetheanimals
apparently could tolerate ahigher dose. Doseswere again
increased atweek 20 to 6,000 and 3,000 mg/kg and main-
tained at these levels to the end of the study. Time-
weighted average doses for the high- and low-dose mice
were, respectively, 5,615 and 2,807 mg/kg. There was a
moderate depression of body weight throughout the
study in both sexes ofmice, and the survival was signifi-
cantly decreased. In the female mice, there was a positive
dose-related trend (P=0.002) in the proportions surviv-
ing.
A variety of neoplasms were represented in both 1,1,1-
trichloroethane-treated and matched-control rats and
mice. However, each type of neoplasm has been encoun-
tered previously as alesion in untreated rats ormice. The
neoplasms observed are not believed attributable to 1,1,1-
trichloroethane exposure, since norelationshipwas estab-
lishedbetweenthe dosage groups, the species, sex, type of
neoplasm, orthesiteofoccurrence. Evenifsucharelation-
ship were inferred, it would be inappropriate to make an
assessment of carcinogenicity of 1,1,1-trichloroethane on
thebasis ofthis test, because ofthe abbreviated life spans
ofboth the rats and the mice.
Synonym: methylchloroform
Report Date: January 1977
Levels ofEvidence ofCarcinogenicity:
Male Rats: Inadequate Study
Female Rats: Inadequate Study
Male Mice: Inadequate Study
Female Mice: Inadequate Study
TR-4 Bioassay ofDimethoate for Possible
Carcinogenicity (CAS No. 60-51-5)
Dimethoate is the common name for the organo-
phosphorous insecticide, o,o-dimethyl-S-(N-methylcarba-
moyl-methyl)phosphorodithioate. This compound, which
hasbeeninusesince1956asaninsecticideandacaricide,is
registeredforinsectandmitecontrolonagriculturalcrops
and ornamental plants. It is also registered as a residual
fly sprayin animal quarters.
A bioassay of the carcinogenicity of technical-grade
dimethoatewasconductedusingOsborne-Mendelratsand
B6C3F1 mice. The testmaterial was administered in feed
to groups of50 rats ofeach sex ateitheroftwo concentra-
tions for 80 weeks, followed by 35 weeks of observation.
Initial doses were notwell tolerated; therefore, theywere
reduced during the study. The "time-weighted average
doses"forratswere155and310ppmformalesand192and
384 ppm for females. All surviving rats were killed
between 113 and 115 weeks.
Dimethoate was administered in feed to groups of 50
male and 50 female mice at two concentrations. Female
mice received diets containing 200 and 500 ppm of
dimethoate for 80 weeks; male mice received the same
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dosage. However, high-dose males were returned to the
control diet at 60 weeks, and low-dose males at 69 weeks.
All surviving mice were killed between 93 and 94 weeks.
Tremors and hyperexcitability, both indications of
dimethoate toxicity, were observed in the treated animals.
However, it is considered that the low-dose group of rats
and both dose groups of mice survived long enough to
permit anevaluation ofcarcinogenicity. Pathologic evalua-
tionrevealedno statisticallysignificantincreaseintumors
associated with dimethoate treatment in either species of
animal, and it is concluded that there was no carcinogenic
effect under the conditions ofthe experiment.
Synonyms: o,o-dimethyl-S-(N-methylcarbamoyl-methyl)
phosphorodithioate
Report Date: January 1977
Levels of Evidence ofCarcinogencity:
Male Rats: Negative
Female Rats: Negative
Male Mice: Negative
FemaleMice: Negative
TR-5 Bioassay ofProflavine for Possible
Carcinogenicity (CAS No. 952-23-8)
Proflavine is a synthetic acridine dyewhich earlyin this
century wasfound tohavebacteriostatic andbacteriocidal
properties when administered topically. During World
War II it was widely used as a would antiseptic. With the
adventofmorespecificandlesstoxicantibiotics, itsclinical
importance declined, until it was reintroduced recently in
combination with ultraviolet light for the treatment of
psoriasis and type-II herpesvirus infection.
A bioassay of the carcinogenicity of proflavine mono-
hydrochloride hemihydrate was conducted using Fischer
344/CR rats and B6C3F1 mice. The compound was admin-
istered in the diet at concentrations of300 and 600 ppm to
groups of 50 rats for 109 weeks and at concentrations of
200 and 400 ppm to groups of50 mice for 104 weeks. The
animals were subjected to necropsy and histopathologic
evaluation as they died or at the end of their periods of
treatment.
Average weights attained by high-dose groups were
consistentlylowerthanthose ofcontrol groups;weights of
low-dose groups showed essentially no differences from
those ofthecontrols. Survivalrates ofthetreatedrats and
mice did not differ from those ofthe controls except for a
lower rate among the female mice.
Five malignant neoplasms of the intestinal tract con-
sisting ofthree leiomyosarcomas ofthe small intestine, a
sarcoma near the colon area, and an adenocarcinoma of
the small intestine were observed in five ofthe high-dose
male rats. None were observed in other treatment or
control groups. If these five intestinal neoplasms are
considered together, they are significant at the P =0.026
level using the Fisher exact test. A positive dose-related
trend (P = 0.034) was also present for the three
leiomyosarcomas.
The observed incidence of hepatocellular carcinoma in
femalemicewas4/50(8%)inthecontrolgroup,20/49(41%)
in the low-dose group, and 22/50 (44%) in the high-dose
group. The test for dose-related trend showed a level of
significance of P<0.001. In male mice, the observed inci-
dence ofhepatocellular carcinoma was 20/49 (41%) in the
control group28/49(57%)inthe low-dose group, and30/50
(60%) in the high-dose group. The dose-related trend was
significant at P=0.057, and the high dose was significant
at P=0.044.
The unusually high incidence of hepatocellular car-
cinomas and hemangiosarcomas in control male mice and
the unusually high incidence of malignant lymphomas in
allgroupsoffemalemiceinconjunctionwiththefactthata
positive-control carcinogen was tested in the same room
with these animals, raises a question of the validity of
these bioassay results.
Synonym: 3,6-diaminoacridine
Report Date: January 1977
Levels of Evidence of Carcinogenicity:
Male Rats: Equivocal
Female Rats: Negative
Male Mice: Equivocal
Female Mice: Equivocal
TR-6 Bioassays ofNitrilotriacetic Acid
(NTA) and Nitrilotriacetic Acid, Trisodium
Salt, Monohydrate (Na3NTAH20) for
Possible Carcinogenicity (CAS No. 139-13-9)
(NTA) (CAS No. 18662-53-8) (Na3NTAH20)
Nitrilotriacetic acid (NTA) is a synthetic amino-
polycarboxylic acid chelating agent used chiefly as a
replacement for phosphates in detergents. NTA seques-
ters magnesium and calcium ions present in hard water,
which would normally inhibit the activity of detergent
surfactants. In December 1970, the detergent industry
voluntarily suspended such applications of NTA in the
United States following an unpublished government
repQrtindicatingthatthecompoundwasteratogenic. Dur-
ingthatyeartheannualproductionofNTAwas150million
pounds, of which 86-92% was used in detergents. Major
nondetergent uses, forwhich NTAis still beingproduced,
include water treatment, textile treatment, metal plating
and cleaning, and pulp and paper processing. To a lesser
extent, NTA is used in leather tanning, photographic
development, synthetic rubber production, the manufac-
ture ofpharmaceuticals, agriculture (in herbicide forma-
tionsandmicronutrientsolutions), andinthe separation of
rare-earth elements.
Bioassaysforthecarcinogenicity ofnitrilotriacetic acid,
trisodium salt, monohydrate (Na3NTA-H2O) were con-
ducted at Stanford Research Institute (SRI), using
Fischer 344 rats and at Litton Bionetics, Inc. (LBI), using
both Fischer 344 rats, and B6C3F1 mice. Similar bio-
assays using rats and mice, were conducted at LBI on the
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free acid, nitrilotriacetic acid (NTA). Each chemical was
mixed in respective diets and administered ad libitum.
The Na3NTAH2O was tested in rats at SRI at 200, 2,000,
and20,000ppmfora24-monthperiod. Itwasalsotestedin
rats at LBI at 7,500 and 15,000 ppm and in mice at 2,500
and 5,000 ppm using 18-month feeding periods for both
species. The NTA was tested in rats and mice at LBI at
7,500 and 15,000 ppm for the 18-month period. The num-
bersofanimalsusedintestsatSRIwere24 ofeachsexfor
eachdosegroupandforthecontrols; atLBI,50ofeachsex
for each dose group and 20 of each sex for the controls.
SinceequimolarquantitiesofNa3NTA-H2OandNTAwere
not used, given concentrations of Na3NTA-H2O repre-
sented 30% less NTAthan did equal concentrations ofthe
free acid.
Average weights attained by high-dose groups of rats
and mice were consistently lower than those of control
groups. Less difference was observed with the low-dose
groups. Survival, however, was not decreased bythe com-
pounds administered, except in rats given 20,000 ppm
Na3NTAH20O
Lesions ofthe urinarytractwere found in mosttreated
groups of both rats and mice. They were characterized,
especially in the high-dose groups, by primary tumors of
epithelial origin. These tumors were particularly signifi-
cant since theywere not found in the urinary tract ofthe
control mice and only rarely occur spontaneously in the
strains of animals on test. Lesions of the urinary tract
were also characterized by hydronephrosis and/or
nephritis in high-dose rats and by nephritis in both high-
and low-dose mice.
Statistical evidence of the carcinogenicity of
Na3NTA-H2O and NTA was provided by incidences of
tumors atdifferentsitesintheurinarytract. Forexample,
among animals given 20,000 ppm Na3NTAH2O at SRI,
tumors of the kidney occurred in male (treated, 9/24;
untreated, 0/24; P=0.001) and female (treated, 4/24;
untreated, 0/24; P=0.054) rats; tumors of the ureter in
male (treated, 8/24; untreated, 0/24; P=0.002) and female
(treated, 6/24; untreated, 0/24; P=0.011) rats; and tumors
of the bladder, in female rats (treated, 5/24; untreated,
0/22;P=0.031).Similarly, amonganimalsgiven15,000ppm
NTAatLBI, tumors ofthebladderoccurredinfemalerats
(treated, 12/48; untreated, 0/18; P=0.014) and tumors of
the kidney occurred in male mice (treated, 24/44; untre-
ated, 0/20; P<0.001). Additional tests at LBI, using15,000
and 7,500 ppm Na3NTA-H2O and 7,500 ppm NTAin male
andfemalerats,15,000ppmNTAinfemalemice, and7,500
ppmNTAinmalemice, alsoinducedtumorsoftheurinary
tract, butinnumbers toolowtobestatisticallysignificant.
Metastatictumors,appearingtohavearisenfromprimary
tumors ofthe urinary tract, were found in 5/24 male and
5/24 female rats given 20,000 ppm Na3NTA-H2O at SRI
and in one male rat given 15,000 ppm NTA at LBI; none
were found in rats given lower doses or in mice.
Thus, NTA and Na3NTAH2O were shown to be car-
cinogenic totheurinarytractsofbothratsandmice atthe
higher doses tested. Lower doses, as delineated in this
report, did not induce significant numbers of such
lesions.
Report Date: January 1977
Levels ofEvidence ofCarcinogenicity:
For Nitrilotriacetic Acid (NTA) at LBI:
Male Rats: Positive
Female Rats: Positive
Male Mice: Positive
Female Mice: Positive
For Nitrilotriacetic Acid risodium Monohydrate at SRI:
Male Rats: Positive
Female Rats: Positive
For Nitrilotriacetic Acid Trisodium Monohydrate at LBI:
Male Rats: Equivocal
Female Rats: Equivocal
Male Mice: Negative
Female Mice: Negative
TR-7 Bioassay ofPhenformin for Possible
Carcinogenicity (CASNo.114-86-3)*
Phenforminis asyntheticoralhypoglycemic agentused
to control maturity-onset diabetes. Pharmacologically,
phenformin actstoenhance anaerobicglycolysis, decrease
gluconeogenesis, and inhibit intestinal absorption of
glucose. This compound was selected for carcinogenicity
testing since, in the treatment of diabetes, it is admin-
istered chronically.
Abioassay ofthe carcinogenicity ofphenformin hydro-
chloride was conducted using Fischer 344 rats and
B6C3F1 mice. Thecompoundwas administeredin the diet
for 78 weeks to groups of 35 animals of each species and
sex,usingconcentrationsof15,000and30,000ppmforrats
and concentrations of1,200 and2,500ppmformice. Treat-
mentwas followed by aperiod ofobservation of26weeks.
Control groups consisted of15 untreated animals ofeach
species and sex.
Averageweights attained bytreated groups ofrats and
micewere consistentlylowerthan those ofcontrol groups
in all tests except that for male rats, in which case the
weights shown bytreated and control animals were indis-
tinguishable. Survival was apparently unaffected in both
species by treatment with phenformin, but was poor in
mice due to intercurrent disease.
Thmors appearingintreatedrats andmicewere similar
in type and numbertothose in controls, and nopathologic
or statistical evidence of induction of tumors in these
species by phenformin was found.
Synonym: 1-phenethylbiguanide hydrochloride
Report Date: January 1977
Levels ofEvidence ofCarcinogenicity:
Male Rats:
Female Rats:
Male Mice:
Female Mice:
Negative
Negative
Negative
Negative
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*The technical report states that Phenformin Hydro-
chloride (CAS No. 834-28-6) was the actual chemical
tested rather than Phenformin in its pure form; there-
fore, the CAS number for Phenformin Hydrochloride is
used to track this study in the NTP CHEMTRACK
database.
TR-8 Bioassay ofChlordane for Possible
Carcinogenicity (CAS No. 57-74-9)
Chlordane is a member of the cyclodiene group of chlo-
rinated insecticides, which includes aldrin, dieldrin, endrin,
heptachlor, and endosulfan. It was introduced in 1945 and
was the first chlorinated cyclodiene developed for insect
control. It is effective on a wide variety of insects of agri-
cultural,industrial,anddomesticimportance.Thecompound
wasregisteredforuseonmorethan40vegetableand27fruit
crops.Aboutathird ofthe amountusedintheUnited States
is applied to pests ofthe home, garden, lawn, and turf
A bioassay of analytical-grade chlordane for possible
carcinogenicity was conducted by administering the test
material in feed to Osborne-Mendel rats and B6C3F1 mice.
Groups of50 rats ofeach sexwereadministered loworhigh
concentrations ofthe chlordane for80weeks, then observed
for29weeks. Becauseoftoxiceffects,doseswerereducedfor
both male and female rats during the course of the tests.
Time-weighted average doses used for the male rats were
203.5 and 407.0 ppm; for the females, 120.8 and 241.5 ppm.
Matched controls consisted ofgroups of10untreatedrats of
each sex; pooled controls consisted of the matched-control
groups combined with 50 untreated male and 50 untreated
female rats from similarbioassays offive othercompounds.
All surviving rats were killed at 109weeks.
Groupsof50miceofeachsexwereadministeredthetest
material at low or high concentrations for 80 weeks, then
observed for 10 weeks. The low- and high-dose groups
were tested at different calendar times, but each of the
treatedgroupswastestedalongwithaconcurrentcontrol.
Because of toxic effects, doses were reduced for female
mice during the course of the tests; however, it was
possible toincreasethe doses forthemalemice. Thetime-
weighted average doses used for the male mice were 29.9
and 56.2 ppm; forthe females, 30.1 and 63.8ppm. Matched
controls consisted of groups of10 untreated mice ofeach
sex; pooled controls consisted of the matched-control
groups combinedwith 70untreatedmaleand80untreated
female mice from similar bioassays of five other com-
pounds. All surviving mice were killed at 90-91 weeks.
Theeffectsofchlordaneonbodyweightsandotherclinical
signs in rats and mice indicated thatthe dosages usedwere
nearthemaximumpermissible. Thiswasevidentinthatthe
averagebodyweights ofthehigh-dosemaleandfemale rats
wereconsistentlylowerthanthoseoftheuntreatedcontrols,
whiledifferencesbetweenthelow-doseandcontrolratswere
negligible. Body weights of mice given either low or high
doses showed little or no effect of the chlordane; however,
other adverse clinical signs were seen with greater fre-
quencythan in control mice.
Theeffects ofchlordane on survivalratesindicatedthat
mortality was dose-related for female rats and for male
mice. However, a substantialproportion ofmost groups of
animals survived to an age at which tumors could
be expected to appear; male control rats, for unknown
reasons, showed an abnormally low survival rate.
Hepatocellular carcinoma showed a highly significant
dose-relatedtrendformice,usingeithermatched controls
(for males, controls 2/18, low dose 16/48, high dose 43/49,
P<0.0001; for females, controls 0/19, low dose 3/47, high
dose 34/49, P<0.0001) or pooled controls (for males, con-
trols17/92,P<0.0001;forfemales,controls3/78,P<0.0001).
These high levels of significance were maintained when
hepatocellular carcinoma was combined with nodular
hyperplasia orwhen the data were subjected to life-table
adjustment. Noothertumorswerefoundinmicein suffici-
ent numbers tojustify analysis.
In contrast to findings with mice, hepatocellular car-
cinomafailed to appearatasigniflcantrate ofincidence in
rats administered chlordane. Further, the number of
lesions ofthe liver in rats did not become significant with
the addition ofnodularneoplasia orwiththe application of
life-table adjustment to the data.
Therewas significant statistical evidence for the induc-
tionintreatedmaleratsofproliferativelesionsoffollicular
cells ofthe thyroid and ofmalignantfibrous histiocytoma,
but these findings were discounted because the rates of
incidence were comparatively low and/or are known to be
variable in control rat populations.
Itisconcludedthatundertheconditionsofthisbioassay
chlordane is carcinogenic for the liver in mice.
Report Date: 1977
Levels ofEvidence ofCarcinogenicity:
Male Rats: Negative
Female Rats: Negative
Male Mice: Positive
Female Mice: Positive
TR-9 Bioassay ofHeptachlor for Possible
Carcinogenicity (CAS No. 76-44-8)
Heptachlor is a member of the cyclodiene group of
chlorinated insecticides (aldrin, dieldrin, endrin, chlor-
dane, heptachlor, and endosulfan) that was developed in
the15yearsfollowingWorldWarII. Itwasregistered as a
commercial pesticide in 1952 for foliar, soil, and structure
applications andformalarial control programs; after1960
it was used primarily in soil applications against agri-
cultural pests and to a lesser extent against termites.
A bioassay of technical-grade heptachlor for possible
carcinogenicity was conducted by administering the test
material in feed to Osborne-Mendel rats and B6C3F1
mice. Groups of50 rats ofeach sexwere administered low
orhighconcentrations oftheheptachlorfor80weeks,then
observed for 30 weeks. Doses for females were first
increased, butbecause oftoxiceffects the doseswere then
reduced twice for both male and female rats during the
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remaining course of the tests. Time-weighted average
doses used for the male rats were 38.9 and 77.9 ppm; for
thefemales,25.7and51.3ppm.Matchedcontrolsconsisted
ofgroups of10untreated rats ofeach sex; pooled controls
consisted ofthematched-control groups combinedwith50
untreated male and 50untreated female rats from similar
bioassays offive othercompounds.Allsurvivingratswere
killed at 110-111 weeks.
Groupsof50miceofeachsexwereadministeredthetest
material at low or high concentrations for 80 weeks, then
observed for 10 weeks. The low- and high-dose groups
were tested at different calendar times, but a concurrent
control group was started with each. Because of toxic
effects, doses were reduced once for the males at 17-18
weeks aftertheinitiation oftests; twiceforthefemales, at
17 and 30 weeks, after the initiation of tests. The time-
weighted average doses used for the male mice were 6.1
and 13.8 ppm; for the females, 9 and 18 ppm. Matched
controls consisted ofgroups of10 untreated mice ofeach
sex; pooled controls consisted of the matched-control
groups combinedwith 90untreatedmaleand 70untreated
female mice from similar bioassays of five other com-
pounds. All surviving mice were killed at 90-91 weeks.
The effects of heptachlor on body weights and other
clinical signs in rats and mice indicated that the dosages
used were near the maximum permissible. This was evi-
dentinthataveragebodyweightsofratstreatedwithhigh
doses were consistently lower than those of untreated
controls, while body weights of low-dose rats were
unaffected. Bodyweights ofmice given either high orlow
doses showed little or no differences fromthose ofcontrol
mice; however, other adverse clinical signs were found in
high-dose mice, predominantly in the females.
The effects of heptachlor on survival rates indicated
that mortality was dose-related for both female rats and
femalemice,butnotformalesofeitherspecies. However, a
substantialproportion ofallgroups ofanimals survivedto
an age at which tumors could be expected to appear.
In mice, hepatocellular carcinoma showed a highly sig-
niflcant dose-related trend in both males (matched con-
trols 5/19, low dose 11146, high dose 34/47, P=0.001) and
females (control 2/10, low dose 3/47, high dose 30/42,
P<0.0001). When pooled controls were used for the com-
parison, thesignificance ofthetrendinmalesincreasedto
P<0.0001. Comparably high levels of significance were
attainedwhenthe datawere subjected tolife-table adjust-
ment. No other tumors were found in mice in sufficient
numbers tojustify analysis.
Inmarked contrasttothefindings observed inmice, no
hepatic tumors were observed in rats administered hep-
tachlor. There was significant statistical evidence for the
induction of proliferative lesions of follicular cells of the
thyroid in treated female rats, but this finding was dis-
counted because the rates of incidence were compara-
tively low and are known to be variable in control rat
populations.
Itisconcludedthatundertheconditions ofthisbioassay,
heptachlor is carcinogenic for the liver in mice.
Report Date: 1977
Levels ofEvidence ofCarcinogenicity:
Male Rats: Negative
Female Rats: Equivocal
Male Mice: Positive
Female Mice: Positive
TR-10 Bioassay ofDichlorvos for Possible
Carcinogenicity (CAS No. 62-73-7)
Dichlorvosis anorganophosphateinsecticidewithcontact
and vapor action. It has been used widely for control of
agricultural, industrial, and domestic pests since the 1950's.
Dichlorvos is available in oil solutions, emulsifiable con-
centrations, and aerosol formulations; the impregnation of
dichlorvosinapolyvinylchloridebase(pellets,strips,blocks,
etc.) for delayed release is a widely used method for the
control ofpests in domestic and industrial situations.
Abioassayforthepossible carcinogenicityoftechnical-
grade dichlorvos was conducted using Osborne-Mendel
rats and B6C3F1 mice. The test material was admin-
istered in the diet at two concentrations for 80 weeks to
groups of 50 animals of each species and sex. The test
animalswereheldforobservation,andsurvivingratswere
killed at 110-111 weeks and surviving mice at 92-94 weeks
from initiation of the study. Initial doses in both species
were notwell tolerated and theywere lowered after a few
weeks. Time-weighted average doses for both males and
females were 150 and 326 ppm for rats and 318 and 635
ppmformice. Thematched controls consisted of10rats of
each sex and 10 mice of each sex; the pooled controls
consisted of 60 rats of each sex, 100 male mice, and 80
female mice. All surviving rats were killed at 106 to 109
weeks; surviving mice, at 92 to 94 weeks.
After the doses were reduced, no toxic signs directly
attributable to the compound were observed. However,
average weights of high-dose animals were slightly
depressed. Survivalwas notdose-related ineitherspecies.
Microscopic study of the tissues of treated animals and
matched and pooled controls revealed no statistically sig-
nificantincrease intheincidence oftumors attributable to
exposure to dichlorvos in either animal species. The sig-
nificance of the three esophageal tumors in male and
female mice and of malignant fibrous histiocytomas in
male mice is unclear and there is insufficient evidence to
indicate they were associated with dichlorvos treatment.
Thusundertheconditionsofthisstudy,dichlorvoswas not
demonstrated to be carcinogenic.
Synonym: 2,2-dichlorovinyl dimethylphosphate
Report Date: 1977
Levels ofEvidence ofCarcinogenicity:
Male Rats:
Female Rats:
Male Mice:
Female Mice:
Negative
Negative
Negative
Negative
Note: Dichlorvos was subsequently studied by gavage in
F344 rats and B6C3F1 mice (See TR-342, reported 1989).
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TR-11 Bioassay of Tisodium
Ethylenediaminetetraacetate frihydrate
(EDTA) for Possible Carcinogenicity (CAS
No.150-38-9)
A bioassay of the chelating agent, trisodium eth-
ylenediaminetetraacetate trihydrate (Na3EDTA-3H2O),
forpossible carcinogenicity was conducted byadminister-
ing the test material in feed to Fischer 344 rats and
B6C3F1 mice. The chemical was administered to 50males
and 50 females ofeach species at low and high concentra-
tions, 3,750 and 7,500 ppm, for103weeks. Matched-control
groups were composed of20 males and 20 females ofeach
species.
No compound-related signs of clinical toxicity were
noted. Although avariety oftumors occurred among test
and control animals of both species, no tumors were
related to treatment. Since survival was satisfactory and
showed no consistent variation among test and control
groups, the absence oftreatment-related tumors could not
be attributed to early mortality.
Synonym: EDTA
Report Date: 1977
Levels ofEvidence ofCarcinogenicity:
Male Rats:
Female Rats:
Male Mice:
Female Mice:
Negative
Negative
Negative
Negative
TR-12 Bioassay of Endrin for Possible
Carcinogenicity (CAS No. 72-20-8)
Endrin is an organochlorine pesticide having a struc-
turalcharacteristic ofthecyclodiene group,whichincludes
aldrin (CAS No. 309-00-2), dieldrin (CAS No. 60-57-1),
chlordane (CAS No. 57-74-9), heptachlor (CAS No.
76-44-8), and endosulfan (CAS No. 115-29-7). Itisthemost
acutely toxic compound in the cyclodiene group but is less
persistent in the environmentthan DDT or dieldrin. As an
insecticide, it is currently used for small grains, sugar-
cane, and cotton; as an avicide, for forest seed and perch
applications; and as a rodenticide, for forest seed and
orchard soilapplications.
A bioassay of technical-grade endrin for possible car-
cinogenicity was conducted by administering the test
chemical in feed to Osborne-Mendel rats and B6C3F1
mice. Groups of50 rats ofeach sex were administered one
oftwodoses ofendrinfor80weeks, thenobservedfor31 or
34 weeks. The doses used for the male rats were 2.5 or 5
ppm. The initial doses of5 or 10 ppm used for the females
werenotwelltolerated and werereducedduringthestudy.
The time-weighted average doses used for the females
were 3 or 6 ppm. Matched controls consisted of groups of
10 rats of each sex; pooled controls, used for statistical
evaluation, consisted ofthe matched-control groups com-
binedwith40untreatedmaleand40untreatedfemalerats
from similar bioassays ofother test chemicals. All surviv-
ing rats were killed at 110 to 114 weeks.
Groups of50mice ofeach sexwereadministeredendrin
atone oftwo dosesfor80weeks, thenobservedfor10 or11
weeks. Initialdosesof2.5or5ppmusedforthemaleswere
notwell tolerated andwere reduced duringthe study. The
time-weighted average doses used for the males were 1.6
or 3.2 ppm; the doses used for the females were 2.5 or 5
ppm. Matched controls consisted of groups of 10 mice of
each sex; pooled controls, used for statistical evaluation,
consisted ofthematched-control groups combinedwith 50
untreatedmaleand 50untreatedfemalemicefrom similar
bioassays ofothertest chemicals. All survivingmicewere
killed at 90 or 91 weeks.
The clinical signs observed in both rats and mice indi-
cated that the doses of endrin used were near the max-
imum tolerated doses. In mice these signs included
hyperexcitability, a manifestation of toxicity of the
organochlorinepesticides. However,meanbodyweightsof
the rats and mice were not affected by administration of
endrin.
Although the survival ofthe high-dose malemice atthe
end of the study was markedly lower than that of the
controls, the survivals of the low- and high-dose female
mice and male and female rats were unaffected by the
endrin.Thesurvivalofthelow-dosemalemicecouldnotbe
evaluated, due to the accidental administration of exces-
sive quantities of endrin to this group during week 66.
However, a substantial portion of all groups of rats and
micesurvivedto an ageatwhichtumorscouldbeexpected
to occur.
Inrats, thecombination ofadenomas and carcinomas of
the adrenal occurred atthefollowingincidences - males:
pooled controls 2/44, matched controls 2/9, low-dose 4/46,
high-dose 8/44; females: pooled controls 4/46, matched
controls 3/9, low-dose 16/49, high-dose 7/47. These inci-
dences did not show consistent statistical significance.
Furthermore, theincidences ofthe tumors in thematched
controls of either sex were higher than those of the
corresponding pooled controls, and the incidences in the
matched controls equaled or exceeded those in any ofthe
respective dosed groups. Thus, these tumors cannot be
clearly related to administration ofthe test chemical.
In mice, no tumors occurred in dosed groups at inci-
dences thatwere significantlyhigherthan those inpooled
or matched controls.
Itisconcludedthatundertheconditionsofthisbioassay,
endrin was not carcinogenic for Osborne-Mendel rats or
for B6C3F1 mice.
Report Date: 1979
Levels ofEvidence ofCarcinogenicity:
Male Rats: Negative
Female Rats: Negative
Male Mice: Negative
Female Mice: Negative
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TR-13 Bioassay ofTetrachloroethylene for
Possible Carcinogenicity (CAS No. 127-18-4)
Tetrachloroethylene is one of a group of halogenated
organic solvents selected bythe National Cancer Institute
(NCI) for inclusion in the Carcinogenesis Bioassay Pro-
gram. These solvents were selected on the basis oflarge-
scale production, extensive use, and lack of adequate
chronic toxicity data.
The bioassay of U.S.P.-grade tetrachloroethylene for
possible carcinogenicity was conducted using Osborne-
Mendel rats and B6C3F1 mice. Tetrachloroethylene in
corn oil was administered by gavage at either of two
dosages togroupsof50maleand50femaleanimalsofeach
species, 5 days aweek, over a period of78weeks followed
byanobservationperiodof32weeksforrats and12weeks
for mice.
Initial dosage levels for the chronic bioassay were
selected on the basis of a preliminary subehronic toxicity
test. Subsequent dosage adjustments were made during
the course ofthe chronic bioassay. The high and lowtime-
weighted average dosages of tetrachloroethylene in the
chronic study were 941 and 471 mg/kg/day for the male
rats, 949 and 474 mg/kg/day for the female rats, 1,072 and
536mg/kg/day for the male mice, and 772 and 386mg/kg/
day for the female mice.
For each species, 20 animals ofeach sexwere placed on
test as vehicle controls. These animals were gavagedwith
corn oil atthe sametime thatdosed animalsweregavaged
with tetrachloroethylene mixtures. Twenty animals of
each sexwereplaced ontestasuntreated controls foreach
species. These animals received no gavage treatments.
No significant increased incidence ofneoplastic lesions
was observed in treated rats. In both dosed and control
rats, respiratory disease was observed with increasing
frequencyforthelatterpartofthefirstyearuntiltermina-
tion ofthe bioassay. Lesions indicative ofpneumonia were
observed in nearlyall rats atnecropsy. Ahighincidence of
toxic nephropathy was observed in treated rats. Toxic
nephropathywas noted in rats that died earlyinthe study
(as early as week 20 for male rats and week 28 for female
rats). Mortality ofrats was dose-related. Fifty percent of
the high dosemales had diedbyweek44 and 50percent of
the high dose females had died byweek 66.
In both male and female mice, administration of
tetrachloroethylene was associated with a significantly
increased incidence of hepatocellular carcinoma.
Hepatocellular carcinomas were observed in 2/17 (12 per-
cent) untreated control males, 2/20 (10 percent) vehicle
controlmales, 32/49 (65percent) low dosemales, 27/48 (56
percent) high dose males, 2/20 (10 percent) untreated
control females, 0/20 vehicle control females, 19/48 (40
percent)lowdosefemales, and19/48(40percent)highdose
females. Hepatocellular carcinomas metastasized to the
kidney in one untreated control male and to the lung in
three low dose males, one low dose female, and one high
dose female. Toxic nephropathy, similar to that observed
in rats, was also observed in treated but not control
mice.
Fisher exact tests indicated a highly significant
increased incidence of hepatocellular carcinoma for each
dosed group compared to each control group. Cochran-
Armitage tests showed a highly significant positive asso-
ciationbetween increased dosage and elevated tumorinci-
dence. Time-adjusted analyses, based on Kaplan and
Meiersurvival curves, indicated thatthe estimatedproba-
bility of observing hepatocellular carcinoma by week 91
was1.00inadosedmalemouseand 0.938inadosedfemale
mouse.
The results of the bioassay of tetrachloroethylene in
Osborne-Mendel rats do not allow an evaluation of the
carcinogenicity ofthis compound due to the high rate of
early death among the treated animals. However, under
the condition of this study, tetrachloroethylene is a liver
carcinogen in B6C3F1 mice ofboth sexes.
Synonyms: perchloroethylene; carbon dichloride
Report Date: 1977
Levels ofEvidence ofCarcinogenicity:
Male Rats:
Female Rats:
Male Mice:
Female Mice:
Inadequate Study
Inadequate Study
Positive
Positive
Note: Tetrachloroethylene was subsequently studied by
inhalation in F344 rats and B6C3F1 mice (See TR-311,
reported1986).
TR-14 Bioassay ofLindane for Possible
Carcinogenicity (CAS No. 58-89-9)
Lindane is an organochlorine pesticide that is registered
foruseinsoil,foliar,andseedtreatmentforalargevarietyof
fruitandvegetable crops, andforuse on livestock, pets, and
agriculturalpremises. Residuesoflindanemaybepersistent
in soil and foods. There may also be direct human exposure
to lindane through its use in pharmaceutical preparation or
in public health pest control.
A bioassay for possible carcinogenicity of lindane was
conductedbyadministeringthetestchemicalinthedietto
Osborne-Mendel rats and B6C3F1 mice.
Groups of50 rats ofeach sexwere administered lindane
at one oftwo doses for 80 weeks, then observed for 29-30
weeks. Time-weighted average doses for males were 236
or 472 ppm; those for females were 135 or 270 ppm.
Matched controls consisted ofgroups of10 untreated rats
ofeach sex; pooled controls, used forstatisticalevaluation,
consisted ofthematched-control groups combinedwith45
untreated male and 45 untreated female rats from similar
bioassays offour other test chemicals. All surviving rats
were killed at 108-110 weeks.
Groupsof50miceofeach sexwereadministeredlindane
atoneoftwodoses,either80or160ppm,for80weeks,then
observed for an additional 10-11 weeks. Matched controls
consisted of groups of 10 untreated mice of each sex;
pooled controls,usedforstatistical evaluation, consisted of
the matched-control groups combined with 40 untreated
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male and 40untreated femalemicefrom similarbioassays
offourothertestchemicals. All survivingmicewere killed
at 90-91 weeks.
Neitherthemeanbodyweightsofratsnorthose ofmice
showed consistent effects from the administration oflin-
dane. Thephysical condition ofthe survivingtreated mice
deteriorated duringthe final 6weeks on study. Exceptfor
the female matched-control group of rats, survival of all
groups of rats and mice was adequate for meaningful
statistical analyses ofthe incidence oftumors.
In rats, no tumors occurred at a statistically significant
incidence in the treated groups ofeither sex.
In mice, the incidence of hepatocellular carcinoma in
low-dose males was significant when compared with that
in the pooled controls (controls 5/49, low-dose 19/49,
P=0.001). Thisfinding, byitself, isinsufficientto establish
the carcinogenicity of lindane. The incidence of
hepatocellular carcinoma in high-dose male mice (9/46)
was not significantly different from that in the matched
(2/10) or pooled controls.
Itisconcludedthatundertheconditionsofthisbioassay,
lindane was not carcinogenic for Osborne-Mendel rats or
B6C3F1 mice.
Report Date: 1977
Levels of Evidence ofCarcinogenicity:
Male Rats:
Female Rats:
Male Mice:
Female Mice:
Negative
Negative
Negative
Netative
TR-15 Bioassay ofCaptan for Possible
Carcinogenicity (CAS No. 133-06-2)
Captan is a broad-spectrum fungicide which inhibits
mycelial growth from germinating fungus spores. As a
result, ithaseffectiveprotection action, althoughitwillnot
eradicate a preexisting infection. Because captan is a
nonpersistent fungicide, directions for use indicate that it
should be reapplied every week as necessary to maintain
control. Ithas been one ofthe mostwidelyusedfungicides
since its introduction in 1950.
A bioassay of technical-grade captan for possible car-
cinogenicity was conducted by administering the test mate-
rial in feed to Osborne-Mendel rats and B6C3F1 mice.
Groups of50 rats ofeach sex were administered one of
two doses ofcaptan for 80 weeks, then observed for 33 or
34weeks. The time-weighted average doses forboth sexes
of rats were 2,525 or 6,050 ppm. Matched controls con-
sisted of groups of 10 untreated rats of each sex; pooled
controls, used for statistical evaluation, consisted of the
matched controls combined with 75untreated male and 75
untreated female rats from similar bioassays of six other
test chemicals. All surviving rats were killed at 113-114
weeks.
Groups of50miceofeach sexwere administeredthetest
material at one oftwodoses, either8,000 or16,000 ppm, for
80 weeks, then observed for 11 weeks. Matched controls
consisted of groups of 10 untreated mice of each sex;
pooledcontrols,usedforstatistical evaluation, consisted of
the matched controls combined with 80 untreated male
and80untreatedfemalemicefromsimilarbioassays ofsix
other test chemicals. All surviving mice were killed at
90-91 weeks.
The mean body weights ofboth low- and high-dose rats
and high-dose mice were lower than those ofthe matched
controls throughout most of the study. Mortality rates did
not show statistically significant dose-related trends in
either sex ofeither species.
In rats, a positive dose-related trend and a difference
between incidences of tumors in high-dose and pooled-
control groups were found in females when the data for
adrenal cortical adenoma were combined with those for
adrenal cortical carcinoma (pooled controls, 0/64, low-dose
2/50, high-dose 3/47, P=0.047). There was also a positive
dose-related trendfortheincidence ofC-cell adenomaofthe
thyroid in female rats (pooled controls 1/66, low-dose 1/49,
high-dose4/44,P=0.035).Theseendocrinetumorsinfemale
ratsarebelievedtohavebeenspontaneous,andnotrelatedto
treatment.
In mice, the incidences ofpolypoid carcinoma (adenocar-
cinomain adenomatous polyp) ofthe duodenumwere statis-
ticallysignificantusingtestsforapositivedose-relatedtrend
both in male mice (pooled controls 0/68, low-dose 1/43, high-
dose3/46,P=0.033)andinfemalemice(pooledcontrols0/68,
low-dose 0/49, high-dose 3/48, P=0.022). When the inci-
dences ofadenomatouspolyp, NOS (nototherwisespecified),
were combinedwiththose ofpolypoid carcinomaforstatisti-
cal analysis, the tests for male mice indicated a substantial
increase in significance (pooled controls 0/68, low-dose 3/43,
high-dose 5/46, P=0.008).
Itisconcludedthatundertheconditionsofthisbioassay,
tumors in the duodenum ofB6C3F1 mice were associated
with treatment with captan, but there was no convincing
evidencethatthetumorsobservedinOsborne-Mendelrats
were related to treatment.
Synonym: N-((trichloromethyl)thio)-4-cyclohexene-1,2-
dicarboximide
Report Date: 1977
Levels ofEvidence ofCarcinogenicity:
Male Rats: Negative
Female Rats: Negative
Male Mice: Positive
Female Mice: Positive
TR-16 Bioassay ofPhosphamidon for
Possible Carcinogenicity (CAS No.
13171-21-6)
Phosphamidon is an organophosphorus compound used
as a broad-spectrum insecticide in agriculture since 1956.
It is toxic both systemically and by contact, and acts
through the inhibition ofcholinesterase. Phosphamidon is
currently registered for use by both ground and aerial
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applications on vegetables, fruits and field crops with
tolerances for residues from 0.1 to 1.0 ppm.
A bioassay of technical-grade phosphamidon for
possible carcinogenicity was conducted using Osborne-
Mendel rats and B6C3F1 mice. The test material was
administered in feed to 50 rats and 50 mice ofeach sex at
one oftwo doses, either 80 or 160 ppm. The rats were fed
the test chemical for 80 weeks, then observed without
compound administration for30 or 31weeks; the low-dose
male mice were fed for 71 weeks, then observed for 19
weeks; the high-dose male mice were fed for 62 weeks,
then observed for 28 weeks; and the low- and high-dose
female micewerefed for80weeks, then observed for10 or
11 weeks. Matched controls consisted of groups of 10
untreated rats or 10 untreated mice of each sex; pooled
controls consisted ofthe matched controls combined with
85 male and 85 female untreated rats or 80 male and 80
female untreated mice from similar bioassays of eight
othertestchemicals.Allsurvivingratswerekilledat110or
111weeks; all survivingmicewere killed at90 or 91weeks.
Hyperexcitabilityandtremors, bothindications ofphos-
phamidon toxicity, were observed in dosed rats and mice.
However, sufficient numbers ofall groups ofboth species
were atriskforthedevelopmentoflate-appearing tumors.
In male rats, the combined incidence of hemangiomas
and hemangiosarcomas in the spleen showed a statis-
tically significant (P=0.012) dose-related trend. However,
the comparison with matched controlswas notsignificant,
and the historical records ofthis laboratory on untreated
males ofthis strain show a tumor incidence of6/240 (3%)
with incidences in individual control groups as high as 3/9
(33%) and2/9 (22%), comparedwith5/49 (10%) seen inthe
high-dose group in this study. No hemangiomas or
hemangiosarcomas were found in the females.
In female rats, the Cochran-Armitage test for dose-
related trend was significant (P =0.003) for C-cell ade-
nomasandcarcinomas ofthethyroidwhenpooledcontrols
were compared with the dosed groups. The incidences of
these tumors were also significantwhen low-dose females
(P=0.003) and high-dose females (P= 0.004) were com-
pared directly with pooled controls. However, the histor-
ical records of this laboratory show a tumor incidence of
16/235 (7%) in untreated female rats of this strain of
femalerats,withincidences inindividual controlgroups as
high as 3/9 (33%) and 3/10 (30%); these data are therefore
considered marginal and insufficient to establish an asso-
ciation between the tumors and administration of the
chemical. In males, the incidence ofthese tumors was not
statistically significant.
In mice, no tumor occurred at a higher incidence in
dosed animals than in controls.
Itisconcludedthatundertheconditionsofthisbioassay,
technical-grade phosphamidon was not carcinogenic for
B6C3F1 mice. The data obtained in this bioassay with
Osborne-Mendel rats are insufficient to allow the inter-
pretation that technical-grade phosphamidon is car-
cinogenic in this species.
Synonym: dimethyl 2-chloro-2-diethyl-carbamoyl-1-
methylvinyl phosphate
Report Date: 1979
Levels ofEvidence ofCarcinogenicity:
Male Rats:
Female Rats:
Male Mice:
Female Mice:
Equivocal
Equivocal
Negative
Negative
TR-17 Bioassay ofPhotodieldrin for
Possible Carcinogenicity (CAS No.
13366-73-9)
Photodieldrin is a photochemical conversion product of
dieldrin. Although it has never been produced commer-
cially, photodieldrin was selected for testing in 1969
because it was a photochemical conversion product of
dieldrin. At that time dieldrin was used extensively as a
pesticide.
A bioassay of dieldrin-free photodieldrin (synthesized
by Gulf South Research Institute) for possible car-
cinogenicity was conducted by administering the test
material in feed to Osborne-Mendel rats and B6C3Fj
mice.
Groupsof50ratsofeach sexwereinitiallyadministered
photodieldrin at one of two doses, either 5 or 10 ppm.
Because of neurotoxic signs, doses in the females were
reducedafter30weeks.Totalperiodsoftreatmentforlow-
and high-doge males andlow-dosefemaleswere80weeks,
followedbyperiodsof31or32weeksofadditionalobserva-
tion; the total period of treatment for the high-dose
females was 59 weeks, followed by a period of additional
observationof53weeks.Thetime-weighted averagedoses
for the females were 3.4 or 7.5 ppm. Matched controls
consisted of10untreated rats ofeach sex; pooled controls,
used for statistical evaluation, consisted of the matched
controls combined with 65 untreated male and 65 untre-
atedfemale ratsfromsimilarlyperformedbioassays ofsix
other test chemicals. All surviving rats were killed at
111-112 weeks.
Groups of 50 mice of each sex were administered pho-
todieldrin at one oftwo doses, either 0.32 or 0.64 ppm, for
80 weeks, then observed for an additional 13 weeks.
Matched controls consisted ofgroups of10untreated mice
ofeach sex at each dose; pooled controls, used for statisti-
calevaluation, consistedofthematchedcontrols combined
with60untreatedmaleand 60untreatedfemalemicefrom
similarly performed bioassays ofsix other test chemicals.
All surviving mice were killed at 93 weeks.
Meanbodyweights attainedbylow- andhigh dosemale
and female rats and mice were essentially unaffected by
photodieldrin. Convulsions and hyperactivity were noted
in treated male and female rats and in male mice. Mor-
talityratesofeithersexoreitherspecieswere notaffected
by treatment.
In rats, benign tumors (adenoma and fibroadenoma) of
the mammary gland in females showed a dose-related
trend (P=0.039) compared with matched, but not pooled,
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controls (8/72 pooled controls, 0/9 matched controls, 5/50
low-dose, 10/49high-dose).Adenocarcinomaofthemamm-
aryglandoccurredintwoadditionallow-dosefemales.The
incidences ofthese tumors in either ofthe treated groups
were not significantly higher than those in the control
groups using either matched or pooled controls. Three
papillary and follicular-cell adenomas and one papillary
adenocarcinoma of the thyroid occurred in the low-dose
females, giving astatistically significant increase overthe
pooled controls (P=0.022), but these thyroid tumors did
notoccurinthehigh-dose animals.Thedose-relatedtrend
was not statistically significant using either pooled or
matched controls, and the incidence in the low-dose group
is not greater than that in the historical controls. In male
rats, the incidence ofhemangiomas showed a statistically
significantdose-relatedtrend (P=0.021)usingpooled con-
trols, butthe directcomparison ofthethreehemangiomas
in the high-dose groupwith the pooled-control group was
not statistically significant. Furthermore, three
hemangiomas is asmall number, and the tumors occurred
in more than one anatomic site (two in the spleen, one in
subcutaneous tissue). The occurrence of these tumors
cannot clearly be associated with treatment.
In mice, there were no tumors that were statistically
significant in treated groups ofeither sex.
Itisconcludedthatundertheconditionsofthisbioassay,
photodieldrin was not carcinogenic for Osborne-Mendel
rats or B6C3F1 mice.
Synonym: 1,1,2,3,3a,7a-hexachloro-exo-5,6-epoxydeca-
hydro-2,4,7-metheno-lH-cyclopenta[a]pentalene
Report Date: 1977
Levels ofEvidence ofCarcinogenicity:
Male Rats: Negative
Female Rats: Negative
Male Mice: Negative
Female Mice: Negative
TR-18 Bioassay of3,3'-Iminobis-l-propanol
Dimethanesulfonate (Ester) Hydrochloride
(IPD) for Possible Carcinogenicity (CAS No.
3458-22-8)
3,3'-Iminobis-1-propanol dimethanesulfonate (ester)
hydrochloride, hereinafter called IPD, was synthesized
from bis(3-hydroxypropyl)amine and methanesulfonic
acid anhydride. It was found to have antitumor activity
against anumber ofexperimental tumors thatwere natu-
rally resistant to nitrogen mustard and has been used in
Japan for the treatment of myelogenous leukemia. IPD
was selected for carcinogen bioassay as one agent in a
series of anticancer drugs that are administered chron-
icallyin the treatment ofhuman cancer.
A bioassay of IPD for possible carcinogenicity was
conducted by administering the test chemical intra-
peritoneally to Sprague-Dawley rats and B6C3F1 mice.
The IPDwasinjected threetimesperweektogroupsof
35 animals, using doses of12,24, or48mg/kgfor therats,
and 20 or 40 mg/kg for the mice. Rats at 12 mg/kg were
treated for 52weeks. Because ofthe toxicity ofthe chemi-
cal, administration of IPD for the group receiving 24 mg/
kg was discontinued atweek 34. Rats receiving 48 mg/kg
weretreateduntilallhaddiedatweek23(males)andweek
27 (females). Both groups of mice were treated for 52
weeks. All survivors were killed afterpost-administration
periods that varied among groups.
With rats, untreated and vehicle-control groups, each
consisting of 10 males and 10 females, were started with
the high- and mid-dose groups and additional untreated
and vehicle-control groups of the same size were started
with the low-dose groups. With mice, untreated and
vehicle-control groups each consisted of 15 males and 15
females.
The toxicity of IPD was associated with lower mean
bodyweights and lower rates ofsurvival ofboth the rats
andmice.Theshortenedlifespans,particularlyintherats,
reduced the likelihood ofthe development oftumors.
Inrats,peritonitis andfibrous adhesions, possibly, from
direct irritation by the test chemical were observed in
mosttreated rats at necropsy. Sarcoma, fibroma, orfibro-
sarcoma oftheperitoneum occurredin twolow-dosemale,
one mid-dose male, and one mid-dose female rats, but not
in any control animals. Because ofthis lowincidence, and
because irritation bythe test chemical have been involved
in the pathogenesis, these tumors may have been due to
local effects ofthe chemical.
In mice, lymphomas were observed at the following
incidences (males: controls 0/14, low-dose 0/26, high-dose
3/21; females: controls1/15,low-dose2/29,high-dose, 6/27).
TheThrone testforlife-table analysis oftheprobabilityof
survivalwithoutlymphomaindicated asignificantpositive
dose-related increase of lymphomas with a probability
level of0.011 for male mice and 0.003 for female mice.
Squamous-cell carcinoma was noted in the mice (low-
dose males 6/26, high-dose females 2/27). Seven of these
tumorswere observed in subcutaneous tissueintheingui-
nal region near the sites ofinjection. Although not statis-
tically significant, this tumor may be associated with
administration of IPD.
TImors of the peritoneum in rats and tumors in the
subcutaneous tissue in mice may have been due to local
effects related to administration ofthe test chemical. The
lymphomas inmice, although marginally significant, were
too few in number to clearly be related to dosing.
Conclusions from this study are limitedbyearlydeaths
and toxicity, but the appearance of tumors in the per-
itoneum near the injection sites in both rats and mice
indicate the carcinogenic potential of IPD.
Report Date: 1978
Levels ofEvidence ofCarcinogenicity:
Male Rats:
Female Rats:
Male Mice:
Female Mice:
Equivocal
Equivocal
Equivocal
Equivocal
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TR-19 Bioassay ofProcarbazine for
Possible Carcinogenicity (CAS No. 366-70-1)
Procarbazine is amethylhydrazine derivativewhichhas
been shown to have effective antineoplastic activity in
advanced Hodgkin's disease and in oat-cell carcinoma of
the lung. It has also been shown to have carcinogenic
activity in rats and mice.
Abioassay ofprocarbazine forpossible carcinogenicity
was conducted by administering the test chemical by
intraperitoneal injection to Sprague-Dawley rats and
B6C3F1 mice.
Groups of 34 or 35 males and 35 or 36 females ofboth
species were administered procarbazine at one of two
doses, either15or30mg/kgforrats, and either6 or12mg/
kgformice. Injectionsweremadethreetimesperweekfor
26weeks forthe rats and 52weeksforthemice. Following
the periods ofinjection, the dosed animals were observed
for a maximum period of 60 weeks for rats and 33 weeks
formice, depending on survival. Vehicle controls, used for
statistical evaluation, consisted of 10 rats and 15 mice of
each sex, administered saline solution on the same sched-
ule as thetestsolution; the samenumbers ofrats andmice
served as untreated controls. Pooled controls consisted of
the vehicle controls from this bioassay together with the
vehicle controls from two other bioassays similarly per-
formed at the same laboratory. The pooled-control groups
consisted of 40 rats of each sex and 45 mice of each sex.
Surviving rats were killed at86weeks and survivingmice
were killed at 85 weeks.
Mean body weights of low- and high-dose rats and of
high-dosefemalemicewerelowerthanthoseofthevehicle
controls. Survival rates of both rats and mice showed
significant dose-related trends.
In rats, malignant lymphomas, adenocarcinomas ofthe
mammary gland, and the combination of olfactory neu-
roblastomas, adenocarcinomas, orcarcinomasofthebrain,
olfactory bulb, or cerebrum were induced in statistically
significant numbers.
In mice, malignant lymphomas or leukemias, olfactory
neuroblastomas or undifferentiated carcinomas, alveolar/
bronchiolar adenomas, and adenocarcinomas oftheuterus
were induced in statistically significant numbers.
Itisconcludedthatundertheconditionsofthisbioassay,
procarbazine was carcinogenic for both Sprague-Dawley
rats and B6C3F1 mice, producing several types oftumors
in both ofthese two species.
Synonym: N-iso-propyl-a-(2-methylhydrazino)-p-tolu-
amide hydrochloride
Report Date: 1979
Levels ofEvidence ofCarcinogenicity:
Male Rats: Positive
Female Rats: Positive
Male Mice: Positive
Female Mice: Positive
TR-20 Bioassay ofDapsone for Possible
Carcinogenicity (CASNo. 80-08-0)
Dapsoneistheparentchemicalofthesulfonedrugs, and
the major therapeutic agent in this group for the treat-
mentofleprosy. Itis also administered to treat dermatitis
herpetiformisandmalaria,andisusedincombinationwith
radiotherapy in the treatment of gynecologic neoplasms.
Dapsone is also sold for use as an accelerator in epoxy
resins.
Abioassay ofdapsone for possible carcinogenicity was
conducted by administering the test material in feed to
Fischer 344 rats and B6C3F1 mice.
Groups of35 rats and 35 mice ofeach sex were admin-
istered dapsone at one of two doses, either 600 or 1,200
ppmforrats andeither500or1,000ppmformice.Therats
and mice were treated for 78 weeks; the rats were then
observed for 26-28 weeks, the mice for 28-30 weeks.
Matched controls consisted ofgroups of15 untreated rats
and14untreatedmiceofeachsex,pooledcontrols,usedfor
statistical evaluation, consisted of the matched controls
combined with 30 male and 30 female untreated rats and
29 male and 29 female untreated mice from similarly
performed bioassays oftwo other test chemicals. All sur-
vivingratswerekilled at104-106weeks, all survivingmice
at 106-108 weeks.
TYeated rats and mice had lower mean body weights
than the corresponding controls; when treatment was
discontinued at week 78, both species showed some
increase in body weight. Survival among rats was
unaffectedbytreatmentwith dapsone; adequate numbers
ofanimals survived for meaningful statistical analyses of
theincidences oftumors. Dapsone did notadverselyaffect
thesurvivalofmice, asshownbythetestforpositive dose-
related trend. Suppurative bronchopneumonia was found
in some mice in all matched-control and treated groups.
Several control males died early in the study, while sur-
vival of the other groups of mice was not affected until
week 75.
Among rats, mesenchymal tumors of the abdominal
organs or peritoneal tissues occurred in 13/35 low-dose
males and 22/33 high-dose males. None occurred among
control males or among control or treated females. The
most commonly occurring tumors were fibroma, fibrosar-
coma, or sarcoma, NOS (not otherwise specified), of the
spleen and the peritoneum. In male rats, these mesenchy-
mal tumors ofthe spleenoccurredin astatistically signifi-
cant incidence in both treated groups (low-dose 6/34,
P=0.006; high-dose 14/32, P<0.001) when compared with
pooled controls. Intheperitoneum, theincidences ofthese
mesenchymal tumors were significant in both treated
groups (low-dose5/35, P=0.014;high-dose6/33,P=0.005)
when compared with the pooled controls. No tumors
related to treatment were found in female rats.
Amongthemice,therewerenotumorsthatcouldclearly
be related to treatment.
Itisconcludedthatundertheconditionsofthisbioassay,
dapsone was not carcinogenic for female Fischer 344 rats
or B6C3F1 mice ofeither sex. Dapsone was carcinogenic
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(sarcomagenic) for male Fischer 344 rats, causing mes-
enchymal tumors in the spleen and the peritoneum.
Synonym: 4,4-sulfonyldianiline
Report Date: 1977
Levels ofEvidence ofCarcinogenicity:
Male Rats: Positive
Female Rats: Negative
Male Mice: Negative
Female Mice: Negative
TR-21 Bioassays ofAldrin and Dieldrin for
Possible Carcinogenicity (CAS No. 309-00-2)
(CASNo.60-57-1)
Aldrin and dieldrin are organochlorine insecticides of
the cyclodiene group. These chemicals are neurotoxins,
and their predominant effect is the stimulation of the
nervoussystem. Bothaldrinanddieldrinarelipophilicand
accumulateinmammaliantissues.Aldrinundergoesmeta-
bolic conversion to the epoxide, dieldrin, and because of
this structural relationship, reports of the bioassays of
both chemicals have been combined in this single report.
Bioassays of technical-grade aldrin and dieldrin for
possible carcinogenicitywereconductedbyadministering
the test materials in feed to Osborne-Mendel rats and
B6C3F1 mice.
Aldrin
Groups of50 rats ofeach sex were administered aldrin
at one of two doses, either 30 or 60 ppm. Male rats were
treated for 74weeks, followed by37-38 weeks ofobserva-
tion; female rats were treated for 80 weeks, followed by
32-33weeks ofobservation. Matched controls consisted of
groups of 10 untreated rats of each sex; pooled controls,
used for statistical evaluation, consisted of the matched-
control groups combined with 58 untreated males and 60
untreated females from similar bioassays ofother chemi-
cals. All surviving rats were killed at 111-113 weeks.
Groups of50mice ofeach sexwere administered aldrin
at one oftwo doses for 80 weeks, then observed for 10-13
weeks. Time-weighted average doses were 4 or 8 ppm for
males and 3 or 6 ppm for females. Matched controls
consisted of groups of 20 untreated male mice and 10
female mice; pooled controls, used for statistical evalua-
tion, consisted of the matched-control groups combined
with92untreatedmaleand79untreatedfemalemicefrom
similar bioassays of other chemicals. All surviving mice
were killed at 90-93 weeks.
Mean body weights attained by the rats and mice fed
dietscontainingaldrinweresimilartothoseofthecontrols
during the first year of the study; however, mean body
weights ofthe treated rats were lower than those of the
controls during the second year of the study. Hyperex-
citabilitywas observed in all treated groups with increas-
ingfrequencyand severity duringthe secondyear. Aldrin
produced nosignificanteffectonthemortalityofrats orof
male mice, but there was a dose-related trend in the
mortalityoffemalemice,primarilyduetotheearlydeaths
in the high-dose groups.
Therewasanincreased combinedincidenceoffollicular-
cell adenoma and carcinoma of the thyroid both in male
rats fed aldrin (matched controls 3/7, pooled controls 4/48,
low-dose 14/38, high-dose 8/38) and female rats fed aldrin
(matched controls1/9,pooled controls3/52, low-dose 10/39,
high-dose 7/46). These incidences were significant in the
low-dose but not in the high-dose groups both of males
(P=0.001) and females (P =0.009) when compared with
the pooled controls. Comparisons with matched controls,
however, were not signiflcant.
Cortical adenoma of the adrenal gland was also
observed in aldrin-treated rats in significant proportions
(P=0.001) in low-dose (8/45) but not in high-dose (1/48)
females when compared with pooled controls (0/55).
Because these increased incidences were not consistently
significant when compared with matched rather than
pooled control groups, it is questionable whether the inci-
dences of any of these adrenal tumors were associated
with treatment.
In male mice, there was a significant dose-related
increase in the incidence of hepatocellular carcinomas
(matched controls 3/20, pooled controls 17/92, low-dose
16/49, high-dose 25/45) when compared with either
matched controls (P =0.001), orpooled controls (P<0.001).
Theincidenceinthehigh-dose groupwas significantwhen
compared with matched controls (P=0.002) or pooled
controls(P<0.001).
Dieldrin
Groups of50 rats and 50 mice ofeach sex were admin-
istered dieldrin at one of two doses. Low-dose rats and
both low- and high-dose mice were treated for 80 weeks,
followedbyobservationperiodsof30-31weeksforratsand
10-13 weeks for mice. Treatment of high-dose rats was
terminated after 59weeks and followed by 51-52weeks of
observation. Time-weighted average doses for rats were
29 or 65 ppm; doses for mice were 2.5 or 5 ppm. Matched
controls consisted of groups of 10 untreated rats of each
sexand20untreatedmale mice and 10femalemice; pooled
controls, used for statistical evaluation, consisted of the
matched-control groups combinedwith untreated animals
from similarbioassays ofother chemicals (58 male and 60
femalerats,92maleand 79femalemice).Allsurvivingrats
werekilled at110-111weeks, andall survivingmiceat90-93
weeks.
Mean body weights attained by the rats and mice fed
diets containing dieldrin showed little or no differences
compared with those ofthe controls during the first year
of the study; however, mean body weights of the treated
rats were lower than those of the controls during the
second year ofthe study. Hyperexcitability was observed
inalltreated groupswithincreasingfrequencyduringthe
second year, especially in high-dose rats.
There was a marked increase in the mortality rate of
rats during the first 90 weeks of the study. However,
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becauseofthehighratesofmortalityinthecontrolgroups
during the remaining 20 weeks, survival could not be
shown to be statistically dose responsive.
In rats, there was a significant (P=0.007) difference
between the combined incidence of adrenal cortical ade-
noma or carcinoma in the low-dose females (6/45) and that
in the pooled controls (0/55).Although this tumorwas also
found in animals treated with aldrin, it is not clearly
associated with treatment, because the incidence in the
high-dose (2/40) was not significant, and the incidences
were not significant when matched, rather than pooled,
controls were used for comparison.
In male mice, there was a significant positive dose-
related trend (P=0.020) in the incidence ofhepatocellular
carcinomas using the pooled controls (pooled controls
17/92, low-dose 12/50, high-dose 16/45). When high-dose
males were comparedwith thepooled controls, the results
were also significant (P=0.025).
It is concluded that under the conditions of these bio-
assays, none ofthe tumors occurring in Osborne-Mendel
rats treatedwith aldrin or dieldrin could clearlybe associ-
ated treatment.
Aldrin was carcinogenic for the liver of male B6C3Fj
mice producing hepatocellular carcinomas. With dieldrin,
there was a significant increase in the incidence of
hepatocellular carcinomas in the high-dose males which
may be associated with treatment.
Report Date: 1978
Levels ofEvidence ofCarcinogenicity:
For Aldrin:
Male Rats:
Female Rats:
Male Mice:
Female Mice:
For Dieldrin:
Male Rats:
Female Rats:
Male Mice:
Female Mice:
Equivocal
Equivocal
Positive
Negative
Negative
Negative
Equivocal
Negative
Note: Dieldrin was also studied by administration in feed
to F344 rats (See TR-022, reported 1978).
TR-22 Bioassay ofDieldrin for Possible
Carcinogenicity (CAS No. 60-57-1)
Dieldrin is achlorinated cyclodienepesticide. Itis also a
metabolic conversion product of aldrin, another pesticide,
and can be expected to appear in the environment follow-
ing the use of either chemical. Dieldrin was first intro-
duced in the 1950's for use by cotton growers when the
chemical was found to be more effective than aldrin, and
later, was used as an insecticide for other crops, for public
health pest control, and for mothproofing woolen goods.
A bioassay of purified technical-grade dieldrin for
possible carcinogenicity was conducted by administering
the test chemical in feed to Fischer 344 rats.
Groupsof24rats ofeach sexwereadministered dieldrin
at one of three doses, either 2, 10, or 50 ppm, for 104-105
weeks. Matched controls consisted ofgroups of24 untre-
ated rats of each sex. All surviving rats were killed at
104-105 weeks.
Bodyweights ofthe ratswere essentiallyunaffected by
the treatment, but typical signs of organochlorine intox-
ication including hyperexcitability, tremors, and coma
were observed in high-dose males beginning in week 76
and in high-dose females beginning in week 80. Survival
was not adversely affected, and adequate numbers ofrats
were available for meaningful statistical analyses of the
incidences oftumors.
Avariety ofneoplasms occurred in control and treated
rats; however, the incidences were not related to treat-
ment.
Itisconcludedthatundertheconditionsofthisbioassay,
dieldrin was not carcinogenic in Fischer 344 rats.
Report Date: 1978
Levels ofEvidence ofCarcinogenicity:
Male Rats:
Female Rats:
Negative
Negative
Note: Dieldrinwas alsostudiedinfeedinOsborne-Mendel
rats and B6C3F1 mice (See TR-21, reported 1978).
TR-23 Bioassay ofPicloram for Possible
Carcinogenicity (CAS No. 1918-02-1)
Picloram is a systemic herbicide registered by EPA for
only nonfood use to control broadleaf weeds and woody
plants.Thechemicalcanreplacetheplantgrowthhormone
indoleacetic acid, and inhibit the synthesis of protein in
plants.
A bioassay of technical-grade picloram for possible car-
cinogenicity was conducted by administering the test che-
mical in feed to Osborne-Mendel rats and B6C3F1 mice.
Groups of 50 rats and 50 mice ofeach sex were admin-
isteredpicloraminthedietatoneofthefollowingdosesfor
80 weeks. Time-weighted average doses for the rats were
7,437 or14,875 ppm; thoseforthemicewere2,531 or5,062
ppm. The rats were then observed for 33 weeks, the mice
for 10 weeks. Matched controls consisted of groups of 10
untreated rats or 10 untreated mice of each sex; pooled
controls, used for statistical evaluation, consisted of the
matched control groups combinedwith 33 untreated male
and 30 untreated female rats or mice from similar bio-
assays of three other test chemicals. All surviving rats
were killed at 113 weeks; all surviving mice were killed at
90weeks.Survivalwasadequateformeaningfulstatistical
analyses of the incidences of tumors in rats and mice of
both sexes.
Mean body weights of the high-dose rats were lower
thanthose ofmatched controls duringthe firstpartofthe
study; however, beginning at approximately 80 weeks,
meanweights ofcontrolswerelowerthan those oftreated
animals. Bodyweights ofthe mice were unaffected bythe
picloram.
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In rats, a relatively high incidence of follicular hyper-
plasia, C-cell hyperplasia, and C-cell adenoma ofthe thy-
roid occurred in both sexes. However, the statistical tests
for adenoma did not show sufficient evidence for associa-
tion ofthe tumor with picloram administration.
An increased incidence of hepatic neoplastic nodules
wasobservedintreatedmaleandfemalerats as compared
with untreated animals. This lesion is considered to be a
benign tumor. In male rats the lesion appeared only in
threeanimalsofthelow-dosetreatmentgroupandwasnot
signiflcantwhen comparedwith the controls; however, the
test forpositive dose-related trend in females was signifi-
cant (pooled controls 0/39, low-dose 5/50, high-dose 7/49,
P=0.016) and the incidence in the high-dose group was
significant (P=0.014) when compared with that in the
pooled-control group.
There was also one hepatocellular carcinoma in a low-
dose male rat and one in a high-dose female rat. In both
males and females, therewas apossiblytreatment-related
lesion of the liver diagnosed as foci of cellular alteration.
The incidences of this latter lesion were, female rats:
matchedcontrols1110,low-dose8/50,high-dose18/49;male
rats:matchedcontrols0/10,low-dose12/49,high-dose5/49.
Thus, there is evidence thatpicloram affected the livers of
rats of both sexes, but more particularly those of the
females.
No tumors were found in male or female mice or male
rats at incidences that could be significantly associated
with treatment, and it is concluded that picloram was not
carcinogenic for B6C3F1 mice or male Osborne-Mendel
rats.
In female rats, however, the incidence of neoplastic
nodules of the liver, benign tumors, was associated with
treatment with picloram. It is concluded that under the
conditions of the bioassay, the findings are suggestive of
theability ofthecompound toinducebenign tumorsinthe
livers offemale Osborne-Mendel rats.
Synonym: 4-amino-3,5,6-trichloropicolinic acid
Report Date: 1978
Levels of Evidence ofCarcinogenicity:
Male Rats:
Female Rats:
Male Mice:
Female Mice:
Negative
Equivocal
Negative
Negative
TR-24 Bioassay of Malathion for Possible
Carcinogenicity (CAS No. 121-75-5)
Malathion is an organophosphorus insecticide and
acaricide first synthesized in the United States in 1952.
Malathion primarily affects the nervous system by inhibi-
tion of cholinesterase activity and subsequent accumula-
tion of acetylcholine. However, it has a low mammalian
toxicity. Malathionisapprovedfor awidevarietyofuses as
aninsecticide and acaricide onfield crops, fruits, nuttrees,
vegetables, livestock, agricultural premises, and land. Tol-
erancesforresidues ofmalathionhavebeenestablished on
many ofthese products.
A bioassay of technical-grade malathion for possible
carcinogenicity was conducted by administering the test
chemical in feed to Osborne-Mendel rats and B6C3Fj
mice.
Groups of 50 rats of each sex were administered mal-
athion at one oftwo doses for 80weeks, then observed for
33 weeks. Time-weighted average doses were 4,700 or
8,150 ppm. Matched controls consisted of groups of 15
untreatedrats ofeach sex;pooledcontrolsconsisted ofthe
matched controls combinedwith 40untreatedmale and40
untreatedfemale rats from similarbioassays offourother
test chemicals. All surviving rats were killed at 108-113
weeks.
Groups of 50 mice of each sex were administered mal-
athion at one oftwo doses, either 8,000 or 16,000 ppm, for
80 weeks, then observed for 14 or 15 weeks. Matched
controls consisted of groups of 10 untreated mice of each
sex; pooled controls consisted of the matched controls
combinedwith 40untreated male and 40untreated female
mice from similar bioassays of four other test chemicals.
All surviving mice were killed at 94 or 95 weeks.
Mortality in either rats or mice was not significantly
relatedtothe administration ofmalathion. Sufficientnum-
bers of animals were at risk in the dosed and control
groupsofratsandmiceofeach sexfordevelopmentoflate-
appearing tumors.
In female rats, three follicular-cell carcinomas and one
follicular-cell adenoma ofthethyroid occurred inthehigh-
dose group, andthreefollicular-cellhyperplasias occurred
in the low-dose group. The incidence of these tumors
showed a statistically significant (P =0.026) dose-related
trend; however, the results of the Fisher exact test for
direct comparison between the dosed and control groups
werenotsigniflcant. Moredosedmalesthandosedfemales
had either tumors or hyperplasia of the follicular cells of
the thyroid; however, because of the higher incidence of
tumors amongthe male controls, none oftheresults ofthe
statistical tests were significant. These thyroid tumors
were not considered to be associated with the administra-
tion ofmalathion.
In male mice, hepatocellular carcinoma occurred at the
following incidences: matched controls 2/10, pooled con-
trols 5/49, low-dose 7/48, high-dose 11149. In addition,
neoplastic nodules occurred in 3/49 pooled-control and
6/49 high-dose animals. When the combined incidence of
these neoplasms in the dosed animals was compared with
that of the pooled controls, the dose-related trend was
P =0.019andthe directcomparisonofthehigh-dosegroup
with the control group was P = 0.031. Thus, none of the
direct comparisons of dosed groups with controls were
significant using the Bonferroni criteria. In addition, the
historical controlsfromthislaboratoryhadseveral control
groups with incidences of 35-40% hepatocellular car-
cinoma, rates which are comparable with the incidence of
this tumor in the dosed male mice of the present study.
Thus, these liver tumors are not considered to be associ-
ated with the administration ofmalathion. The incidences
of liver tumors in dosed females were not statistically
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significant when compared with that in control animals.
Itisconcludedthatundertheconditions ofthisbioassay,
therewas no clearevidence oftheassociation ofthe tumor
incidence with the administration of malathion to
Osborne-Mendel rats or B6C3F1 mice.
Synonym: S-(1,2-dicarbethoxyethyl)-Q O-dimethyldithio-
phosphate
Report Date: 1978
Levels ofEvidence ofCarcinogenicity:
Male Rats:
Female Rats:
Male Mice:
Female Mice:
Negative
Negative
Negative
Negative
Note: Malathion was subsequently studiedbyadministra-
tion in feed to F344 rats (See TR-192, reported 1979).
TR-25 Bioassay of Chloramben for
Possible Carcinogenicity (CAS No. 133-90-4)
Chloramben has been used since 1958 as apreemergent
herbicide to control shallow, germinating,broadleafweeds
and annual grasses. Applied as a spray at the time of
planting, chloramben remains effective in the soil for
several weeks until crops have become well established.
A bioassay of technical-grade chloramben for possible
carcinogenicity was conducted by administering the test
material in feed to Osborne-Mendel rats and B6C3F1
mice. Groups of 50 rats and 50 mice of both sexes were
administered chloramben at oneoftwodoses, either10,000
or 20,000 ppm. The rats were treated for 80 weeks, then
observed for 32 or 33 weeks; the mice were treated for 80
weeks, then observed for 11 or 12weeks. Matched controls
consisted of groups of10 untreated rats and 10 untreated
mice of each sex; pooled controls, used for statistical
evaluation, consisted of these matched controls combined
with 75untreated male and 75 untreated female rats or 70
untreated male and 70 untreated female mice from simi-
larly performed bioassays of six other test chemicals.
Surviving rats were killed at 112 or 113 weeks; surviving
mice were killed at 91 or 92 weeks.
Bodyweights andmortalityofthetreated animals were
notmarkedlyaffectedbychloramben undertheconditions
of the bioassay. The various clinical signs observed were
common to both treated and control groups.
In male rats, hemangiomas occurred at a significantly
higherincidence inthelow-doseanimals thaninthepooled
controls (controls 0/73, low-dose 5/48, P = 0.009). This
lesion was not considered to be related to the administra-
tion of chloramben, since the tumor did not occur at a
significantly higherincidence in the high-dose group than
in the pooled-control group, and the incidences did not
show a significant dose-related trend.
In both male and female mice, the incidences of
hepatocellular carcinoma showed significant dose-related
trends using pooled controls (for females: controls 9/69,
low dose 16/48, high-dose 14/48, P = 0.029; for females
controls 2/67, low-dose 7/48, high-dose 10/50, P= 0.004).
Direct comparisons showed significantly higher inci-
dences ofthe tumor in the low-dose males (P=0.008) and
in the high-dose females (P= 0.003) than in the pooled
controls. Probabilitylevels ofP=0.028in high-dose males
and P=0.027 in low-dose females were attained. In male
mice, however, the incidence of hepatocellular carcinoma
was considered to be only marginally associated with the
administration ofchloramben because ofthe variations in
the spontaneous incidence of this lesion in male mice
encountered at this laboratory.
In conclusion, under the conditions of this bioassay,
there were no tumors in Osborne-Mendel rats that were
significantly related to administration ofthe chemical. In
B6C3F1 female mice, chloramben was carcinogenic, pro-
ducing hepatocellular carcinomas in treated animals.
Report Date: 1977
Levels of Evidence ofCarcinogenicity:
Male Rats: Negative
Female Rats: Negative
Male Mice: Equivocal
Female Mice: Positive
TR-26 Bioassay ofNitrofen for Possible
Carcinogenicity (CAS No. 1836-75-5)
Nitrofen, a substituted diphenyl ether, is one ofseveral
agricultural pesticides selected for bioassay by the
National Cancer Institute because of a lack of adequate
chronic toxicity data.
Abioassay oftechnical-grade nitrofen for possible car-
cinogenicity was conducted using Osborne-Mendel rats
and B6C3F1 mice. Nitrofen was administered in the feed,
ateitheroftwoconcentrations, togroupsof50maleand50
female animals of each species. The time-weighted aver-
age high and low dietary concentrations ofnitrofen were
3,656 and 2,300ppmformale rats,2,600and 1,300ppmfor
female rats, and 4,696 and 2,348 ppm for both male and
female mice, respectively. After a 78-week treatment
period, observation of the low dose and control male and
all female rats continued for an additional 32 weeks;
observation of the high dose male rats continued for an
additional 4 weeks. All mice were observed for an addi-
tional 12 weeks after the 78-week treatment period.
For each species, 20 animals ofeach sexwere placed on
test as controls. No nitrofen was added to their diet.
The incidence of carcinomas of the pancreas had a
statistically significant positive association with con-
centration of nitrofen in the diet of female rats. The
incidence of this tumor in high dose female rats was
significant when compared to controls. Poor survival
related tochemicaltoxicityprecludedtheevaluation ofthe
carcinogenicity ofnitrofen in male rats.
In mice of both sexes, the incidence of hepatocellular
carcinoma at both high and low dose levels was highly
significant when compared to the controls. The incidence
ofhemangiosarcoma ofthe liverhad astatistically signifi-
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cantrelationshipwithnitrofen concentration inthedietfor
mice of both sexes, and the incidence in high dose male
mice was significant when compared to controls.
The results of this study indicate that orally admin-
istered technical-grade nitrofen is a liver carcinogen in
B6C3F1 mice ofboth sexes. Nitrofen is also carcinogenic
to female Osborne-Mendel rats.
Synonyms: 2,4-dichloro-1-(4-nitrophenoxy)-benzene;
2,4-dichlorophenyl-p-nitrophenyl ether; nitrophene, Tok
E-25; Nip
Report Date: 1978
Levels ofEvidence ofCarcinogenicity:
Male Rats: Inadequate Study
Female Rats: Positive
Male Mice: Positive
Female Mice: Positive
Note: Nitrofen was subsequently studied by administra-
tion in feed to F344 rats and B6C3F1 mice (See TR-184,
reported 1979).
TR-27 Bioassay of1,1,2,2-
Tetrachloroethane for Possible
Carcinogenicity (CAS No. 79-34-5)
1,1,2,2,-Tetrachloroethane, an aliphatic chlorinated
hydrocarbon, is one of a group of halogenated solvents
selected for bioassay by the National Cancer Institute.
Solvents were selected on the basis oflarge-scale produc-
tion, extensive use, and lack of adequate chronic toxicity
data.
A bioassay for possible carcinogenicity of technical-
grade 1,1,2,2-tetrachloroethane was conducted using
Osborne-Mendel rats and B6C3F1 mice. At initiation of
thestudytheratswereapproximately 7weeksold,andthe
mice were approximately 5 weeks old. 1,1,2,2-
Tetrachloroethaneincornoilwasadministeredbygavage,
at either oftwo dosages, to two groups of50 male and 50
female animals ofeach species, 5 days a week. Treatment
was over a period of 78 weeks, followed by observation
periods of32weeks forthe rats and 12weeks forthemice.
The high and low time-weighted average dosages were,
respectively, 108 and62mg/kg/dayformalerats, 76and43
mg/kg/day forfemale rats, and 282 and 142 mg/kg/day for
the mice ofboth sexes.
For each species, 20 animals ofeach sexwere placed on
testasvehiclecontrols.Theseanimalswereintubatedwith
corn oil atthe same rate as the high dose animals. Twenty
animals of each sex were placed on test as untreated
controls for each species. These animals were not intu-
bated.
Among mice, hepatocellular carcinomas were observed
in 2/16 (13 percent) male untreated controls, V18 (6 per-
cent) male vehicle controls, 13/50 (26 percent) low dose
males, 44/49 (90 percent) high dose males, 0/18 female
untreated controls, 0/20 female vehicle controls, 30/48 (63
percent) low dose females, and 43/47 (91 percent) of the
high dose females. This incidence of hepatocellular car-
cinoma indicated a highly significant (P<0.001) positive
dose-related trend in mice ofboth sexes.
No statistically significant incidence of neoplastic
lesions was observed in male orfemale rats. However, two
hepatocellular carcinomas and one neoplastic nodule,
which are rare tumors in the male Osborne-Mendel rat,
were observed in the high dose males.
Under the conditions ofthis study, orally administered
1,1,2,2-tetrachloroethane is a liver carcinogen in B6C3Fj
mice ofboth sexes. The results do not provide conclusive
evidence for the carcinogenicity of 1,1,2,2-
tetrachloroethane in Osborne-Mendel rats.
Synonyms: acetylene tetrachloride; sym-tetrachloroe-
thane
Report Date: 1978
Levels of Evidence of Carcinogenicity:
Male Rats:
Female Rats:
Male Mice:
Female Mice:
Equivocal
Negative
Positive
Positive
TR-28 Bioassay ofDibromochloropropane
for Possible Carcinogenicity (CAS No.
1836-75-5)*
Dibromochloropropane, a halogenated aliphatic hydro-
carbon and agricultural pesticide, was one of several
widely used pesticides selected for bioassay by the
National Cancer Institute. Atthis timetherewas alack of
adequate chronic toxicity data on this compound.
A bioassay for possible carcinogenicity of technical-
grade dibromochloropropane (DBCP) was conducted
using Osborne-Mendel rats and B6C3F1 mice. DBCP in
corn oil was administered by gavage 5 days a week, at
either oftwo dosages, to groups of50 male and 50 female
animals ofeach species.
Initial dosage levels for the chronic bioassay were
selected on the basis of a preliminary subchronic toxicity
test. Subsequent dosage adjustments were made during
the course of the chronic bioassay. The time-weighted
average dosages of DBCP in the chronic study were 29
mg/kg/dayfor thehigh dose rats ofboth sexes, and 15mg/
kg/day for the low dose rats of both sexes. The time-
weighted average concentrations for the high dose male
andfemalemicewere219 and209mg/kg/day, respectively.
The time-weighted average concentrations for the low
dose male and female mice were 114 and 110 mg/kg day,
respectively.
For each species, 20 animals ofeach sexwere placed on
testasvehiclecontrols.Theseanimalswereintubatedwith
corn oil at the same time that dosed animals were intu-
bated with DBCP mixtures. Twenty animals of each sex
wereplaced on test as untreated controls for each species.
These animals received no gavage treatments.
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DBCPwas administered tothehighdosemaleandhigh
dose female rats for 64weeks priorto sacrifice, and tothe
low dose female rats for 73 weeks prior to sacrifice. The
low dose male rats were treated for 78 weeks followed by
an additional 5 weeks ofobservation. The high dose male
and female mice were treated for 47weeks prior to sacri-
fice; the low dose male mice were treated for 59 or 60
weekspriortosacrifice, andthelowdosefemalemicewere
treated for 60 weeks prior to sacrifice.
In rats and mice of both sexes, statistically significant
incidences of squamous-cell carcinomas ofthe forestomach
occurred in each dosed group and a significant positive
association existed between dosage level and tumor inci-
dence. The incidences ofadenocarcinomas ofthe mammary
gland were statistically significant in female rats when the
treated groups were compared to the controls. Toxic
nephropathy was also observed at elevated incidences in all
ofthe treated rats andmicewhen compared totheirrespec-
tive untreated orvehicle control groups.
Under the conditions ofthis study, DBCP is a stomach
carcinogen in rats and mice of both sexes and is car-
cinogenic to the mammary gland in female rats.
Synonyms: 1,2-dibromo-3-chloropropane; Nemagong;
Fumazoneg; DBCP
Report Date: 1978
Levels ofEvidence ofCarcinogenicity:
Male Rats: Positive
Female Rats: Positive
Male Mice: Positive
Female Mice: Positive
*The technical report states that the Chemical Abstract
Service (CAS) Ninth Collective Index (1977) nameforthis
compound is 1,2-dibromo-3-chloropropane (CAS No.
96-12-8). This is the CAS number used to track this study
in the NTP CHEMTRACK database.
Note: Dibromochloropropane was subsequently studied
byinhalation to F344 rats and B6C3F1 mice (SeeTR-206,
reported 1982).
TR-29 Bioassay of2-Methyl-l-
Nitroanthraquinone for Possible
Carcinogenicity (CASNo. 129-15-7)
2-Methyl-1-nitroanthraquinone, an intermediate in the
synthesis ofanthraquinone dyes,wasselectedforbioassay
bythe National CancerInstitutein anattempttoelucidate
those chemicals which may be responsible for the
increased incidence of bladder cancer among workers in
the dye manufacturing industry. Aromatic nitro com-
pounds are one ofseveral classes ofchemicals thought to
contribute to the increased cancer risk in this industry.
A bioassay of 2-methyl-1-nitroanthraquinone for
possible carcinogenicity was conducted using Fischer 344
rats. 2-Methyl-1-nitroanthraquinone was administered in
the feed at either of two concentrations to groups of 50
male and 50 female animals. The high and low dietary
concentrations used were 0.12 and 0.06 percent, respec-
tively, for the male and female rats. After a 78-week
treatment period, observation ofthe rats continued for an
additional 31 weeks. Fifty rats ofeach sexwere placed on
test as controls. No 2-methyl-1-nitroanthraquinone was
added to their diet.
Survival in both the male and female ratswas adequate
for a meaningful statistical analysis of late-developing
tumors; however, there was a significant positive associa-
tion between increased dosage and elevated mortality in
female rats.
Hepatocellularcarcinomasandneoplasticnodulesofthe
liver occurred in both the male and female treated rats. A
statisticallysignificantassociationbetweenincreaseddos-
ageandanelevatedincidenceofhepatocellularcarcinomas
was indicatedbythe Cochran-Armitage testforthemales
(1148, 5/48, and 9/49 in control, low dose, and high dose,
respectively); however, the Fisher exact tests supported
theseresults onlyforthehighdosemales.Theincidence of
neoplastic noduleswas statistically significantin the male
rats (0/48, 2/48, and 6/49 in control, low dose, and high
dose, respectively), asindicatedbythe Cochran-Armitage
test and supported by the Fisher exact test for the high
dose group. When those rats having either hepatocellular
carcinomas or neoplastic nodules of the liver were com-
bined and evaluated simultaneously, the Cochran-
Armitage tests indicated statistically significant associa-
tions between increased dosages and elevated tumor inci-
dences in both the males and females. Thiswas supported
bytheFisherexacttestsformalesbutnotforfemales.The
incidences ofone tumortype, subcutaneous fibroma, were
foundtobestatisticallysignificantinbothmaleandfemale
rats. No other tumors occurred in treated animals in
statistical]y significant incidences when compared to con-
trols.
Squamous-cell papillomas and squamous cell carcinomas
of the forestomach were observed only in high dose rats.
Although the incidences of these gastric tumors were not
statistically significant, historical data indicate that these
tumors arerareinFischer344rats.The occurrenceofthese
tumors in high dose rats, togetherwith the frequent occur-
rence of nonneoplastic proliferative lesions of the for-
estomach in treated rats, indicates that the occurrence of
these tumors was related to administration of 2-methyl-i-
nitroanthraquinone. An increased incidence of bladder
tumors (papillomas, transitional-cell papillomas, and sar-
comas) was observed among female rats.
Under the conditions of this bioassay, the results indi-
cate that orally administered 2-methyl-1-nitroanth-
raquinone is carcinogenic in male Fischer 344 rats,
producing hepatocellular carcinomas. Increased inci-
dences ofsubcutaneous fibromas in both male and female
Fischer344ratswerealsoassociatedwiththeadministra-
tion of the compound. Thmors of the forestomach and
bladderin these animals mayalso havebeen related to the
administration ofthe test chemical.
Synonyms: 2-methyl-1-nitro-9,10-antracenedione;
1-nitro-2-methyl-anthraquinone
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Report Date: 1978
Levels ofEvidence ofCarcinogenicity:
Male Rats: Positive
Female Rats: Positive
Male Mice: Positive
Female Mice: Positive
TR-30 Bioassay ofDiarylanilide Yellow
for Possible Carcinogenicity (CAS No.
6358-85-6)
Diarylanilide yellow, one member ofa family oforganic
azopigments known asbenzidineyellows,was selectedfor
bioassaybythe NationalCancerInstitutein anattemptto
elucidate those dyes and dye intermediates which may be
responsible for the increased incidence ofbladder cancer
observed amongworkers in the dyemanufacturing indus-
try.
A bioassay of technical-grade diarylanilide yellow for
possible carcinogenicity was conducted using Fischer 344
rats and B6C3F1 mice. Diarylanilide yellow was admin-
istered in the feed, at either of two concentrations, to
groups of50 male and 50 female animals ofeach species.
The high and low dietary concentrations used in the
chronic study for the male and female rats and mice were
5.0 and 2.5 percent, respectively, of the chemical in the
feed.After a78-weektreatmentperiod, observation ofthe
rats continued for an additional 28weeks and observation
ofthe mice continued for an additional 19 weeks for high
dosemalesandlowandhighdosefemalesand18weeksfor
low dose males. For each species, 50 animals of each sex
wereplaced ontestas controls, andfed onlythebasal diet.
The high concentration administered to both species in
this study was the maximum recommended in the Guide-
lines for Carcinogen Bioassay in Small Rodents. These
guidelinesindicatethatachronic dietarylevelof5percent,
or50,000ppm, should notbe exceeded evenwhen no signs
oftoxicity are observed during subchronic testing, except
underspecial circumstances (e.g., when the compound is a
majorcomponent ofthe human diet). No toxic effectswere
reported during subchronic testing and diarylanilide
yellow did notqualifyforexception; therefore, the highest
permissible concentration (5 percent) was utilized in the
chronic bioassay.
The dietary concentrations of diarylanilide yellow
administered during the chronic bioassay had no signifi-
cant effect on survival or body weight gain in either
species. Except for yellow staining and some isolated
neoplasms, the only adverse clinical sign or pathologic
lesion observed in treated rats or mice was basophilic
cytoplasm changes in hepatocytes oftreated rats.
In both species the survival in all groups was adequate
for statistical analysis oflate-appearing tumors.
No treatment-related increase in the incidence of neo-
plasms ornonneoplasticlesionswas evidentintreatedrats
or mice. A few unusual findings were observed in both
species,includingsingle cases ofmetastatic chordoma and
osteogenic sarcomain rats, and single cases ofsquamous-
cell carcinomaoftheear,infiltratingductcarcinomaofthe
mammarygland, and subcutaneous mastocytomain mice.
Theresults ofthestudydid notprovideevidenceforthe
carcinogenicity ofdiarylanilide yellowin Fischer 344 rats
or B6C3F1 mice.
Synonyms: 2,2'-[(3,3'-dichloro(1,1'-biphenyl)-4,4'-diyl)-bis
(azo)] bis(3-oxo-N-phenyl)-butanamide; C.I. Pigment
Yellow 12; Diarylide yellow
Report Date: 1978
Levels ofEvidence ofCarcinogenicity:
Male Rats: Negative
Female Rats: Negative
Male Mice: Negative
Female Mice: Negative
TR-31 Bioassay ofTolbutamide for
Possible Carcinogenicity (CAS No. 64-77-7)
Tolbutamidewasthefirstoralhypoglycemic agentused
in the management of diabetes. It is one of the
arylsulfonylurea hypoglycemics, a group which included
tolazamide, chlorpropamide, and acetohexamide. All of
these compounds function by stimulating the secretion of
insulin by the pancreas and, therefore, are used only in
patients with at least minimal pancreatic function, as in
maturity-onsetdiabetics.
A bioassay of tolbutamide for possible carcinogenicity
was conducted by administering the test material in the
diet to Fischer 344 rats and B6C3F1 mice.
Groups of 35 rats of each sex were administered
tolbutamide at one of two doses, either 12,000 or 24,000
ppm, 5 days a week for 78 weeks, then observed for an
additional 28 weeks. Matched-control groups consisted of
15untreatedratsofeach sex.Allsurvivingratswerekilled
at 106 or 107 weeks.
Groups of 35 mice of each sex were administered
tolbutamide at one of two doses, either 25,000 or 50,000
ppm, 5 days a week for 78 weeks, then observed for an
additional 24-26weeks. Matched-control groups consisted
of15 untreated mice ofeach sex. All surviving mice were
killed at 102-104 weeks.Mean bodyweights ofthe treated
rats and mice were lower than those ofthe corresponding
matched controls during the entire study; however, sur-
vival was not significantly affected by treatment in either
species. Inboth sexes ofboth species, survivalwas consid-
ered to be adequate for meaningful statistical analyses of
the incidence oftumors.
In both the rats and the mice, a variety of neoplasms
were found in both tolbutamide-treated and control
groups. None of the neoplasms were present at a statis-
tically significantincreased incidence in treated groups of
either species as compared with control groups and were
not considered to be compound related.
Itisconcludedthatundertheconditionsofthisbioassay,
tolbutamide was not carcinogenic for either Fischer 344
rats or B6C3F1 mice.
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Synonym: 1-butyl-3-(p-methylbezenesulfonyl)urea
Report Date: 1977
Levels ofEvidence of Carcinogenicity:
Male Rats:
Female Rats:
Male Mice:
Female Mice:
Negative
Negative
Negative
Negative
TR-32 Bioassay of Isophosphamide for
Possible Carcinogenicity (CAS No.
3778-73-2)
- A bioassay of the anticancer drug isophosphamide for
possible carcinogenicity was conducted by injecting the
test chemical intraperitoneally into Sprague-Dawley rats
and B6C3F1 mice.
Groups of35 rats and 35mice ofeach sexweregiventhe
injections at one oftwo doses three times perweek for 52
weeks. Doses for rats were either 6 or 12 mg/kg, and for
miceeither10 or20mg/kg.Aftertheperiod ofadministra-
tion of the isophosphamide, the surviving rats were
observed for 31 weeks and the mice for 28 weeks. Untre-
ated controls as well as vehicle controls (buffered saline)
were used. The matched vehicle-control groups each con-
sisted of 10 rats or 15 mice of each sex; pooled vehicle-
control groups, used for statistical evaluation, consisted of
thematchedvehiclecontrolsofeachspecies combinedwith
20 male and 20 female matched vehicle-control rats or 15
male and 15 female matched vehicle-control mice from a
similar bioassay of another test chemical. All surviving
rats were killed at 79-84 weeks, all surviving mice at 79-81
weeks.
Mean body weights ofthe high-dose rats of either sex
werelowerthanthoseofthematchedvehiclecontrolsafter
approximately 25weeks on study. Survivalwaslowamong
the high-dose male and female rats, but in the low-dose
groups itwas adequate formeaningful statistical analyses
oftheincidences oftumors. Meanbodyweightsofthemice
did not show any consistent effect from the iso-
phosphamide treatment. Survival was adequate formean-
ingful statistical analyses in both groups offemale mice,
while survival of the males was 31% for both treated
groups at the end ofthe study.
In male rats, tumors of the hematopoietic system
included six malignant lymphomas and two granulocytic
leukemias. With the unadjusted analysis, these tumors
showed a dose-related trend in male rats using pooled
vehicle controls (controls 0/29, low-dose 3/32, high-dose
5/34, P = 0.032) and a higher incidence in the high-dose
males than in the pooled vehicle controls (P = 0.040).
These tumors were not signiflcant when compared with
matched vehicle controls using adjusted analyses, and
they cannot clearly be associated with treatment. How-
ever, it should be noted that five rats with these tumors
were observed in the high-dose group whose median
survival was only 35 weeks.
In female rats, the incidence ofuterine leiomyosarcoma
was significant in the low-dose group usingpooled vehicle
controls (controls 0/27, low-dose 15/32, P<0.001). There
was also a significant incidence of mammary fibro-
adenoma among low-dose females using pooled vehicle
controls (controls 8/28, low-dose28/33, P<0.001). The inci-
dence ofeach tumor was also significant when compared
with matched vehicle controls using time-adjusted analy-
ses. The low survival ofthe high-dose group (median time
onstudy,35weeks)mayexplainthelowerincidences ofthe
uterine leiomyosarcoma and the mammary fibroadenoma
in this group. In some rats, the leiomyosarcomas metasta-
sized to the lungs, urinary bladder, spleen, and other
abdominal sites.
Infemale mice, theincidence ofmalignantlymphomaof
the hematopoietic system showed a significant dose-
related trend using either matched vehicle controls (con-
trols 0/14, low-dose 3/32, high-dose 13/34, P= 0.001) or
pooled vehicle controls (controls 1129, P<0.001). Further,
incidences of this tumor in the high-dose females were
significantlyhigherthanincidencesinthematchedvehicle
(P=0.005) or pooled vehicle (P=0.001) controls.
Itisconcludedthatundertheconditionsofthisbioassay,
isophosphamide was not carcinogenic in male Sprague-
Dawley rats or in male B6C3F1 mice. However, the inci-
dence of leiomyosarcomas of the uterus indicates that
isophosphamide was carcinogenic in female Sprague-
Dawley rats, and the incidence of fibroadenoma of the
mammarygland in female rats was associated with treat-
ment with isophosphamide. Isophosphamide was car-
cinogenic in female B6C3F1 mice, producing malignant
lymphomas ofthe hematopoietic system.
Synonyms: 3-(2-chloroethyl)-2-[2-chloroethyl)amino]-
tetrahydro-1,3,2-oxazaphosphorine-2-oxide; ifosfamide
Report Date: 1977
Levels ofEvidence ofCarcinogenicity:
Male Rats:
Female Rats:
Male Mice:
Female Mice:
Negative
Positive
Negative
Positive
TR-33 Bioassay ofTetrachlorvinphos for
Possible Carcinogenicity (CAS No. 961-11-5)
Tetrachlorvinphos is an organophosphorous pesticide
introduced in 1966 by Shell Development Company. It is
registered for use against various pests offruits, vegeta-
bles, ornamentalplants,foresttrees,andlivestock, andfor
use on agricultural premises, agricultural equipment, and
recreational areas.
A bioassay of technical-grade tetrachlorvinphos for
possible carcinogenicity was conducted by administering
the test chemical in feed to Osborne-Mendel rats and
B6C3F1 mice.
Groups of 50 rats of each sex were administered
tetrachlorvinphos at one of two doses for 80 weeks, then
observed for 31 additional weeks. Time-weighted average
doses were either 4,250 or 8,500 ppm. Matched controls
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consisted ofgroups of10untreatedrats ofeach sex;pooled
controls, used for statistical evaluation, consisted of the
matched controls combined with 45untreated male and45
untreated female rats from similarbioassays offour other
test chemicals. All surviving rats were killed at 111weeks.
Groups of 50 mice of each sex were administered
tetrachlorvinphos at one of two doses, either 8,000 or
16,000 ppm, for 80 weeks, then observed for 12 additional
weeks. Matched controls consisted ofgroups of 10 untre-
ated mice ofeach sex; pooled controls, used for statistical
evaluation, consisted of the matched controls combined
with40untreated male and40untreatedfemalemicefrom
similar bioassays offour other test chemicals. All surviv-
ing mice were killed at 90-92 weeks.
The mean body weights of the treated rats and mice
were generally lower than those ofthe matched controls;
however, the mortality rate was affected adversely by
tetrachlorvinphos only in the male rats. Survival of all
groups of rats and mice was adequate for meaningful
statistical analyses oftheincidence oftumors, exceptfor a
matched-control group of female rats for which the sur-
vival was abnormally low.
In rats, C-cell adenoma ofthe thyroid showed a signifi-
cant dose-related trend in the females, using pooled con-
trols (controls 1/46, low-dose 2/50, high-dose 7/46,
P= 0.013), and by direct comparison, an increased inci-
dence in the high-dose group (P=0.027). High incidences
ofC-cell hyperplasia in treated males and females further
indicated a chemical-related effect on proliferative lesions
of the thyroid. Cortical adenoma of the adrenal also
showed a significant dose-related trend in the females,
using pooled controls (controls 0/50, low-dose 2/49, high-
dose 5/50, P = 0.017), and by direct comparison, an
increased incidence in the high-dose group (P=0.022).
Hemangioma of the spleen occurred in male rats at a
significantlyhigherincidenceinthelow-dosegroupthanin
the pooled controls (controls 0/52, low-dose 4/48,
P=0.049); however, neither theincidence in the high-dose
group (0/47) nor the testresult for dose-related trend was
statistically significant.
In mice, hepatocellular carcinoma in males showed a
highly significant dose-related trend, using either
matched controls (controls 0/9, low-dose 36/50, high-dose
40/50,P<0.001) orpooledcontrols(controls5/49,P<0.001).
This finding was supported by direct comparisons oflow-
and high-dose groups of males with matched- or pooled-
control groups, which showed highly significant increases
in incidences of the tumor in the treated groups in all
instances (P<0.001). In females, the incidence of
hepatocellular carcinomawas notsignificant; however, the
incidence ofneoplastic nodule was significantly higher in
both the low- and high-dose groups than in the pooled
controls (controls 1148, low-dose 14/49, P<0.001; high-dose
9/47, P=0.007), using pooled controls for tests for both
doses. Because of this higher incidence in the low-dose
group than in the high-dose group, therewas a significant
departure from linear trend (P=0.006).
Granulomatous lesions of the liver were found in high
proportionsinbothtreatedratsandtreatedmice,butnone
were found in matched controls.
Itisconcludedthatundertheconditions ofthisbioassay,
theadministration oftechnical-gradetetrachlorvinphosin
Osborne-Mendel rats was associated with proliferative
lesions ofthe C cells ofthe thyroid and cortical adenomas
of the adrenal in females. In female B6C3F1 mice, the
incidence ofneoplastic nodule ofthe liver was associated
with treatment, and in male mice tetrachlorvinphos was
carcinogenic, causing hepatocellular carcinoma of the
liver.
Synonym: 2-chloro-1-(2,4,5-trichlorophenyl)vinyl di-
methyl phosphate
Report Date: 1978
Levels ofEvidence ofCarcinogenicity:
Male Rats:
Female Rats:
Male Mice:
Female Mice:
Negative
Positive
Positive
Positive
TR-34 Bioassay ofTrifluralin for Possible
Carcinogenicity (CAS No. 1582-09-8)
Trifluralin, a tertiary aromatic amine and dinitrotoluene
derivative, is one of several widely used agricultural pes-
ticidesselectedforbioassaybytheNationalCancerInstitute
because ofa lack ofadequate chronic toxicity data.
A bioassay for possible carcinogenicity of technical-
grade trifluralin was conducted using Osborne-Mendel
rats and B6C3F1 mice. Analysis ofthe technical product
established the presence of 84 to 88 ppm dipropyl-
nitrosoamine. The product was administered in the feed,
ateitheroftwoconcentrations, togroupsof50maleand50
female animals ofeach species. Fifty animals ofeach sex
were placed on test as controls for the rat bioassay, while
20ofeachsexwereutilizedascontrolsforthemousestudy.
The time-weighted average high and low dietary con-
centrations of trifluralin were, respectively, 8,000 and
4,125 ppm for male rats, 7,917 and 4,125 ppm for female
rats, 3,744 and 2,000 ppm for male mice, and 5,192 and
2,740 ppm for female mice. After a 78-week treatment
period, there was an additional observation period of 33
weeks for rats and 12 weeks for mice.
Forfemale micethe associationbetweenincreased dos-
age and elevated incidence of hepatocellular carcinomas
was significant (0/20, 12/47, and 21/44 of the control, low
dose, and high dose, respectively) as was the relationship
between dose and incidence of alveolar/bronchiolar ade-
nomas. Significance ofincidence for both types oftumors
was supported by tests for significance at each dose level.
Squamous-cell carcinomas ofthe stomach were observed
in dosed female mice, but not in controls. Although inci-
dences of these tumors were not statistically significant,
they are unusual lesions in B6C3F1 mice and are consid-
ered to be treatment-related.
Neoplasms observed in treated rats were types that
have occurred spontaneously in this strain and were
apparently unrelated to trifluralin treatment.
Evaluation ofthe results ofthis bioassay indicates that
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technical-grade trifluralin is a carcinogen in female
B6C3F1 mice, being associated in these animals with an
elevated incidence of hepatocellular carcinomas, alveolar/
bronchiolar adenomas and squamous-cell carcinomas of
the forestomach. Sufficient evidence was not provided for
the carcinogenicity ortumorigenicity oftrifluralin inmale
B6C3F1 mice or in Osborne-Mendel rats ofeither sex.
Synonyms: 2,6-dinitro-N,N-dipropyl-4-(trifluorome-
thyl) benzeneamine; Q,(x,-trifluoro-2,6-dinitro-N,N-
dipropyl-p-toluidine; N,N,-dipropyl-4-trifluoromethyl-2,6-
dinitroaniline; Treflan
Report Date: 1978
Levels ofEvidence of Carcinogenicity:
Male Rats:
Female Rats:
Male Mice:
Female Mice:
Negative
Negative
Negative
Positive
TR-35 Bioassay of Methoxychlor for
Possible Carcinogenicity (CAS No. 72-43-5)
Methoxychlor, a synthetic organochlorine insecticide and
structural analog of DDT, was one of several widely used
agricultural pesticides selected forbioassaybythe National
Cancer Institute because of a lack of adequate chronic
toxicitydata. The suspect state ofall DDT-related chemicals
was an important additional factor in its selection.
A bioassay for possible carcinogenicity of technical-
grade methoxychlor was conducted using Osborne-
Mendel rats and B6C3F1 mice. Methoxychlor was admin-
istered in the feed, at either of two concentrations, to
groups of 50 male and 50 female animals ofeach species.
For each species, 20 animals of each sex were placed on
test as controls. The time-weighted average high and low
dietaryconcentrations ofmethoxychlorwere, respectively,
845 and 448 ppm for male rats, 1,385 and 750 ppm for
female rats, 3,491 and 1,746 ppm for male mice, and 1,994
and 997 ppm for female mice. After a treatment period of
78 weeks, the rat groups were observed for an additional
34weeks andthemouse groups for an additional 15weeks.
A dose-related mean group body weight depression was
observed in both rats and mice, but no effect on survival
was detected.
Under the conditions of this study, methoxychlor was
not found to be carcinogenic in Osborne-Mendel rats or
B6C3F1 mice ofeither sex.
Synonyms: 1,1'-(2,2,2-trichloroethylidene)bis (4-methoxy)-
benzene;1,1,1-trichloro-2,2'-bis(p-methoxyphenyl)-ethane;
dianisyl trichloroethane; Dimethoxy DDT; DMDT
Report Date: 1978
Levels ofEvidence of Carcinogenicity:
TR-36 Bioassay ofAnthranilic Acid for
Possible Carcinogenicity (CAS No. 118-92-3)
Anthranilic acid is an aromatic amine which occurs
physiologically as a metabolite of the amino acid tryp-
tophan. It is used commercially as an intermediate in dye
synthesis.
A bioassay of anthranilic acid for possible car-
cinogenicity was conducted by administering the test
chemical in feed to Fischer 344 rats and B6C3F1 mice.
Groups of35 rats and 35 mice ofeach sex were admin-
istered anthranilicacidatoneofthefollowingdoses, either
15,000 or 30,000 ppm for the rats, and either 25,000 or
50,000ppmforthemice,5daysperweekfor78weeks,then
observed for an additional 26-27 weeks. Matched controls
consisted of groups of 15 rats and 15 mice of each sex;
pooledcontrols, usedfor statistical evaluation, consisted of
thematchedcontrolscombinedwith15untreatedmaleand
15untreated female animals ofeach species from a similar
bioassay ofanothertestchemical Except forthematched-
control male mice, all surviving animals in the studywere
killed at 104-106 weeks. Halfofthe matched-control male
mice, which were accidentally killed at week 12, were
excluded from the report; the remaining matched-control
males died by week 94.
Mean bodyweights ofthe low- and high-dose male and
high-dose female ratswere lowerthan those ofthe corres-
ponding matched controls for the duration of the study.
The weights ofthe low-dose females were similar to those
ofthe matched controls for the first 45weeks, afterwhich
they declined slightly. The weights of the low-dose male
mice were similar to those of the matched controls, while
those ofthehigh-dosemalesandofthelow- andhigh-dose
females were slightly lower.
Survival ofboth treated and matched-control groups of
rats of both sexes was high; survival of treated mice of
both sexes and offemale matched controls, although lower
thanthatoftherats,was sufficientformeaningful statisti-
cal analyses ofthe incidences oftumors.
In rats, a variety of neoplasms were observed in both
treated and control animals. Few malignant tumors were
found, and no tumors occurred in treated animals in
statistically significant incidences when compared with
control animals.
In mice, a variety of neoplasms were observed in both
treated and control animals. These neoplasms are not
uncommon in this strain of mouse and none occurred in
treated animals in statisticallysignificantincidenceswhen
compared with control animals.
Itisconcludedthatunderthe conditions ofthisbioassay,
anthranilic acid was not carcinogenic for either Fischer
344 rats or B6C3F1 mice.
Synonym: 2-aminobenzoic acid
Report Date: 1978
Male Rats:
Female Rats:
Male Mice:
Female Mice:
Negative
Negative
Negative
Negative
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Levels of Evidence ofCarcinogenicity:
Male Rats:
Female Rats:
Male Mice:
Female Mice:
Negative
Negative
Negative
Negative
TR-37 Bioassay ofToxaphene for Possible
Carcinogenicity (CAS No. 8001-35-2)
Toxaphene is an organochlorine insecticide thatbelongs
to the class of compounds known as polychlorinated
bicyclic terpeneswith chlorinated camphenes predominat-
ing; an insecticide marketed as Strobane-TO (Tenneco
Chemical Co., Piscataway, N.J.) is identical with tox-
aphene.
A bioassay of technical-grade toxaphene for possible
carcinogenicity was conducted by administering the test
chemical in feed to Osborne-Mendel rats and B6C3Fj
mice.
Groups of 50 rats of each sex were administered tox-
aphene at one oftwo doses for80weeks, then observed for
28 or 30 weeks. Time-weighted average doses for males
were 556 or 1,112 ppm; for females they were 540 or 1,080
ppm. Matched controls consisted ofgroups of10untreated
rats ofeach sex; pooled controls consisted ofthe matched-
control groups for toxaphene combined with 45 untreated
male and 45 untreated female rats from similar bioassays
offive other test chemicals. All surviving rats were killed
at 108-110 weeks.
Groups of 50 mice of each sex were administered tox-
apheneat oneoftwodosesfor80weeks, thenobservedfor10
or 11 weeks. Time-weighted average doses were 99 or 198
ppmforboth males andfemales. Matched controls consisted
of groups of10 untreated mice ofeach sex; pooled controls
consisted ofthe matched-control groups fortoxaphene com-
bined with 40 untreated male and 40 untreated female mice
from similar bioassays of four other test chemicals. All
surviving mice were killed at 90-91 weeks.
Mean body weights attained by low- and high-dose
female rats and high-dose male mice were lower than
those of matched controls, but weights of other dosed
groups were essentially unaffected by the toxaphene.
Other clinical signs oftoxicityin rats included generalized
body tremors at week 53 in high-dose male and female
animals, and later, leg paralysis, ataxia, epistaxis,
hematuria, and vaginal bleeding, predominantly in the
dosed groups of rats of each sex. Abdominal distention,
diarrhea, dyspnea, and rough hair coats were common to
both dosed rats and dosed mice. There were dose-related
decreases in survival rates in mice but not in rats. Suffici-
ent numbers of both rats and mice were at risk for the
development oflate-appearing tumors.
In the male rats, the incidence of follicular-cell car-
cinomas or adenomas of the thyroid was dose related
(P =0.007) usingthepooledcontrols (matched controls 1/7,
pooled controls 2/44, low-dose 7/41, high-dose 9/35). In the
females, the incidence of follicular-cell adenomas of the
thyroid was dose related using either the matched
(P= 0.022) or pooled (P= 0.008) controls (matched con-
trols 0/6, pooled controls 1146, low-dose 1/43, high-dose
7/42). Direct comparisons of dosed and pooled-control
groups but not matched controls showed significantly
increased incidences of follicular-cell carcinomas or ade-
nomas in the high-dose males (P=0.008) and offollicular-
cell adenomas in the high-dose females (P= 0.021). Two
follicular-cell tumors in the high-dose males were car-
cinomas; all other follicular-cell tumors in the rats were
adenomas.
In the mice, the incidence ofhepatocellular carcinomas
was dose related (P<0.001) for both males (matched con-
trols 0/10, pooled controls 4/48, low-dose 34/49, high-dose
45/46) and females (matched controls 0/9, pooled controls
0/48,low-dose5/49,high-dose34/49),usingeithermatched
or pooled controls. Direct comparisons showed that the
incidences ofhepatocellular carcinomas in low- and high-
dosemalemice andhigh-dosefemalemicewere all signifi-
cantly higher (P<0.001) than those in the respective
matched or pooled controls. Statistical significance was
maintained when the incidence of hepatocellular car-
cinomas was combined with that ofneoplastic nodules of
the liver.
Itisconcludedthatundertheconditionsofthisbioassay,
toxaphene was carcinogenic in male and female B6C3Fj
mice, causing increased incidences of hepatocellular car-
cinomas. The test results also suggest carcinogenicity of
toxaphene for the thyroid of male and female Osborne-
Mendel rats.
Report Date: 1979
Levels ofEvidence ofCarcinogenicity:
Male Rats: Equivocal
Female Rats: Equivocal
Male Mice: Positive
Female Mice: Positive
TR-38 Bioassay ofAroclor® for Possible
Carcinogenicity (CAS No. 27323-18-8)*
Aroclor® is the registered trademark ofthe Monsanto
Chemical Company for their polychlorinated biphenyls
(PCBs). PCBswere developed in 1929primarilyforuse as
heat transfer fluids and dielectrics (insulators). Aroclor®
1254, abiphenylcontainingapproximately 54%chlorine, is
anonflammableheattransferagentwhichfunctionsinthe
range of250-360° C.
AbioassayofAroclor® 1254forpossible carcinogenicity
was conducted by administering the test chemical in feed
to Fischer 344 rats.
Groups of 24 rats of each sex were administered
Aroclor® 1254 at one of three doses, either 25, 50, or 100
ppm, for 104-105 weeks. Matched controls consisted of
groups of24 untreated rats ofeach sex. All surviving rats
were killed at 104-105 weeks.
Mean bodyweights ofmales and females receivingmid
and high doses and females receiving low doses of the
chemicalwere consistently belowthose ofthecorrespond-
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ing controls, beginning at aboutweek 10 ofthe study. The
decrease in survival amongmales, but notamongfemales,
showed a significant dose-related trend. Adequate num-
bers of animals of both sexes survived for meaningful
statistical analyses ofthe incidences oftumors.
The combined incidences of lymphomas and leukemias
showed a signiflcant dose-related trend in males (controls
3/24, low-dose 2/24, mid-dose 5/24, high-dose 9/24,
P=0.009). However, the direct comparisons ofeach dosed
group with those ofthe matched controls were not statis-
ticallysignificant, andthetumorscannotclearlyberelated
to administration ofwith Aroclor® 1254.
Hepatocellular adenomasand carcinomaswerefound in
the dosed groups, but notinthe controls (males: mid-dose
1124, high-dose 3/24; females: mid-dose 1124, high-dose
2/24). Additionally, a high incidence of nonneoplastic
hyperplastic nodules was noted in the dosed animals
(males: controls 0/24, low-dose 5/24, mid-dose 8/24, high-
dose 12/24; females: controls 0/23, low-dose 6/24, mid-dose
9/22, high-dose 17/24). Although the incidences oftumors
were not significant, the occurrence of the hyperplastic
nodules appeared to be related to administration of the
chemical.
In the stomach, jejunum, or cecum, adenocarcinomas
were observed in two dosed males and in two dosed
females as well as a carcinoma in one dosed male. None of
these lesions was found in control animals in this study.
Historical incidences of these tumors at this laboratory
(6/600 males [1%], 2/600 females [0.3%] suggest that the
lesions, although not statistically significant, may be
related to the administration ofAroclor® 1254.
Itisconcludedthatundertheconditions ofthisbioassay,
Aroclor® 1254 was not carcinogenic in Fischer 344 rats;
however, a high incidence of hepatocellular proliferative
lesions in both male and female ratswas related to admin-
istrationofthechemical. Inaddition,thecarcinomasofthe
gastrointestinal tract maybe associatedwith administra-
tion ofAroclor® 1254 in both males and females.
Report Date: 1978
Levels ofEvidence ofCarcinogenicity:
Male Rats: Equivocal
Female Rats: Equivocal
*The technical report states that Aroclor® (CAS No.
11097-69-1) was the actual chemical. The CAS number
listed in the technical report is for Chloro-1,1'-Biphenyl,
the generic form of the compound tested; therefore, the
CASnumberforAroclor® isusedtotrackthis studyinthe
NTP CHEMTRACK database.
TR-39 Bioassay ofLasiocarpine for
Possible Carcinogenicity (CAS No. 303-34-4)
Lasiocarpine is a pyrrolizidine alkaloid that is found in
the seeds ofHeliotropium lasiocarpum, Heliotropium
europaeum, and several otherplant species, all members
ofthe familyBoraginaceae.
A bioassay of lasiocarpine for possible carcinogenicity
was conducted by administering the test chemical in the
diet to Fischer 344 rats.
Groups of 24 rats of each sex were administered
lasiocarpine at one ofthree doses, either 7, 15, or 30 ppm,
for 104 weeks. Matched controls consisted ofgroups of24
untreatedrats ofeach sex.Allsurvivingratswere killed at
104weeks.
Mean body weights of the high-dose male and female
rats were lower than those ofthe matched-control groups
throughout most of the study, while weights of the mid-
dose rats were lower only during the second year, and
weights of the low-dose groups were unaffected. There
was a positive dose-related trend in mortality for both
sexes, with none ofthe high-dose animals, onlyfive ofthe
mid-doseanimals,23ofthelow-dose animals, and43ofthe
matched controls survivingto termination ofthe study. In
spite of these early deaths, all male rats except one low-
dose animal and one high-dose animal developed tumors,
and among the females, 23 low-dose and 22 mid-dose
animals developed tumors. Time-adjusted analysis ofthe
incidence oftumors was performed in the female rats.
In male rats, there was a positive dose-related trend
(P<0.001) in the incidence of angiosarcoma of the liver;
furthermore, the incidences in the mid- and high-dose
groups, but not that in the low-dose, were significantly
higher (P<0.001, both groups) than that in the controls
(controls 0/24, low-dose 5/24, mid-dose 11/24, high-dose
13/24). Infemales, the incidences in both the low- and mid-
dose groups, but not that in the high-dose, were signifi-
cantly higher (P=0.002 and P=0.005, respectively) than
thatinthecontrols (controls 0/24, low-dose8/24,mid- dose
7/24, high-dose 2/9). Metastatic angiosarcomas were pre-
sentin the lungs from afewofthe rats in all three treated
groups ofboth sexes.
In both male and female rats, therewas apositive dose-
related trend in the combined incidence of hepatocellular
carcinoma and adenoma of the liver (males, P= 0.003;
females,P<0.001);furthermore,thecombinedincidenceof
thesetumorsinthehigh-dosefemales, butnotthoseinthe
low-andmid-dose,wassignificantlyhigher(P<0.001)than
thatin the controls (controls 0/24, low-dose 5/24, mid-dose
1/24,high-dose7/9).TheP-value ofthecombinedincidence
in the high-dose males (P=0.025) is above the 0.016 level
required by the Bonferroni inequality criterion, when
multiple comparison is considered (controls 0/24, low-dose
0/24, mid-dose 3/24, high-dose 5/24). Nodular hyperplasia
was observed in additional animals ofeach treated group
of each sex. Thus, lasiocarpine was associated with pro-
liferative lesions ofhepatocytes as well as with angiosar-
comas arising from endothelial cells ofthe liver.
The combined incidence of lymphoma or leukemia was
significant in both the low- and mid-dose female groups
(P. 0.018), but not in the high-dose group, perhaps
because of the early deaths in this group (controls 2/24,
low-dose 9/24, mid-dose 11124, high-dose 1V23). The inci-
dences ofthese tumors in the males were not significant.
Itisconcludedthatundertheconditionsofthisbioassay,
lasiocarpine was carcinogenic in Fischer 344 rats produc-
ing hepatocellular tumors and angiosarcomas ofthe liver
inboth sexes and hematopoietic tumors infemale animals.
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Report Date: 1978
Levels ofEvidence ofCarcinogenicity:
Male Rats: Positive
Female Rats: Positive
TR-40 Bioassay ofHexachlorophene for
Possible Carcinogenicity (CAS No. 70-30-4)
Hexachlorophene is achlorinated bisphenolwhichwas
widely used as an antiseptic prior to 1972. It is highly
effectiveagainstgram-positivebacteriaandmanypatho-
genic fungi.
A bioassay of hexachlorophene for possible car-
cinogenicity was conducted by administering the test
chemical in feed to Fischer 344 rats.
Groups of 24 rats of each sex were administered hex-
achloropheneatoneofthreedoses,either17,50,or150ppm,
for 105-106 weeks. Higher doses of 200-600 ppm, used in
8-weeksubehronicstudies,inducedneuronalnecrosisofthe
brain andclinical signs oftoxicity. Matched-control groups
consisted of 24 untreated rats of each sex. All surviving
animals were killed at 105-106 weeks.
Mean bodyweights ofthe ratswere unaffected bythe
hexachlorophene, and no clinical signs of toxicity were
recorded. Survival also was unaffected, and adequate
numbers of animals survived, permitting meaningful
evaluation ofthe incidences oflate-appearing tumors.
No tumors were present in a statistically significant
incidence at any site in the treated rats.
It is concluded that under the conditions of this bio-
assay, hexachlorophene did not induce malignant or
benign tumors in Fischer 344 rats.
Synonym: 2,2'-methylenebis(3,4,6-trichlorophenol)
Report Date: 1978
Levels ofEvidence ofCarcinogenicity:
Male Rats:
Female Rats:
Negative
Negative
TR-41 Bioassay ofChlorothalonil for
Possible Carcinogenicity (CAS No.
1897-45-6)
Chlorothalonil is a broad-spectrum fungicide which
has been in use in the United States since 1963. It is
registered for foliar and root applications on vegetables,
fruits, green house plants, and turf, and as a seed treat-
ment for cotton. Chlorothalonil is also used in formulat-
ingpaints and stains for mildew resistance.
A bioassay of technical-grade chlorothalonil for
possiblecarcinogenicitywasconductedbyadministering
the test chemical in the diet to Osborne-Mendel rats and
B6C3F1 mice.
Groups of 50 rats of each sex were administered chlo-
rothalonil at one oftwo doses for 80weeks, then observed
for 30-31 weeks. Time-weighted average doses for both
males and females were 5,063 or 10,126 ppm. Matched
controls consisted of groups of 10 untreated rats of each
sex; pooled controls consisted of the matched-control
groups combined with 55 untreated male or female rats
from similar bioassays of five other test chemicals. All
surviving rats were killed at 110-111 weeks.
Groups of 50 mice of each sex were administered
chlorothalonil at one of two doses for 80 weeks, then
observed for 11-12 weeks. Time-weighted average doses
formaleswere2,688 or5,375ppm, andforfemales, 3,000
or6,000ppm. Matched controls consisted ofgroups of10
untreated mice ofeach sex; pooled controls consisted of
the matched-control groups combined with 50 untreated
male or female mice from similar bioassays offive other
test chemicals. All surviving mice were killed at 91-92
weeks.
Clinicalsignsthatappearedwithincreasingfrequency
in dosed ratsincludedhematuriaand, fromweek72until
termination of the study, bright-yellow urine. Since the
dosed female mice did not have depression in meanbody
weights or decreased survival compared with the con-
trols, they may have been able to tolerate a higher dose.
Inrats, adenomas and carcinomas oftherenaltubular
epitheliumoccurredwith asignificantdose-relatedtrend
in both the males (P =0.030) and the females (P =0.007).
These neoplasms also occurred at a higher incidence in
the high-dose males (P = 0.035) and the high-dose
females (P=0.016) than in the corresponding controls
(males: pooled controls 0/62, low-dose 3/46, high-dose
4/49; females: pooled controls 0/62, low-dose 1148, high-
dose 5/50). These tumors included both adenomas and
carcinomas which are considered to be histogenically
related. Thus these findings areinterpreted as sufficient
evidence for the carcinogenicity ofchlorothalonil.
In mice, no tumors were found to occur at a greater
incidence among dosed animals than among controls.
It is concluded that under the conditions of this bio-
assay,technical-grade chlorothalonilwascarcinogenicto
Osborne-Mendel rats, producing tumors of the kidney.
Chlorothalonil was not carcinogenic for B6C3F1 mice.
Synonym: 2,4,5,6-tetrachloro-1,3-benzenedicarbonitrile
Report Date: 1978
Levels ofEvidence ofCarcinogenicity:
Male Rats:
Female Rats:
Male Mice:
Female Mice:
Positive
Positive
Negative
Negative
TR-42 Bioassay of 5-Azacytidine for
Possible Carcinogenicity (CAS No.
320-67-2)
5-Azacytidine, a synthetic analogue of cytidine, has
been used as an investigational anticancer drug in the
United States since 1970.
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A bioassay of 5-azacytidine for possible car-
cinogenicity was conducted by administering the test
chemical byintraperitoneal injection to Sprague-Dawley
rats and B6C3F1 mice.
Groups of 35 rats of each sex were administered
5-azacytidine at one oftwo doses, either2.6 or 5.2 mg/kg
bodyweight, in buffered saline three times perweek for
34 weeks, and were then observed for 46 or 47 weeks.
Controls consisted of groups of15 rats of each sex that
received injections of buffered saline (vehicle controls)
and 15 rats of each sex that were untreated (untreated
controls). All survivingrats were killed at80 or81weeks.
Groups of 35 mice of each sex were administered the
chemical at one oftwo doses, either2.2 or4.4mg/kgbody
weight, in buffered saline three times per week for 52
weeks, and were then observed for 29 or 30 weeks.
Controls consisted of groups of15 mice ofeach sex that
received injections of buffered saline (vehicle controls)
and 15 mice of each sex that were untreated (untreated
controls).Allsurvivingmice werekilledat81 or82weeks.
5-Azacytidine wastoxictotheanimalsinthisbioassay,
since meanbodyweights ofbothtreated ratsandtreated
mice were lower than those ofthe corresponding vehicle
controls, andsince none ofthehigh-dosemaleandfemale
rats and high-dose female mice lived to the end of the
bioassay. In treated male and female rats andmale mice,
survival wasinadequate formeaningful statistical analy-
ses ofthe incidences oftumors.
Only one male and three female high-dose rats had
tumors, and none ofthe tumors in the low-dose group of
either sex were present at a significantly increased inci-
dence using any of the statistical tests. Bone-marrow
atrophywaspresentinbothtreated groups ofboth sexes
ofrats.
Only five high-dose male mice and one high-dose
female mouse had neoplasms. In low-dose female mice,
however, lymphocytic and granulocytic neoplasms ofthe
hematopoietic system occurred in 17 animals, even
though only 54% survived until week 81. Granulocytic
neoplasms were observed in 10/29 low-dose female mice,
but in no other group, and were significant (P =0.010)
compared with the vehicle controls. The incidence of
combined lymphoma and granulocytic neoplasms was
highly significant in the low-dose females (vehicle con-
trols 0/14, low-dose 17/29, P<0.001). No tumors were
observed at a significant incidence in male mice. Bone-
marrow atrophy was present in high-dose female
mice.
It is concluded that under the conditions of this bio-
assay, the shortlife span and short duration oftreatment
ofSprague-Dawleyrats ofeither sexand ofmaleB6C3F1
mice precluded evaluation of the carcinogenicity of
5-azacytidine in these groups; however, the induction of
tumors of the hematopoietic system in female B6C3F1
mice was associated with the administration of
5-azacytidine.
Synonym: 4-amino-i-3-D-ribofuranosyl-1,3,5-tri-
azine-2(1H)-one
Report Date: 1978
Levels of Evidence ofCarcinogenicity:
Male Rats: Inadequate Study
Female Rats: Inadequate Study
Male Mice: Inadequate Study
Female Mice: Positive
TR-43 Bioassay ofEmetine for Possible
Carcinogenicity (CASNo.483-18-1)*
A bioassay of emetine, an amebicide and anticancer
drug, for possible carcinogenicity was conducted by
administering the testmaterial byintraperitoneal injec-
tion to Sprague-Dawley rats and B6C3F1 mice.
Groups of 35 rats of each sex were administered
emetine at one of two doses, either 0.5 or 1 mg/kg body
weight, three times per week for 52 weeks, and then
observedforanadditional31or32weeks. Controlgroups
of each sex consisted of 10 untreated rats (untreated
controls)and10ratsinjectedwithbufferedsaline(vehicle
controls). Pooled-control groups,usedforstatisticaleval-
uation,consistedofthevehicle-controlratsofeachsexfor
this study combined with 15 vehicle-control rats ofeach
sex from a similar bioassay ofanother test chemical. All
surviving rats were killed at 83 or 84 weeks.
Initially, groups of 35 mice of each sex were admin-
istered emetine at one oftwo doses, either3.2 or 6.4 mg/
kg body weight (mid- and high-dose), three times per
week. Control groups of each sex consisted of 15 untre-
ated mice (untreated controls) and 15 mice injected with
buffered saline (vehicle controls). Due to high mortality
ratesintheinitialtreatedgroups, additionalgroupsof35
miceofeach sexwerelaterputonstudyat1.6mg/kg(low-
dose), togetherwith 10 untreated-control and 10vehicle-
control mice of each sex. The high-dose males were
treated for28weeks and the mid- andhigh-dose females
for40and33weeks,respectively. Mid-andlow-dosemale
miceandlow-dosefemalemiceweretreatedfor52weeks,
and then observed for an additional 20 or 26 weeks. All
surviving mice were killed at 78-83 weeks.
Emetinewastoxictomaleratsatthehighdose,toboth
sexes of mice at the high and mid doses and to a lesser
extent at the low dose, as shown by the low survival in
these groups. Twenty-six percent ofthe high-dose male
ratsand69%ofthehigh-dosefemalerats,butnoneofthe
high-andmid-dosemiceofeithersex,survivedtotheend
ofthe study. In the low-dose mice, 30/35 males and21135
femaleslivedatleast1year,andthemediantimeonstudy
was 72 weeks for males and 59 weeks for females.
No tumors occurred at a statistically significant inci-
dence in treated rats or mice compared with controls;
however, it should be noted that in this study, treatment
of both species was stopped at week 52 and the studies
were terminated by week 83, which is earlier than in
currentbioassayswhereanimals aretreateduntiltermi-
nation of the studies at 2 years. In addition, there was
poor survival among the treated mice.
Itis concluded thatthe results ofthis studydo notallow
evaluation ofthe possible carcinogenicity ofemetine.
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Report Date: 1978
Levels ofEvidence ofCarcinogenicity:
Male Rats: Inadequate Study
Female Rats: Inadequate Study
Male Mice: Inadequate Study
Female Mice: Inadequate Study
*The technical report states that Emetine Hydro-
chloride (CAS No. 316-42-7) was the actual chemical
tested rather than Emetine in its pure form; therefore,
the CAS number for Emetine Hydrochloride is used to
track this study in the NTP CHEMTRACK database.
TR-44 In Vitro Carcinogenesis: Guide to
the Literature, Recent Advances and
Laboratory Procedures
Note to the Reader: This document is the published
proceedings ofaseminarandworkshopheldinJuly,1976
and sponsored by the National Cancer Institute.
Report Date: 1978
TR-45 Bioassay ofChlorpropamide for
Possible Carcinogenicity (CAS No. 94-20-2)
Chlorpropamide is an oral hypoglycemic agent ofthe
arylsulfonylurea type. Chlorpropamide was selected for
testing in the carcinogenesis program because itis used
extensively and for prolonged periods in humans.
A bioassay of chlorpropamide for possible car-
cinogenicity was conducted by administering the test
material in feed to Fischer 344 rats and B6C3F1 mice.
Groups of 35 rats and 35 mice of each sex were
administered chlorpropamide as follows: rats 5 days per
weekfor103to105weeks at3,000 or6,000ppm, andmice
5 days per week for 34 weeks at 5,000 or 10,000 ppm,
followed by 70 weeks at 2,500 or 5,000 ppm. The time-
weighted average doses formicewere 3,317ppmforlow-
dose males and females, and 6,635 ppm for high-dose
males andfemales. Matchedcontrols consisted ofgroups
of15untreatedratsand15untreatedmiceofeachsex.All
surviving rats and mice were killed at 103 to 105 weeks.
Mean body weights of both low- and high-dose rats
were lower than those ofthe matched controls through-
out the study. In mice, doses were reduced at week 34,
due to early deaths in the high-dose groups; following
this adjustment the treated mice gained weight, but the
weights never reached those ofthe controls. Survival of
the treated rats and the low-dose mice was adequate for
meaningful statistical analyses of the incidences of
tumors.
Inbothrats andmice, theincidences oftumors among
the treated groups were not significantly increased in
comparison with matched controls.
It is concluded that under the conditions of this bio-
assay, chlorpropamide was not carcinogenic for Fischer
344 rats or B6C3F1 mice.
Synonym: 1-[(p-chlorophenyl)sulfonyl]-3-propylurea
Report Date: 1978
Levels ofEvidence ofCarcinogenicity:
Male Rats: Negative
Female Rats: Negative
Male Mice: Negative
Female Mice: Negative
TR-46 Bioassay ofEthionamide for
Possible Carcinogenicity (CAS No.
536-33-4)
Abioassay ofthe chemotherapeutic drugethionamide
for possible carcinogenicity was conducted by admin-
isteringthe test chemical in feed to Fischer344 rats and
B6C3F1 mice.
Groups of35 rats and 34 or 35 mice ofeach sex were
administered ethionamide at one ofthe following doses,
either 1,500 or 3,000 ppm for the rats and either 1,000 or
2,000 ppm for the mice. The animals were treated 5 days
perweekfor78weeks,thenobservedforanadditional25
or 26 weeks. Matched controls consisted ofgroups of15
untreated rats and 15 untreated mice of each sex. All
surviving animals were killed at 103 or 104 weeks.
Mean bodyweights ofthe treated rats and mice were
lower than those ofthe corresponding matched controls
during most or all ofthe study. Survival in the rats was
sufficientto allowdevelopment oflate-appearingtumors.
In the mice, survival of the high-dose males (27%),
matched-control males (7%), and low-dosefemales (37%)
to the end of the study was low, and the deaths were
associated with suppurative lung lesions. However, tests
fordose-relatedtrendinmortalitywerenotsigniflcantin
either sex, and 47% or more ofall groups ofmice except
control males were alive at 78 weeks.
In the rats, a variety of neoplasms were observed in
treated and control groups ofeach sex. The lesions were
oftypescommonlyfound in Fischer344 rats, and none of
the incidences of tumors in dosed animals were statis-
tically significant when compared with controls.
In the mice, the incidences of malignant lymphoma
wereslightlyhigherindosedthanincontrolmice (males:
controls 2/15, low-dose 8/34, high-dose 4/34; females:
controls 2/15, low-dose 4/31, high-dose 10/34). The inci-
dences were not significantbyanyofthe statistical tests
used, including the Tarone and Cox tests using the life-
table method.
It is concluded that under the conditions of this bio-
assay, ethionamide was not carcinogenic in either
Fischer 344 rats or B6C3F1 mice.
Synonym: 2-ethylthioisonicotinamide
Report Date: 1978
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Levels of Evidence ofCarcinogenicity:
Male Rats: Negative
Female Rats: Negative
Male Mice: Negative
Female Mice: Negative
TR-47 Bioassay of4,4'-Thiodianiline for
Possible Carcinogenicity (CAS No.
139-65-1)
4,4'-Thiodianiline is an intermediate in the manufac-
ture ofseveral diazo dyes.
A bioassay of 4,4'-thiodianiline for possible car-
cinogenicity was conducted by administering the test
chemical in feed to Fischer 344 rats and B6C3F1
mice.
Groups of 35 rats and 35 mice of each sex were
administered 4,4'-thiodianiline 5 days perweek at one of
thefollowingdoses, either1,500 or3,000ppmfortherats
and either2,500 or5,000 ppmforthe mice. The period of
administration of the chemical was 68-72 weeks for the
rats and 77 or 79 weeks for the mice, depending on the
length ofsurvival time ofthe animals. Matched controls
consisted ofgroups of15untreatedrats and 14untreated
mice ofeach sex.Allsurvivingmatched-control ratswere
killed at 104 weeks; all surviving matched-control mice
were killed at 91 weeks.
The administration of 4,4'-thiodianiline resulted in
marked reduction in mean bodyweights ofthe rats and
mice ofeach sex, and all dosed animals died prior to the
scheduled end ofthe study.
Tumors ofepithelial originwerefoundinmanyorgans,
andalldosedratsexceptonewereaffected atone ormore
sites (males: skin, ear canal, lungs, liver, colon, and
thyroid; females: ear canal, lung, liver, thyroid, and
uterus). These tumors were not found among any ofthe
matched-control animals.
In male rats, several of these neoplastic lesions
occurredwithstatisticallysignificantincidencesinoneor
both ofthe dosed groups. The incidences ofhepatocellu-
lar carcinoma (controls 0/15, low-dose 21133, high-dose
10/33) and of follicular-cell carcinoma of the thyroid
(controls 0/15, low-dose 28/33, high-dose 32/33) were
significant in each of the groups at P< 0.014. The com-
bined incidences of squamous-cell carcinoma and
squamous-cell papilloma ofthe ear canal in the low- and
high-dose groups ofmaleswerebothsignificantlyhigher
(low-dose P=0.001, high-dose P=0.037) than thatin the
control group (controls 0/15, low-dose 15/33, high dose
8/33). The first such tumor in the high-dose group was
observed at 25 weeks.
Also in low-dose male rats, squamous-cell papilloma of
the skin occurred in 4/33 animals, and squamous-cell
carcinomaoftheskinin1/33,butnotumorsofeithertype
occurred in the controls. The incidences ofthese lesions
weretoolowtohavestatisticalsignificance.Themajority
ofthe squamous-cell tumors ofthe skin were located in
one area near the commissure of the mouth. Only one
such tumor occurred among the 235 historical-control
male rats at this laboratory; thus, the tumors ofthe skin
may be associated with administration of the chemical.
Adenocarcinoma of the colon occurred in six low-dose
male rats andin one high-dose male rat, butnotin anyof
thecontrols. Thisincidenceisnotstatisticallysignificant;
however, no such tumors occurred among the 235
historical-control male rats at this laboratory; thus, the
tumors of the colon are considered to be related to
administration of4,4'-thiodianiline.
In female rats, the incidences of hepatocellular ade-
noma or carcinoma in the dosed groups were greater
than those in the controls, but not statistically signifi-
cant (controls 0/15, low-dose 6/32, high-dose 3/33).
Follicular-cell carcinoma of the thyroid and adenocar-
cinoma of the uterus occurred in the females admin-
istered the test chemical at statistically significant
incidences (P<0.001) inboth dosed groups (follicular-cell
carcinoma: controls 0/14, low-dose 24/33, high-dose
32/32; adenocarcinoma: controls 0/15, low-dose 31V33,
high-dose 23/32). Squamous-cell papilloma or carcinoma
of the ear canal occurred at increased, but not statis-
ticallysignificant, incidencesinfemalerats(controls0/15,
low-dose 6/33, high-dose 3/33). However, no such tumors
occurred among the 235 historical-control female rats
at this laboratory; thus, the tumors of the ear canal
are considered to be related to administration of the
chemical.
In mice of each sex, the incidence of hepatocellular
carcinomawas statistically significant (P<0.001) in each
ofthe dosed groups (males: controls1113, low-dose32/34,
high-dose 22/24, females: controls 0/12, low-dose 32/34,
high-dose30/31). Inthemales,follicular-cell carcinomaof
the thyroid occurred at statistically significant inci-
dences(P. 0.001) in both the low- and high-dose groups
(controls 0/14, low-dose 15/33, high-dose 20/23). In the
females, the incidence was significant (P= 0.002) only
at the high dose (controls 0/11, high-dose 15/30);
however, when follicular-cell adenoma and carcinoma
were combined, the incidences in both the low- and high-
dose groups of females were significantly higher (low-
dose P=0.025, high-dose P<0.001) than that in the
control group (controls 0/11, low-dose 11133, high-dose
18/30).
It is concluded that under the conditions of this bio-
assay,4,4'-thiodianiline was carcinogenic forFischer344
rats, inducing tumors in the liver, thyroid, colon, and ear
canal ofmale rats, and thethyroid, uterus, and ear canal
of female rats. 4,4'-Thiodianiline was carcinogenic for
B6C3F1 mice,inducingtumorsintheliverandthyroid of
both males and females.
Report Date: 1978
Levels ofEvidence ofCarcinogenicity:
Male Rats:
Female Rats:
Male Mice:
Female Mice:
Positive
Positive
Positive
Positive
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TR-48 Bioassay ofPyrazinamide for
Possible Carcinogenicity (CAS No. 98-96-4)
A bioassay of the tuberculostatic drug pyrazinamide
for possible carcinogenicity was conducted by admin-
isteringthe testchemical infeed to Fischer344 rats and
B6C3F1 mice.
Groups of 35 rats and 35 mice of each sex were
administered pyrazinamide at one of two doses, either
5,000 or 10,000ppm, for 78weeks, and then observed for
an additional26 or27weeks. Matched controls consisted
of groups of15 untreated rats and 15 untreated mice of
each sex. High-dose male mice died or were killed by
week92; allothersurvivinganimalswerekilled atweeks
104 or 105.
Mean body weights of the dosed male rats were
slightly lower than those ofthe matched controls, while
mean body weights of the dosed females were more
nearly comparable to those of the controls. A sufficient
numberofratsineachgroupwasatrisktoterminationof
the study at weeks 104-105 for the development of late-
appearing tumors.
Inmice,administrationofpyrazinamidehadnoconsis-
tent effect on mean body weights. Survival to termina-
tion ofthe studywas low, particularly amongthe control
groups.
In rats, no lesions could clearly be related to admin-
istration ofthe chemical.
Inmice,interstitialandsuppurativemyocarditisinthe
dosed animals and suppurative bronchopneumonias in
both dosed and matched control mice of each sex were
associated with increased deaths. In the females, there
was a significant positive dose-related trend (P=0.037)
intheincidence oflymphoma(matched controls 0/13, low-
dose 2/25, high-dose 6/29); however, the incidences in
each of the dosed groups were not significant when
comparedwith that in the matched controls. In addition,
the poor survival and the small size ofthe control group
precluded making a clear association ofthe incidence of
these tumors with administration ofthe chemical.
It is concluded that under the conditions of this bio-
assay,theearlydeaths andsmallsizeofthecontrolgroup
precluded a conclusion regarding the carcinogenicity of
pyrazinamide infemaleB6C3F1 mice. Pyrazinamidewas
not carcinogenic for Fischer 344 rats or for male
mice.
Synonym: pyrazinecarboxamide
Report Date: 1978
Levels ofEvidence ofCarcinogenicity:
TR-49 Bioassay ofAcronycine for
Possible Carcinogenicity (CAS No.
7008-42-6)
Acronycine, an alkaloid derived from the bark of the
Australianscrubash,hasbeeninvestigated asanexperi-
mental anticancer drug. Acronycine was selected for
screeninginthecarcinogenesisprograminan attemptto
evaluatethecarcinogenicityofcertaindrugsthatmaybe
used for prolonged periods in humans.
A bioassay of acronycine for possible carcinogenicity
was conducted by administering the test chemical by
intraperitoneal injection to Sprague-Dawley rats and
B6C3F1 mice.
Initially, groups of 35 rats of each sex were admin-
isteredacronycine atoneoftwodoses,either7.5or15mg/
kg bodyweight, in a vehicle composed of0.05% polysor-
bate 80 in phosphate-buffered saline. Control groups of
each sex consisted of 10 untreated rats (untreated con-
trols) and 10 rats injected with the vehicle (vehicle con-
trols). Because of high mortality rates in the dosed
animals, new dosed groups of 35 rats of each sex were
startedlateratadoseof3.75mg/kg.Additionalgroupsof
10untreated and10vehicle controls ofeach sexwere also
started. The rats were administered the acronycine or
the vehicle for 51 or 52 weeks, then observed for an
additional 28-30 weeks. All surviving rats were killed at
80-82 weeks.
Initially, groups of 35 mice of each sex were admin-
istered acronycine at one of two doses, either 12.5 or 25
mg/kg body weight, in a vehicle composed of 0.05%
polysorbate 80 in phosphate-buffered saline. Control
groups ofeach sexconsisted of10untreated mice (untre-
ated controls) and 10 mice injected with the vehicle
(vehicle controls). Because ofhigh mortality rates in the
dosed animals, twoadditionaldosed groupswere started
later: 35 mice ofeach sex at 6 mg/kg and 40 mice ofeach
sex at 2 mg/kg, together with 10 untreated controls and
10 vehicle controls ofeach sex for the groups dosed at 6
mg/kg, and 20untreated controls and 20vehicle controls
for the groups dosed at 2 mg/kg. Periods ofadministra-
tion ofthe chemical to the mice varied from 25 weeks to
92 weeks, depending on toxicity or length of time of
survival. Surviving control animals were killed at 78-105
weeks.
Acronycinewastoxictorats andmice ofeach sexatthe
doses used in this bioassay, as shown by the high mor-
tality rates in all but the low-dose groups and by the
lower mean body weights in dosed rats and mice at all
doses throughout most ofthe bioassay.
Because ofthis high number ofdeaths, time-adjusted
statistics are used for the analyses of all incidences of
tumors.In male rats, the dose-related trend in the mid-
and high-dose groups for the incidence ofosteosarcoma
at all sites was significant (P =0.002) using the respec-
tive vehicle-control group (vehicle controls 0/8, mid-dose
13/30, high-dose 12/18). Comparisons of the individual
groups with respective control groups were also signifi-
cant for the mid-dose (P = 0.022) and high-dose
Male Rats:
Female Rats:
Male Mice:
Female Mice:
Negative
Negative
Negative
Inadequate Study
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(P=0.002) groups, but not for the low-dose group. In
female rats, osteosarcomawasobserved onlyin1/8high-
dose animals.
Sarcomas and other related tumors ofthe peritoneum
were observedinallthreedosed groups ofbothmaleand
female rats,butinnone ofthe controlgroups (males: low-
dose 5/30, mid-dose 3/26, high-dose 7/16; females: low-
dose 1/35, mid-dose 5/30, high-dose 13/28). Inboth sexes,
the dose-related trends were significant (males,
P=0.006; females, P=0.002), and the comparison ofthe
incidences in the high-dose females with the vehicle-
control group was significant (P=0.016). None of the
incidences in the individual dosed groups ofmales were
significant when compared with vehicle controls. How-
ever, since the tumorswere observed in all dosed groups
but did not occur in historical-control animals at this
laboratory, they are considered to be related to the
administration ofthe chemical.
In female rats, the incidence ofall tumors ofepithelial
origin ofthe mammary gland was significant only at the
low dose (low-dose vehicle controls /10, low-dose 22/35,
P =0.004). Adenocarcinomas of the mammary gland
were observed in seven low-dose, five mid-dose, and two
high-dose female rats, but in no control females. The
reverse dose relationship ofboth benign and malignant
tumors was probably due to the higher number ofearly
deaths which occurred in the high-dose group.
Inmice, thelowsurvivalinalldosedgroupsexceptthe
low-dose animals precluded an evaluation ofthe signifi-
cance ofthe incidences oftumors. Lymphomas occurred
in low-dose groups ofboth males and females; however,
the incidence of lymphoma in different control groups
was highly variable. The high incidence in the low-dose
vehicle controls may have been due to a procedural
problem associated with the possibility of transfer of
tumor cells or oncogenic viruses during the intra-
peritoneal injection ofthe test chemical.
It is concluded that under the conditions of this bio-
assay, the low survival ofthe dosed and control mice and
the possible procedural problems associated with the
intraperitoneal injection ofthe chemical did not allow a
determination to be made ofthe carcinogenicity ofacro-
nycine inthis species.
In Sprague-Dawley rats, acronycine in the vehicle of
0.05% polysorbate 80 in phosphate-buffered saline was
carcinogenic, producing tumors of the mammary gland
in females, osteosarcomas in males, and sarcomas and
otherrelated tumors oftheperitoneuminbothmalesand
females.
Synonym: 3,12-dihydro-6-methoxy-3,3,12-trimethyl-7H-
pyrano(2,3-c)acridin-7-one
Report Date: 1978
Levels ofEvidence ofCarcinogenicity:
Male Rats: Positive
Female Rats: Positive
Male Mice: Inadequate Study
Female Mice: Inadequate Study
TR-50 Bioassay ofAcetohexamide for
Possible Carcinogenicity (CAS No.
968-81-0)
Acetohexamide is an oral hypoglycemic agent of the
arylsulfonyl-urea group with a potency between that of
tolbutamide and chlorpropamide.
A bioassay of acetohexamide for possible car-
cinogenicity was conducted by administering the test
chemical in feed to Fischer 344 rats and B6C3F1 mice.
Groups of 35 rats of each sex were administered
acetohexamide in the diet at one of two doses, either
10,000or20,000ppm,for103weeksandthenobservedfor
2 to 4 additionalweeks. Matched controls consisted of15
untreated rats ofeach sex. All survivingrats were killed
at 105 to 107 weeks.
Groups of 35 mice of each sex were administered
acetohexamide atoneoftwodosesfor103weeksandthen
observed for 4 or 5 additional weeks. Time-weighted
average doses were 6,359 or 12,718 ppm. Matched con-
trols consisted of 15 untreated mice of each sex. All
surviving mice were killed at 107 or 108 weeks.
Meanbodyweights ofthe dosed rats and mice ofboth
sexes were lower than those of the corresponding
matched controls throughout the study, and the depres-
sions inweightwere dose related. Except for the female
mice,sufficientnumbersofanimalssurvivedlongenough
to be at risk for development of late-appearing tumors.
In the rats, the only tumor occurring with greater
incidence in dosed than in matched-control animals was
leukemia (males: matched controls 0/15, low-dose 10/35,
high-dose 4/35; females: matched controls 0/14, low-dose
7/35, high-dose 4/34). Only the incidence in the low-dose
maleswas statisticallysignificant(P=0.018).Allofthese
animals had undifferentiated (mononuclear cell) leuke-
mia, which commonly occurs spontaneously in Fischer
344 rats, except for two with lymphocytic leukemia. The
incidence of combined leukemia and lymphoma in
historical-control male rats at this laboratory in the
bioassay program to date is 24/235 (10.2%), which is
higher than that in the matched controls. Thus, the
incidence in the low-dose males cannotbe clearly associ-
ated with administration ofthe test chemical.
In the mice, the only neoplasms that occurred at a
higher incidence in dosed groups than in matched con-
trols were lymphomas in the males, but the incidences
were not statistically significant (matched controls 1/15,
low-dose 9/35, high-dose 3/34).Thesetypes oflesions are
found commonly in untreated B6C3F1 mice. The inci-
denceoflymphomasinthehistorical-controlmalemiceis
28/536 (5.2%).
It is concluded that under the conditions of this bio-
assay, acetohexamide was not carcinogenic for either
Fischer 344 rats or B6C3F1 mice.
Synonym: 1-[(p-acetylphenyl)-sulfonyl]-3-cyclohexyl-
urea
Report Date: 1978
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Levels ofEvidence ofCarcinogenicity:
Male Rats:
Female Rats:
Male Mice:
Female Mice:
Negative
Negative
Negative
Negative
TR-51 Bioassay ofTolazamide for
Possible Carcinogenicity (CAS No.
1156-19-0)
Tolzamide is an oral hypoglycemic agent of the
arylsulfonylurea type, similar to tolbutamide, chlo-
rpropamide, and acetohexamide.
A bioassay of the hypoglycemic drug tolazamide for
possible carcinogenicity wasconductedbyadministering
the test chemical in feed to Fischer344 rats andB6C3Fj
mice.
Groups of 35 rats and 35 mice of each sex were
administered tolazamide at oneoftwo doses, either5,000
or10,000 ppm, for103weeks. Matched controls consisted
of15 rats and 15 mice ofeach sex. All surviving rats and
mice were killed at 104 or 105 weeks.
Survival rates for the dosed rats of each sex were
higher than those for the matched controls, and were
adequate for the development oflate-appearing tumors.
Survival rates forthe mice were lowerthan those for the
rats,particularlyforthedosedfemales (matchedcontrols
67%, low-dose 34%, high-dose 32%). However, a large
number of these deaths in the dosed females occurred
after 90 weeks on study, and survival ofboth males and
females was adequate for the development of late-
appearing tumors.
All observed tumors were oftypes commonly found in
the strains of animals used, and there were no statis-
tically significant increases in the incidence oftumors in
the dosed animals as compared with controls.
It is concluded that under the conditions of this bio-
assay, tolazamide was not carcinogenic for Fischer 344
rats or B6C3F1 mice.
Synonym: N-(p-toluenesulfonyl)-N'-hexamethyleni-
minourea
Report Date: 1978
Levels of Evidence ofCarcinogenicity:
Male Rats:
Female Rats:
Male Mice:
Female Mice:
Negative
Negative
Negative
Negative
TR-52 Bioassay of 3-Nitropropionic Acid
for Possible Carcinogenicity (CAS No.
504-88-1)
3-Nitropropionic acid was selected for testing for car-
cinogenic activity because it was known to demonstrate
varying degrees of toxicity in man and animals, and
becauseitsuseinfoodpreparations and itsidentification
as a contaminant in foods suggested there was a pos-
sibilityoflong-term human exposure.
A bioassay of 3-nitropropionic acid (95% pure) for
possible carcinogenicity was conducted by administer-
ing the test chemical by gavage to Fischer 344 rats and
B6C3F1 mice.
Groups of 50 rats and 50 mice of each sex were
administered3-nitropropionic acid atoneofthefollowing
doses by gavage 5 days per week. For male rats, the
doseswere0.425or0.85mg/animaVday; forfemales,they
were0.6or1.2mg/animaVday. Forboth sexes ofmice,the
doses were 0.375 or 0.75 mg/animaVday. The rats were
administered the chemicalfor110weeks and themicefor
104 weeks. The controls consisted of 50 untreated rats
and 50 untreated mice of each sex. All surviving rats
were killed at 111 weeks and all surviving mice at 104 or
105weeks.
Meanbodyweightsandmortalityofthedosedanimals
were not markedly affected by 3-nitropropionic acid
under the conditions ofthis bioassay, indicating that the
maximumtolerated dosemaynothavebeenreached.The
various clinical signs observed were common to both
dosed and control groups.
In rats, the combination of neoplastic nodule of the
liverand hepatocellular carcinomaoccurred inthemales
with asignificantdose-related trend (P =0.010) andwith
a higher incidence (P=0.012) in the high-dose group of
animalsthaninthecontrols(controls0/49,low-dose3/50,
high-dose6/49).Allbutoneofthesetumorswereneoplas-
tic nodules. In the females, only two neoplastic nodules
occurred, one in each ofthe dosed groups. Biliaryhyper-
plasia occurred at a higher incidence in the dosed males
than in the corresponding controls (controls 19/50, low-
dose 32/50, high-dose 36/50), but the incidence of this
lesion in the dosed females was not increased as com-
paredwith controls. There was also a dose-related trend
(P =0.033) in the incidence of pancreatic islet-cell ade-
nomainthemale rats (controls 4/49, low-dose 6/50, high-
dose 11150); however, direct comparisons ofincidences in
thedosedandcontrolgroupswerenotstatisticallysignif-
icant. The historical incidence of pancreatic islet-cell
adenoma among 100 control Fischer 344 rats at the
laboratory was 7/100 (7%). In addition, focal myocardial
fibrosis was observed at a higherincidence in dosed rats
than among controls (males: controls 1/4, low-dose 17/49,
high-dose 24/48; females: controls 2/48, low-dose 9/46,
high-dose 9/50).
In mice, each type ofneoplasm found in the dosed and
control mice has been encountered previously as a spon-
taneous lesion. No specific tumorwas found to occur at a
statistically significantly higher incidence among dosed
mice than among the respective control groups.
It is concluded that under the conditions of this bio-
assay, there was an elevated incidence ofhepatocellular
neoplasms, primarily benign, and of islet-cell adenomas
of the pancreas in male Fischer 344 rats receiving
3-nitropropionic acid as compared with controls; how-
ever, there was no conclusive evidence that 3-nitropro-
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pionic acid wascarcinogenic inthese animals. Thechemi-
cal was not carcinogenic in female rats or in male or
female B6C3F1 mice.
Synonyms: 3-nitropropionic acid; hiptagenic acid
Report Date: 1978
Levels ofEvidence ofCarcinogenicity:
Male Rats:
Female Rats:
Male Mice:
Female Mice:
Equivocal
Negative
Negative
Negative
TR-53 Bioassay of2-Amino-5-
Nitrothiazole for Possible Carcinogenicity
(CASNo.121-66-4)
2-Amino-5-nitrothiazole is an antiprotozoal drug for
animals which is now used in the form of the acetyl
derivative to control histomoniasis (blackhead) in tur-
keys. Theuse ofacetyl-2-amino-5-nitrothiazole inanimal
feed and the allowable residues in food products from
treated animals (0.1 ppm) are regulated bythe Food and
Drug Administration.
Abioassay of2-amino-5-nitrothiazole forpossible car-
cinogenicity was conducted by administering the test
chemical in feed to Fischer 344 rats and B6C3F1 mice.
Groups of 50 rats and 50 mice of each sex were fed
2-amino-5-nitrothiazole at one of the following doses,
either 300 or 600 ppm for rats, and either 50 or 100 ppm
formice. Theratswere dosedfor110weeks,followedby1
week ofobservation; the mice were dosed for 104 weeks.
Matched controls consisted of 50 untreated rats and 50
untreated mice ofeach sex.Allsurvivingratswerekilled
at week 111, all surviving mice atweek 104.
The mean bodyweights ofthe groups ofrats andmice
fed 2-amino-5-nitrothiazole in the diet were slightly
lower than those ofthe controls throughout most ofthe
period ofadministration. No other clinical signs related
to administration ofthe chemical were noted. Therewas
a dose-related trend in mortality only in the male rats;
however, sufficient numbers of rats were at risk in all
groups for development oflate-appearing tumors.
Inmalerats,therewasasignificantdose-relatedtrend
(P=0.044) in the incidences of malignant lymphomas,
lymphocytic leukemias, or undifferentiated leukemias,
although the results ofdirect comparisons ofincidences
in each of the dosed groups with those in the controls
were not significant. There was also a signiflcant dose-
relatedtrend in theincidence ofgranulocytic leukemia in
the male rats (P=0.014) and a signiflcantly increased
incidence ofthistumor(P =0.023)inthehigh-dosegroup
(matched controls 2/50, low-dose 4/50, high-dose 9/49).
When theincidences ofall neoplasms ofthe hematopoie-
ticsystemlymphomasandallleukemias)werecombined,
greater significance was attained for both the dose-
related trend (P = 0.001) and the direct comparison
(P=0.002) ofthe incidence ofthe high-dose group with
that in the matched controls (controls 13/50, low-dose
9/50, high-dose 28/49). The reliability ofthe incidence of
hematopoietictumorsinthemalecontrolswassupported
bythatformalecontrolsobservedinasimilarbioassayof
anothertestchemical atthe samelaboratory (13/50). The
incidences ofthe combined hematopoietic tumors in the
dosed female rats were not significant when compared
with the incidence in the matched controls.
In female rats, there was a significant dose-related
trend in the incidence of chromophobe adenomas of the
pituitary (P=0.016) and ahigherincidence (P=0.021) in
the high-dose group than in the matched controls (con-
trols 19/45, low-dose 29/47, high-dose 29/44). The inci-
dence of this lesion in dosed male rats was much lower
than that in dosed females, and the dose-related trend
(P= 0.048) was only marginally significant (controls
3/46, low-dose 3/45, high-dose 8/43). The incidences of
chromophobe adenomas of the pituitary which were
observed in control groups of rats used in a similar
bioassay ofanother testchemical atthe same laboratory
were 13/49 (27%) for the males and 26/50 (52%) for the
females. Because of the variability in incidences of the
tumor amongdifferentcontrol groups, the occurrence of
chromophobe adenomas of the pituitary in the dosed
female rats cannotbe clearly associatedwith the admin-
istration of2-amino-5-nitrothiazole.
Also in female rats, there was a higher incidence of
endometrial stromalpolyps ofthe uterus in the low-dose
group (P=0.023) than in the matched controls (controls
2/50, low-dose 9/49, high-dose 3/50). Since, however, only
three high-dose animals had this tumor, the occurrence
ofuterine tumorsinthelow-dosegroupcannotbeclearly
associated with administration ofthe test chemical.
In the mice, no neoplasms were observed at a statis-
tically significant incidence in the dosed groups when
compared with the controls.
It is concluded that under the conditions of this bio-
assay, the occurrence of tumors of the hematopoietic
system, i.e., lymphoma and granulocytic leukemia, in
dosed male Fischer 344 rats was associated with ad-
ministration of 2-amino-5-nitrothiazole. 2-Amino-5-
nitrothiazole was not carcinogenic in female Fischer344
rats or in male or female B6C3F1 mice.
Report Date: 1978
Levels ofEvidence ofCarcinogenicity:
Male Rats:
Female Rats:
Male Mice:
Female Mice:
Positive
Negative
Negative
Negative
TR-54 Bioassay of2,4-Dinitrotoluene for
Possible Carcinogenicity (CAS No. 121-14-2)
2,4-Dinitrotoluene, a precursor in the synthesis ofazo
dyes, was selected for bioassay by the National Cancer
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Institute along with other dye intermediates in an
attempt to elucidate those chemicals which may be
responsible fortheincreased incidence ofbladder cancer
observed among workers in the dye manufacturing
industry. 2,4-Dinitrotoluene is used by the munitions
industry as a modifier for smokeless powders and, to a
limited extent, as agelatinizing andwaterproofing agent
in military and commercial explosive compositions.
A bioassay of practical-grade 2,4-dinitrotoluene for
possible carcinogenicity was conducted using Fischer
344 rats and B6C3F1 mice. 2,4-Dinitrotoluene was
administered in the feed, ateither oftwo concentrations,
to groups of 50 male and 50 female animals of each
species. Formale and female rats, the high andlowtime-
weighted average dietary concentrations of 2,4-
dinitrotoluene were 0.02 and 0.008 percent, respectively.
For male and female mice, the high and low time-
weighted average concentrations were 0.04 and 0.008
percent, respectively. After a 78-week period of com-
pound administration, observation ofthe rats continued
for an additional 26 weeks and observation of the mice
continued for 13 additional weeks.
For the chronic rat bioassay, 25 rats ofeach sex were
placed on test as high dose controls, and 50 rats ofeach
sex served as the low dose controls. For the mice, 50
males and 50 females were placed on test as controls for
each ofthe high dose and low dose groups.
Inboth speciesthe survivalinallgroupswas adequate
for statistical analysis oflate-appearing tumors.
In the male rats, a significantly increased incidence of
fibroma ofthe skin and subcutaneous tissue occurred in
both thehigh andthelowdose groupswhencompared to
their respective controls. A statistically significant inci-
dence offibroadenoma ofthe mammary gland occurred
in the high dose female rats.
Amongthe mice avariety oftumors was observed but
none were considered to be associated with the dietary
administration of2,4-dinitrotoluene.
Under the conditions of this bioassay dietary admin-
istrationof2,4-dinitrotoluenetoFischer344ratsinduced
benigntumors (i.e., fibromaofthe skinandsubcutaneous
tissueinmales andfibroadenoma ofthemammarygland
in females). No evidence was provided for the car-
cinogenicity of the compound in B6C3F1 mice of either
sex.
Synonyms: 1-methyl-2,4-dinitrobenzene; 2,4-dinitro-
toluol; 2,4-DNT
Report Date: 1978
Levels ofEvidence ofCarcinogenicity:
TR-55 Bioassay of1,2-Dichloroethane for
Possible Carcinogenicity (CAS No.
107-06-2)
1,2-Dichloroethane, a chlorinated aliphatic hydrocar-
bon, is one of several halogenated solvents selected for
bioassay bythe National Cancer Institute. Although the
major use of1,2-dichloroethane is as an intermediate in
the synthesis ofvinyl chloride, the compound also finds
application as a constituent in lead-containing antiknock
preparations, as an ingredient in fumigant-insecticide
formulations and, to a more limited extent, as a compo-
nentofmetal degreasingmixtures. 1,2-Dichloroethane is
additionallyemployed as anintermediateinthesynthesis
of the chlorinated solvents 1,1,1-trichloroethane, tri-
chloroethylene, and perchloroethylene and as a constitu-
ent of rubber cements and acrylic-type adhesive
formulations.
A bioassay of technical-grade 1,2-dichloroethane for
possible carcinogenicity was conducted using Osborne-
Mendel rats and B6C3F1 mice. 1,2-Dichloroethane in
corn oil was administered by gavage, at either of two
dosages, to groups of 50 male and 50 female animals of
eachspecies.The78-weekperiodofchemicaladministra-
tion was followed by an observation period of 32 weeks
for the low dose rats of both sexes. The last high dose
male rat died after 23 weeks ofobservation and the last
high dose female rat died after 15 weeks of observation.
All treated groups of mice were observed for an addi-
tional 12 or 13 weeks following chemical administration.
Initial dosage levels for the chronic bioassay were
selected on thebasis ofapreliminary subchronic toxicity
test. Subsequent dosage adjustments were made during
the course of the chronic bioassay. The time-weighted
average high and low doses of1,2-dichloroethane in the
chronicstudywere95 and47mg/kg/day,respectively, for
rats of both sexes. The high and low time-weighted
average doses for the male mice were 195 and 97mg/kg/
day, respectively, and 299 and 149 mg/kg/day, respec-
tively, for the female mice.
Foreach species,20 animals ofeach sexwereplaced on
test as vehicle controls. These animals were gavaged
with corn oil at the same times that dosed animals were
gavaged with the 1,2-dichloroethane mixtures. Twenty
animals of each sex were placed on test as untreated
controls for each species. These animals were not intu-
bated.
A statistically significant positive association between
dosage and the incidence ofsquamous-cell carcinomas of
the forestomach and hemangiosarcomas of the circula-
tory system occurred in the male rats, but not in the
females. There was also a significantly increased inci-
dence of adenocarcinomas of the mammary gland in
female rats.
The incidences of mammary adenocarcinomas in
female mice were statistically significant. There was a
statistically significant positive association between
chemical administration and the combined incidences of
endometrial stromal polyps and endometrial stromal
Male Rats:
Female Rats:
Male Mice:
Female Mice:
Positive
Positive
Negative
Negative
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sarcomas in female mice. The incidence of alveolar/
bronchiolar adenomas in both male and female micewas
also statistically significant.
Under the conditions ofthis study, 1,2-dichloroethane
was carcinogenic to Osborne-Mendel rats, causing
squamous-cell carcinomas of the forestomach,
hemangiosarcomas, and subcutaneous fibromas in male
rats and causing mammary adenocarcinomas in female
rats. This compoundwas also found tobe carcinogenic to
B6C3F1 mice, causing mammary adenocarcinomas and
endometrial tumorsinfemalemice, andcausingalveolar/
bronchiolar adenomas in mice ofboth sexes.
Synonyms: ethylene chloride; ethylene dichloride; alpha
beta dichloroethane
Report Date: 1978
Levels ofEvidence ofCarcinogenicity:
Male Rats:
Female Rats:
Male Mice:
Female Mice:
Positive
Positive
Positive
Positive
TR-56 Bioassay ofN,N'-
Dicyclohexyithiourea for Possible
Carcinogenicity (1212-29-9)
N,N'-dicyclohexylthiourea is a chemical intermediate
used in the production of dicyclohexylcarbodimide, a
reagent used in the synthesis of peptide and phos-
phodiester internucleotide bonds.
A bioassay of N,N'-dicyclohexylthiourea for possible
carcinogenicity was conducted byadministering the test
chemical in feed to Fischer 344 rats and B6C3F1 mice.
Groups of 50 rats and 50 mice of each sex were
administered N,N'-dicyclohexylthiourea at one of two
doses, either25,000 or50,000 ppm, for109weeks forrats
or 104 weeks for mice. Matched controls consisted of 50
untreated rats or 50 untreated mice ofeach sex.
Mean body weights ofmale rats and male mice were
unaffected by the compound, whereas mean body
weights ofthe females ofeach species showed mild dose-
related retardation over the bioassay period, when com-
pared with the matched controls. Survival was sufficient
to termination ofthe study in all groups ofboth rats and
mice for the development oflate-appearing tumors.
In male rats there was an increased incidence of
hyperplasia of the follicular cells of the thyroid (males:
controls 3/43, low-dose 16/49, high-dose 15/49; females:
controls 1/48, low-dose 7/48, high-dose 5/49). The inci-
dences of tumors of the follicular cells of the thyroid,
although increased among the dosed male rats, were not
statistically significant in either sex.
In mice, a variety of neoplasms of the type usually
encountered in the B6C3F1 strain were observed in both
dosed and control animals. None ofthe tumors occurred
at statistically significant incidences. Follicular-cell
hyperplasia ofthe thyroid was observed at an increased
incidence in both the dosed males and females (males:
controls 3/39, low-dose 12/46, high-dose 9/45; females:
controls 8/38, low-dose 22/46, high-dose 21146).
An increase in proliferative lesions of the follicular
cells ofthe thyroid was associated with the administra-
tion of N,N'-dicyclohexylthiourea in both Fischer 344
rats and B6C3F1 mice. However, because statistical sig-
nificance was not achieved and because thyroid tumors
are not rare, spontaneous lesions in these strains of
animals and occur with a variable incidence, it is con-
cluded that under the conditions ofthis bioassay, N,N'-
dicyclohexylthiourea was not demonstrated to be car-
cinogenic in either species.
Report Date: 1978
Levels ofEvidence ofCarcinogenicity:
Male Rats:
Female Rats:
Male Mice:
Female Mice:
Negative
Negative
Negative
Negative
TR-57 Bioassay of 13-TGdR for Possible
Carcinogenicity (CAS No. 789-61-7)
Beta-2'-deoxy-6-thioguanosine monohydrate (I-
TGdR) is an experimental anticancer drug and a deriva-
tive ofthe anticancer drug 6-thioguanine (6-TG).
A bioassay ofbeta-2'-deoxy-6-thioguanosine monohy-
drate (,B-TGdR) for possible carcinogenicity was con-
ducted by administering the test chemical by
intraperitoneal injection to Sprague-Dawley rats and
B6C3F1 mice.
Groups of 35 rats of each sex were administered
,-TGdRinabuffered salineandpolysorbate80vehicle at
oneoftwodoses,either3.5or7mg/kgbodyweight,three
times per week for 52 weeks, then observed for an
additional 26 weeks. Controls consisted of groups of 10
rats of each sex, which were either administered the
vehicle alone (matched vehicle controls) or were untre-
ated (matched untreated controls). Pooled controls con-
sisted of the matched vehicle controls of each sex from
the current bioassay, combined with 20 corresponding
vehicle controls ofeach sexfromsimilarbioassays oftwo
other test chemicals. All surviving rats were killed at 78
or 79 weeks.
Groups of 35 mice of each sex were administered the
chemicalinabufferedsalineandpolysorbate80vehicleat
one of two doses, either 2 or 4 mg/kg, three times per
weekfor 52weeks, then observed forperiods ofup to 27
weeks, depending on length of survival. Because of
severe toxicity at the high dose, resulting in loss of all
mice byweek 12 (males) orweek 25 (females), additional
groups of35mice ofeach sexwere administered 1mg/kg
on the same schedule. Controls consisted ofgroups of15
mice of each sex, which were either administered the
vehicle or were untreated. Pooled controls consisted of
groups of 15 vehicle-control animals of each sex from
studies using the doses of2 or 4 mg/kg, combined with
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corresponding groups of 15 vehicle-control animals of
each sex from the study using the dose of1 mg/kg.
,B-TGdR was toxic to rats at the doses used in this
study. Meanbodyweights ofthe high- and low-dose rats
ofboth sexeswerelowerthanthoseofthecorresponding
vehicle controls throughout the study. There was also
severe early mortality in the high-dose groups of both
sexes and positive dose-related trends in mortality over
theperiod ofthebioassay. However, 66% ofthe low-dose
males and 77% of the low-dose females survived until
termination ofthe study.
In mice, ,B-TGdR was toxic at the doses originally
selected. Mean body weights were not consistently
affected; however, at the high dose onlythree males and
seven females lived past week 7, and all were dead by
week 25. In the mid-dose group, only 14% of the males
and 6% ofthe females survived until termination ofthe
studyatweek79; inthelow-dose group, the survival rate
was 31% for the males and 29% for the females.
Because ofthe high mortality, time-adjusted statisti-
cal analyses were performed for both rats and mice.
In rats, the incidence of carcinomas of the ear canal
(combined carcinomas and squamous-cell carcinomas)
was statistically significant in both sexes. In males, the
results ofthe testfordose-related trendwere significant
usingeithermatchedvehicle (P=0.046) orpooledvehicle
(P=0.014)controls,butdirectcomparisons ofdosedmale
rats with matched vehicle or pooled vehicle controls did
not show significant differences (matched vehicle con-
trols 0/10, pooled vehicle controls 0/28, low-dose 1131,
high-dose2/7). Infemales,theresults ofthetestfordose-
relatedtrendwere significant usingeithermatchedvehi-
cle (P=0.002) or pooled vehicle (P<0.001) controls, and
the incidence in the high-dose group was significantly
higherthanthatineitherthematchedvehicle (P=0.023)
or pooled vehicle (P<0.001) controls (matched vehicle
controls 0/9, pooledcvehicle controls 0/28, low-dose 2/32,
high-dose 6/13). There were no such ear canal tumors
among 165 historical vehicle controls of either sex or
among 220 female untreated controls at the laboratory,
and only two such tumors occurred among 215 male
untreated controls.
Inmice, notumors appearedinstatisticallysignificant
incidences in the dosed groups compared with the
matched vehicle controls, and there was no significant
evidence ofdose-related trend for any tumors. The inci-
dences of the combination of lymphoma and leukemia
were significantly higher in thematched vehicle controls
ofeach sexthaninthecorrespondingmatcheduntreated
controls (males: matched untreated controls 1/30,
matched vehicle controls 19/29; females: matched untre-
ated controls 2/30, matched vehicle controls 21129). This
high incidence in the matched vehicle controls may have
been due to a systematic procedural problem associated
with injection ofthe drug.
It is concluded that under the conditions of this bio-
assay, the low survival of the dosed and vehicle-control
groups ofmice, as well as the possible procedural prob-
lem that may have affected the incidences of tumors in
these groups, does not allow a determination to be made
ofthe carcinogenic potential of ,B-TGdR in this species.
,B-TGdR in the vehicle of 0.05% polysorbate 80 was,
however, carcinogenic in rats, producing carcinomas of
the ear canal in the females and possibly also in the
males.
Report Date: 1978
Levels ofEvidence ofCarcinogenicity:
Male Rats: Equiocal
Female Rats: Positive
Male Mice: Inadequate Study
Female Mice: Inadequate Study
TR-58 Bioassay ofThio-TEPA for
Possible Carcinogenicity (CAS No. 52-24-4)
Thio-TEPA is an ethyleneimine alkylating agent that
was introduced in 1953 for clinical use in cancer chemo-
therapy. At one time thio-TEPA was an important thera-
peutic drug in the management of ovarian carcinoma. It
has been used effectively in the treatment of Hodgkins
disease, bronchogenic carcinoma, bladder cancer, reti-
noblastoma, and breast cancer and for the control of
pleural, pericardial, and peritoneal neoplastic effusions.
A bioassay of thio-TEPA for possible carcinogenicity
was conducted by administering the test chemical by
intraperitoneal injection to Sprague-Dawley rats and
B6C3F1 mice.
Groups of 31-39 rats of each sex were administered
thio-TEPA in phosphate-buffered saline at one of three
doses, either 0.7, 1.4, or 2.8 mg/kg body weight, three
times per week for a maximum of 52 weeks, then
observed for additional periods of time. The maximum
time on study (administration of chemical and observa-
tion) was 86 weeks. The groups at the low dose were
started 69 weeks after those at the mid and high doses,
because ofhighmortalitiesobserved inthe groups atthe
higherdoses. Matched controls consisted ofgroups of10
untreated rats and 10 vehicle-control rats of each sex.
Pooled-control groups also were used. Surviving control
rats were killed at 82-87 weeks; surviving dosed rats
were killed at 81 or 82 weeks.
Groups of35 mice ofeach sexwere administered thio-
TEPA at one oftwo doses, either 1.15 or 2.3 mg/kg body
weight, threetimesperweekforamaximumof52weeks,
then observed for a maximum additional period of 34
weeks. Matched controls consisted ofgroups of15 untre-
ated mice and 15vehicle-control mice ofeach sex. Pooled
controls also were used. Surviving control and dosed
mice were killed at 86 or 87 weeks.
Thio-TEPA was toxic to both rats and mice, causing
decreased mean body weight gains and early deaths in
the mid- and high-dose rats and in the high-dose mice.
Because of the early deaths, statistical analyses were
based only on time-adjusted incidences oftumors. Since
all high-dose male and female rats had died by 21 weeks,
microscopic evaluation oftissues was performed only on
the low- and mid-dose animals.
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In rats, the incidence of combined neoplasms of the
hematopoietic system (lymphoma, lymphocyticleukemia,
orgranulocytic leukemia) was significantin themales in
both the low-dose (P=0.020) and mid-dose (P=0.001)
groups, using pooled controls (pooled controls 0/29, low-
dose 6/34; pooled controls 0/30, mid-dose 6/16).
Squamous-cell carcinoma of the skin or ear canal
occurred at a significant incidence in the male rats in
both the low-dose (P=0.009) and mid-dose (P=0.023)
groups, using pooled controls (pooled controls 0/29, low-
dose 7/33; pooled controls 0/30, mid-dose 3/13) and in the
mid-dose females (P<0.001), using pooled controls
(pooledcontrols0/28,mid-dose8/21);inaddition,twolow-
dosefemaleshadsuchtumors,withnoneoccurringinthe
corresponding low-dose controls.
The incidence of adenocarcinoma of the uterus was
significant in the mid-dose female rats (P=0.001), using
pooled controls (pooled controls 0/28, mid-dose 7/21); in
addition, two low-dose females had adenocarcinoma of
the uterus, with no such tumor occurring in the corres-
ponding low-dose controls.
In rats, neuroepitheliomas (neuroblastomas) or nasal
carcinomas occurred in three low-dose males, two low-
dose females, and two mid-dose females. Although these
are not statistically significant incidences, these tumors
did not occur amongcontrol animals and no such tumors
have occurred in 380 Sprague-Dawley control rats of
each sexin otherbioassays atthe samelaboratory. Thus,
they may be associated with administration of the
chemical.
In the high-dose groups ofbothmale andfemalemice,
but not in the low-dose groups, the incidences of lym-
phomaorlymphocyticleukemiaweresignificantlyhigher
(P<0.001) foreach sexthanthose ofeitherthevehicle or
pooled controls (males: vehicle controls 118, pooled con-
trols1118,low-dose2/24,high-dose26/28;females:vehicle
controls 0/14, pooled controls 0/29, low-dose 5/26, high-
dose 32/32).
In the low-dose male mice squamous-cell carcinoma
was found in the skin of seven animals, in the preputial
glands ofsixanimals, andintheearcanaloftwoanimals.
A carcinoma of the preputial gland was also found in a
high-dose male.Whentheincidences ofthetumorsatthe
different sites were combined, the incidence in the low-
dose group was statistically significant using either the
vehicle (P=0.004) orthepooled (P<0.001) controls (vehi-
clecontrols0/8,pooledcontrols0/18,low-dose14/24,high-
dose 112).
It is concluded that under the conditions of this bio-
assay, thio-TEPA was carcinogenic in both Sprague-
Dawley rats and B6C3F1 mice. In the rats, the chemical
induced squamous-cell carcinomaofthe skin orearcanal
in both males and females, and hematopoietic neoplasms
inthemales; inthemice,itinducedlymphomaorlympho-
cytic leukemia in both sexes and squamous-cell car-
cinoma in the skin and associated glands ofmales.
Synonym: tris(1-aziridinyl)phosphine sulfide
Report Date: 1978
Levels ofEvidence ofCarcinogenicity:
Male Rats:
Female Rats:
Male Mice:
Female Mice:
Positive
Positive
Positive
Positive
TR-59 Bioassay ofEstradiol Mustard for
Possible Carcinogenicity (CAS No.
22966-79-6)
A bioassay of the experimental anticancer drug
estradiol mustard for possible carcinogenicity was con-
ducted by administering the chemical by gavage to
Sprague-Dawley rats and B6C3F1 mice.
Groups of 35 rats and 34-36 mice of each sex were
administered estradiol mustard at one of the following
doses, either0.62 or1.25mg/kgbodyweightforrats and
either 15 or 30 mg/kg bodyweight for mice. The vehicle
usedforthetestchemicalconsisted of0.05%polysorbate
80 in phosphate-buffered saline. The rats and mice were
dosed three times perweek for 52weeks, then observed
for an additional 30-34 weeks. Controls consisted of
groups of 10 rats and 15 mice of each sex that were not
administered the chemical (untreated controls) and also
of groups of 10 rats of each sex, 14 male mice, and 16
female mice administered the vehicle alone (vehicle con-
trols). Pooled controls were also used. All surviving rats
werekilledat84-86weeksandallsurvivingmice at82-86
weeks.
Mean bodyweights ofmale rats and male and female
mice administered estradiol mustard were lower
throughout the greater part of the study than those of
corresponding vehicle or untreated controls; mean body
weights of dosed female rats were unaffected. Admin-
istration ofthe test chemical had no significanteffect on
thesurvivalofeithermaleorfemalerats.Alargenumber
of dosed mice died prior to the end of the study. The
numbersofdosedmalemicewhichwereatriskaslongas
52 weeks were sufficient, however, for development of
tumors appearing up to that time. Time-adjusted anal-
ysis andlife-table analyseswereapplied to dataobtained
with the mice.
In rats, no tumors were observed in a statistically
significant incidence in the animals administered
estradiol mustard.
In mice, lymphoma or lymphocytic leukemia occurred
atsignificantincidences inlow-dose (P=0.018) andhigh-
dose (P<0.001) groups ofmales compared with those in
the pooled vehicle controls (controls 0/28, low-dose 6/32,
high-dose17/29) and atsignificantincidencesinlow-dose
(P=0.020) and high-dose (P=0.002) groups of females
compared with those in the corresponding vehicle con-
trols (controls 0/14, low-dose 9/30, high-dose 11/23). In
addition, the incidences of lymphoma were statistically
significant for dose-related trend for both the males
(P<0.001) and the females (P= 0.003). Since lymphoma
wasobservedinmalemice asearlyas25weeks,life-table
analyses of the incidence in each sex were performed.
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The results indicated a dose association (P= 0.001)
between the administration of estradiol mustard and
the time of observation of lymphoma in either sex of
mice.
In mice, alveolar/bronchiolar adenoma or carcinoma
occurred at a significant incidence (P=0.004) in the low-
dose group of males compared with the pooled vehicle
controls (controls 2/28, low-dose 12/30, high-dose 5/24)
and at a significant incidence (P=0.022) in the low-dose
group offemales compared with the pooled vehicle con-
trols (controls 1128, low-dose 7/27, high-dose 118). Sar-
coma of the myocardium similarly occurred at a
significant incidence (P=0.015) in the low-dose group of
males compared with the pooled vehicle controls (con-
trols 0/28, low-dose 6/30, high-dose2/24) and atasignifi-
cant incidence (P=0.002) in the low-dose group of
females compared with the pooled vehicle controls (con-
trols 0/28, low-dose 8/27, high-dose 1112). The survival of
bothhigh-dosemalesandhigh-dosefemaleswasslightly
lower than that of the respective low-dose groups and
may account for the higher numbers of pulmonary
tumors and myocardial sarcomas among low-dose mice
of both sexes. The association of myocardial sarcoma
withadministration ofthe chemical inboth dosedgroups
ofeach sexis strengthened bythefactthatthesetumors
of the myocardium have not occurred in the more than
500 male and 500 female historical-control mice of this
strain at the laboratory.
Squamous cell carcinoma of the stomach occurred in
the dosed male mice (high-dose 2/29) and in the dosed
female mice (low-dose 2/26, high-dose 2/14) but was
absent in all controls. Although the incidences in this
bioassay were too low to be statistically significant, the
fact that no squamous-cell carcinomas of the stomach
have occurred in the more than 500 male and 500 female
historical-control mice of this strain at this laboratory
indicates that these gastric tumors were related to the
administration ofthe estradiol mustard.
It is concluded that under the conditions of this bio-
assay, estradiol mustard administered in a buffered
saline vehicle was not carcinogenic in Sprague-Dawley
rats. Estradiol mustard was carcinogenic in both male
and female B6C3F1 mice, inducing lymphoma, sarcoma
ofthe myocardium, alveolar adenoma or carcinoma, and
squamous-cell carcinoma ofthe stomach.
Synonym: estradiol, bis((p-bis(2-chloroethyl)-amino)
phenyl)acetate
Report Date: 1978
Levels ofEvidence ofCarcinogenicity:
Male Rats: Negative
Female Rats: Negative
Male Mice: Positive
Female Mice: Positive
TR-60 Bioassay ofPhenesterin for
Possible Carcinogenicity (CAS No.
3546-10-9)
Phenesterin, an experimental anticancer agent, is a
steroidal alkylating agent composed of the carboxylic
acid ester of cholesterol and an aryl nitrogen mustard.
Abioassay ofphenesterin forpossible carcinogenicity
was conducted by administering the chemical by gavage
to Sprague-Dawley rats and B6C3F1 mice.
Groups of 35 rats of each sex were administered
phenesterinatoneoftwodoses,either5or10mg/kgbody
weight,threetimesperweekfor52weeks,thenobserved
for an additional 32 or 33 weeks. The vehicle used was
0.05% polysorbate 80 in buffered saline. Controls con-
sisted ofgroups of10 rats ofeach sexwhich received the
vehicle (vehicle control) and 10 rats of each sex which
were untreated (untreated control). All surviving rats
were killed at 84 or 85 weeks.
Groups of35 mice of each sex were administered the
chemical at one oftwo doses, either 15 or 30 mg/kgbody
weight, three times per week for 52 weeks. The males
receiving 15 mg/kg were observed for an additional
period of29weeks, andthose survivingtothistimewere
then killed; the animals of the remaining groups were
observed for additional periods ofonly 10-22 weeks, due
to earlydeaths. Seventy-sevenweeks afterthe foregoing
groupswerestarted,additional groupsof40miceofeach
sexwerestartedandwereadministeredthechemicalat7
mg/kgbodyweightthreetimesperweek; administration
ofthe chemical terminated atweek102 forthemales and
atweek88 forthefemales, due to deaths ofall females at
this time. Controls for the low-dose (7 mg/kg) groups of
mice consisted of groups of 20 mice of each sex which
received the vehicle (vehicle control) and 20 mice ofeach
sex which were untreated (untreated control); controls
forthemid-dose (15mg/kg) andthehigh-dose (30mg/kg)
controls consisted of groups of 15 mice of each sex
similarlyreceivingthevehicle oruntreated.All surviving
low-dosecontrolswere killed at104weeks, andallsurviv-
ing mid- and high-dose controls were killed at 81-84
weeks.
Phenesterin was toxic to rats and mice at the doses
used, as shown by reduced mean body weights and
survival. Time-adjusted analyses were used for evalua-
tion ofincidences oftumors in the female mice.
In female rats, a dose-related trend (P= 0.019) was
presentinadenocarcinomaofthemammarygland,using
thepooledcontrols, andtheincidencesofthetumorinthe
individual dosedgroupsweresignificant(P<0.009)when
comparedwiththoseinthepooled controls (controlsV18,
low-dose 12/29, high-dose 12/30).
In male mice, the incidence of alveolar/bronchiolar
carcinomas or combined alveolar/bronchiolar adenomas
and carcinomas in thelow-dose group (18/40)wassignifi-
cantlyhigher(P<0.020)thanthatinthelow-dosevehicle-
control group (0/16). In female mice, seven low-dose
animals had alveolar/bronchiolar adenomas and eight
other low-dose animals had alveolar/bronchiolar car-
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cinomas. When these tumors were combined, their time-
adjusted incidencewas significant (P=0.004)when com-
paredwith thatin the low-dosevehicle controls (controls
V18, low-dose 15/35). The lower and nonsignificant inci-
dences of these tumors observed in the mid- and high-
dose groups maybe due to the earlier mortalityin these
groups compared with the low-dose groups.
In each sex ofmid- and high-dose mice, incidences of
lymphoma and leukemia were dose related (P<0.005),
using vehicle controls; they were also significant
(P<0.018) in direct comparisons of mid- and high-dose
groups of both sexes with respective vehicle controls
(males: controls 0/14, mid-dose 9/29, high-dose 11/25;
females, time-adjusted: controls 0/15, mid-dose 14/18,
high-dose 17/19). The significance of the incidence of
lymphoma and leukemia in the mid- and high-dose
groups of males was increased (P<0.001) when the
pooled-control group was used, both in the testfor dose-
related trendandintestsfordirectcomparisons ofdosed
groups with the controls.
In each sexofmice, sarcomas ofthemyocardiumwere
found in all groups of dosed animals, but in no control
animals (males: low-dose 5/40, mid-dose 7/29, high-dose
2/25;females: low-dose8/34,mid-dose2/7,high-dose3/7).
Inmales,theincidenceinthemid-dosegroupwassignifi-
cant when compared with that in the pooled controls
(P=0.006); in females, the incidences in the low- and
high-dose groupswere significant (P<0.023).
It is concluded that under the conditions of this bio-
assay, phenesterin was carcinogenic in female Sprague-
Dawley rats, producing adenocarcinomas ofthe mamm-
ary gland, and in both sexes ofB6C3F1 mice, producing
alveolar/bronchiolar carcinomas, hematopoietic tumors,
andmyocardial sarcomas.
Synonym: cholesteryl p-bis(2-chloroethyl)-minopheny-
lacetate
Report Date: 1978
Levels ofEvidence ofCarcinogenicity:
Male Rats:
Female Rats:
Male Mice:
Female Mice:
Negative
Positive
Positive
Positive
TR-61 Bioassay of
Pentachloronitrobenzene for Possible
Carcinogenicity (CAS No. 82-68-8)
Pentachloronitrobenzene (PCNB), a halogenated ben-
zene derivative and agricultural pesticide, was selected
for bioassay by the National Cancer Institute following
its classification as a tumorigenic agent by the Secre-
tary's Commission on Pesticides and Their Relationship
to Environmental Health.
A bioassay of technical-grade pentachloronitro-
benzene (PCNB) for possible carcinogenicity was con-
ducted using Osborne-Mendel rats and B6C3F1 mice.
PCNB was administered in the feed, at either of two
concentrations, to groups of 50 male and 50 female
animals of each species. The time-weighted average
dietary concentrations of PCNB were, respectively,
10,064 and 5,417ppmformale rats, 14,635 and 7,875ppm
for female rats, 5,213 and 2,606 ppm for male mice, and
8,187 and 4,093 ppm for female mice. After a 78-week
period of compound administration, observation of the
rats continued for an additional 33 to 35 weeks and
observation ofthe mice continued for 14 or 15 additional
weeks.
Foreachspecies,20animalsofeach sexwereplaced on
test as controls and fed only the basal diet.
No rare or unusual tumors were observed during the
histopathologic examinations and no statistically signifi-
cant positive associations were demonstrated between
chemical administration and the incidence ofneoplasms
in either sex ofeither species.
It is concluded that under the conditions of this bio-
assay PCNB was not carcinogenic in either Osborne-
Mendel rats or B6C3F1 mice.
Synonyms: quintozene; terrachlor; PCNB
Report Date: 1978
Levels ofEvidence ofCarcinogenicity:
Male Rats:
Female Rats:
Male Mice:
Female Mice:
Negative
Negative
Negative
Negative
Note: Pentachloronitrobenzene was subsequently stud-
ied by administration in feed to B6C3F1 mice (See
TR-325, reported 1978).
TR-62 Bioassay of Endosulfan for
Possible Carcinogenicity (CAS No.
115-29-7)
Endosulfan is a synthetic chlorinated cyclodiene and
was introduced in 1956 as a broad spectrum insecticide.
A bioassay oftechnical-grade endosulfan for possible
carcinogenicity was conducted using Osborne-Mendel
rats and B6C3F1 mice. Endosulfan was administered in
the feed, at either oftwo concentrations, to groups of50
male and 50 female animals ofeach species.
The time-weighted average high and low dietary con-
centrations ofendosulfanwere,respectively, 952 and 408
ppmforthemalerats,and445and223ppmforthefemale
rats. In mice the high and low time-weighted average
concentrationswere,respectively, 6.9 and 3.5ppmforthe
males and 3.9 and 2.0 ppm for the females. Twenty
animals of each sex and species were placed on test as
controls. The bioassay ofhigh dose male rats was termi-
nated duringweek 82, and thebioassay oflow dose male
rats was terminated during week 74. After a 78-week
period ofchemical administration, observation offemale
rats continued for33 additionalweeks and observationof
mice continued for 14 additional weeks.
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At the doses administered to rats in this study
endosulfan was toxic, inducing a high incidence of toxic
nephropathy in both sexes and testicular atrophy in
males.
In both species high early mortality was observed in
the male groups and no conclusions concerning the car-
cinogenicityofendosulfan canbedrawnfromthispartof
the bioassay. However, survival among females of both
species was sufficient for meaningful statistical evalua-
tion of the incidence of late-developing tumors. It is
concluded that under the conditions of this bioassay,
technical-grade endosulfan was not carcinogenic in
female Osborne-Mendel rats or in female B6C3F1 mice.
Synonym: 6,7,8,9,10,10-hexachloro-1,5,5a,6,9,9a-
hexahydro-6,9-methano-2,4,3-benzodioxathiepin-3-oxide
Report Date: 1978
Levels ofEvidence ofCarcinogenicity:
Male Rats: Inadequate Study
Female Rats: Negative
Male Mice: Inadequate Study
Female Mice: Negative
TR-63 Bioassay of4-Chloro-
o-phenylenediamine for Possible
Carcinogenicity (CAS No. 95-83-0)
4-Chloro-o-phenylenediamine, anaromatic amineused
as an intermediate in dye production, was selected for
bioassaybythe National Cancer Institutebecause ofthe
high incidence of bladder cancer reported among dye
manufacturing industry workers.
A bioassay for the possible carcinogenicity of
technical-grade 4-chloro-o-phenylenediamine was con-
ducted using Fischer 344 rats and B6C3F1 mice.
4-Chloro-o-phenylenediamine was administered in the
feed, ateitheroftwoconcentrations, togroupsof49 or50
maleand 50femaleanimalsofeach species. Formaleand
female rats, the high and low time-weighted average
dietary concentrations of 4-chloro-o-phenylenediamine
were 1.0 and 0.5 percent, respectively. For male and
female mice, the high and low time-weighted average
dietary concentrations were 1.4 and 0.7 percent, respec-
tively.Aftera78-weekperiodofchemicaladministration,
observation ofthe rats continued for up to an additional
28weeks and observation ofthe mice continued forup to
an additional 18weeks. Fifty animals ofeach species and
sex were placed on test as controls for the chronic
bioassay.
There was a statistically significant positive associa-
tionbetweenincreased dosageandacceleratedmortality
infemaleratsandmalemice; however, survival amongall
groups ofwas adequate for meaningful statistical anal-
ysis oflate-developing tumors.
In male and female rats receiving the test chemical, a
significantly increased incidence of neoplasms of the
urinarybladder occurred. Neoplastic nodules intheliver
and tumors of the forestomach may also have been
related to administration ofthe chemical. Asignificantly
increased incidence of hepatocellular carcinomas
occurred in chemically treated male and female mice.
It is concluded that under the conditions of this bio-
assay 4-chloro-o-phenylenediamine was carcinogenic in
Fischer 344 rats and B6C3F1 mice, including tumors of
theurinarybladderandforestomachinbothsexesofrats
and hepatocellular carcinomas in both sexes ofmice.
Synonyms: 4-chloro-1,2-benzenediamine; 4-chloro-1,2-
diaminobenzene; Ursol Olive 6G
Report Date: 1978
Levels ofEvidence ofCarcinogenicity:
Male Rats:
Female Rats:
Male Mice:
Female Mice:
Positive
Positive
Positive
Positive
TR-64 Bioassay of1-Nitronaphthalene for
Possible Carcinogenicity (CAS No. 86-57-7)
1-Nitronaphthalene is used as an intermediate for the
preparation of 1-naphthylamine, which is used in the
manufacture ofnumerousdyesandintermediates, andin
the production of rodenticides. 1-Nitronaphthalene is
also sulfonated to produce 1-nitronaphthalene-5-sulfonic
acid, a dye intermediate. 1,5- and 1,8-Dinitronaphtha-
lenes, produced by further nitration of 1-nitro-
naphthalene, have had limited use in the dye industry.
1-Nitronaphthalene is also used as a deblooming agent
for petroleum and oils (in concentrations of 2-3
parts/1,000 parts oil), and as a modifier to decrease the
burning rate ofexplosives.
A bioassay of technical-grade 1-nitronaphthalene for
possible carcinogenicity was conducted using Fischer
344 rats and B6C3F1 mice. 1-Nitronaphthalene was
administered inthefeed, ateither oftwo concentrations,
to groups of 50 male and 50 female animals of each
species. The high and low time-weighted average con-
centrations used in the chronic studywere, respectively,
0.18 and 0.06 percent for rats and 0.12 and 0.06 percent
for mice.After a 78-weekperiod ofchemical administra-
tion,theratswereobservedforanadditionalperiodofup
to 31weeks and themicefor an additional period ofup to
20weeks. Forrats 50 animals ofeach sexwere placed on
testascontrolsforthelowdosegroupsand25ofeach sex
forthehighdosegroups. Formice 50 animals ofeach sex
were placed on test as controls for each dosed group.
In both species adequate numbers of animals in all
groups survived sufficiently long for the development of
late-appearing tumors; however, no compound-related
increase in the incidence of neoplasms, nonneoplastic
lesions, or other toxic effects was evident.
Under the conditions of this bioassay 1-nitro-
naphthalene was not demonstrated to be carcinogenic in
Fischer 344 rats or B6C3F1 mice.
4142 NTP/NIEHS
Synonyms: alpha-nitronaphthalene, nitronaphthalene
Report Date: 1978
Levels ofEvidence ofCarcinogenicity:
Male Rats: Negative
Female Rats: Negative
Male Mice: Negative
Female Mice: Negative
TR-65 Bioassay ofChloropicrin for
Possible Carcinogenicity (CAS No. 76-06-2)
Chloropicrin is an agricultural fumigant, once widely
usedbutnowbeingphased out. Itwasdevelopedasatear
gas, butwasfoundtobeuseful as afumigantin1918.The
primary use of chloropicrin as a fumigant was in the
treatment of stored grain. It also functions as a
nematicide, fungicide, and insecticidewhenused as a soil
fumigant prior to planting.
Abioassayoftechnical-grade chloropicrinforpossible
carcinogenicity was conducted using Osborne-Mendel
rats and B6C3F1 mice. Chloropicrin in corn oil was
administered 5 days a week by gavage, at either of two
dosages, to groups of 50 male and 50 female animals of
each species. Time-weighted average dosages of25 mg/
kg/day for low dose male rats and 20 mg/kg/day for low
dose female rats were administered during weeks 1
through 33, then administered cyclically (1 dose-free
week followed by 4weeks ofadministration) fromweeks
34through78.Time-weighted averagedosages of26mg/
kg/dayforhighdosemaleratsand22mg/kg/dayforhigh
dose female rats were administered from weeks 1
through 17, weeks 31 through 33, and cyclically (1 dose-
freeweek followed by4weeks ofadministration) during
weeks 34through 78. Time-weighted average dosages of
66 and 33 mg/kg/day, respectively, for male and female
mice were administered for 78 weeks. These dosing
regimens were followed by observation periods of 32
weeks for rats and 13 weeks for mice.
Foreachspecies,20animalsofeach sexwereplaced on
test as vehicle controls. These animals were gavaged
with corn oil. Twenty animals ofeach sexwereplaced on
test as untreated controls for each species. These ani-
malswere notgavaged.
A high incidence of early death was observed among
chloropicrin-dosed rats. Deaths among dosed rats
occurred as early as week 1 for females and week 6 for
males. Median survivalwasweek48forhigh dosemales,
week54forlowdosemales,week70forhighdosefemales
and week 59 for low dose females. Statistical tests indi-
cate a positive association between chloropicrin dosage
and mortality ofrats.
No neoplasms were observed at higher incidences in
dosed than control rats. In rats ofboth sexes, incidences
of adenoma of the pituitary and of adenocarcinoma or
fibroadenoma of the mammary gland were higher in
control groups than dosed groups. It is likely that most
dosed rats did not survive longenough tobe atriskfrom
late-appearing tumors.
Arapid decrease in survival after the firstyear ofthe
studywas observed amonghigh dose mice ofboth sexes.
Survival of high dose male mice decreased from 80
percent in week 54 to 26 percent in week 90. Survival of
highdosefemalemicedecreasedfrom82percentinweek
54 to 36 percent in week 90.-Statistical tests indicated a
positive association between chloropicrin dosage and
mortality ofmice.
In chloropicrin-dosed mice, proliferative lesions ofthe
squamous epithelium of the forestomach included two
carcinomas andapapilloma.Althoughthesetumorswere
uncommon in control animals, statistical analysis did not
demonstrate that they were related to administration of
chloropicrin. Other proliferative lesions of the for-
estomach occurring at an increased incidence in dosed
mice were acanthosis and hyperkeratosis. No statis-
tically significant increase of tumor incidence was
observed in mice.
The bioassay of chloropicrin using Osborne-Mendel
rats did not permit an evaluation of carcinogenicity
because ofthe short survival time ofdosed animals. The
bioassay of chloropicrin using B6C3F1 mice did not
provide conclusive statistical evidence for the car-
cinogenicity ofthis compound.
Synonyms: trichloronitromethane, nitrochloroform
Report Date: 1978
Levels ofEvidence ofCarcinogenicity:
Male Rats: Inadequate Study
Female Rats: Inadequate Study
Male Mice: Negative
Female Mice: Negative
TR-66 Bioassay of1,1-Dichloroethane for
Possible Carcinogenicity (CAS No. 75-34-3)
1,1-Dichloroethane is used as a chemical intermediate
and as a solvent for extraction and degreasing.
A bioassay of technical-grade 1,1-dichloroethane for
possible carcinogenicity was conducted using Osborne-
Mendel rats and B6C3F1 mice. 1,1-Dichloroethane in
corn oil was administered by gavage, at either of two
dosages, to groups of50 male and 50 female animals of
each species, 5 days a week for a period of 78 weeks,
followed by an observation period of 33 weeks for rats
and 13 weeks for mice.
Apreliminary subchronic toxicity test, consisting of6
weeksof1,1-dichloroethane administration atfivedosage
levelsfollowedby2weeks ofobservation, wasperformed
for the purpose of selecting initial dosages. Subsequent
dosage adjustments were made during the course ofthe
study. The high and lowtime-weighted average dosages
of1,1-dichloroethane were, respectively, 764 and 382 mg/
kg/day for male rats; 950 and 475 mg/kg/day for female
rats; 2,885 and 1,442 mg/kg/day for male mice; and 3,331
and 1,665 mg/kg/day for female mice.